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ABSTRACT
The genus Glycyrrhiza, encompasses several species exhibiting complex structural
diversity of secondary metabolites and hence biological activities. The intricate nature of
botanical remedies, such as licorice, rendered them obsolete for scientific research or medical
industry. Understanding and finding the mechanisms of efficacy or safety for a plant-based
therapy is very challenging, yet it remains crucial and warranted.
The licorice plant is known to have Selective Estrogen Receptor Modulatory effects
(SERMs), with a spectrum of estrogenic and anti-estrogenic activities attributed to women’s
health. On the contrary, licorice extract was shown to induce pregnane xenobiotic receptor
(PXR), which may manifest as a potential route for deleterious effects such as herb-drug
interaction (HDI). While many studies attributed these divergent activities to a few classes of
compounds such as liquiritigenin (a weak estrogenic SERM) or glycyrrhizin (weak PXR
agonist), no attempt was made to characterize the complete set of compounds responsible for
these divergent activities. A plethora of licorice components is undermined, which might have
the potential to be developed into novel phytoSERMS or to trigger undesirable adverse effects by
altering drug metabolizing enzymes and thus pharmacokinetics.
In this work, we explored the mechanism associated with the efficacy and safety of
components reported in the licorice plant. We utilized smart screening techniques such as
cheminformatics tools to reveal the high number of secondary metabolites produced by licorice,
which are capable of interfering with the human Estrogen Receptors (hERs) and/or PXR or other
ii

vital cytochrome P450 enzymes.
After the validation of our in silico models by using the previous knowledge in this area,
the alerting phytochemicals from two Glycyrrhiza species (G. glabra and G. uralensis) were
clustered. Exhaustive computational mining of licorice metabolome against selected endocrinal
and metabolic targets led to the discovery of a unique class of compounds, which belong to the
dihydrostilbenoids (DHS) class appended with prenyl groups at various positions. To the best of
our knowledge, this interesting group of compounds has not been studied for their estrogenic
activities or PXR activation. In addition, some of the bis-prenylated DHS have been reported to
be present only in G. uralensis.
Thus, we have ventured to synthesize a set of constitutional isomers of stilbenoids and
DHS (archetypal of those found in licorice) with different prenylation patterns. Sixteen
constitutional isomers of stilbenoids (M2-M10) and DHS (M12-M18) were successfully
synthesized, of which six of them (M8, M9, M14, M15, M17, and M18) are synthesized for the
first time to be further tested and validated with cell-based methods for their estrogenic activities.
We have unveiled a novel class of compounds, which possess a strong PXR activation.
These results, which were in accord with the in silico prediction, were observed for multiple
synthesized prenylated stilbenoid and DHS by the luciferase reporter gene assay at µM
concentrations. Moreover, this activation was further validated by the six-fold increase in mRNA
expression of Cytochrome P450 3A4 (CYP3A4), where three representative compounds (M7,
M10, and M15) exceeded the activation fold of the positive control.
Another aspect of the current project was to predict the phase I primary metabolites of
iii

compounds found in both species of Glycyrrhiza and assess them with computational tools to
predict their binding potential against both isoforms of hERs or drug metabolizing enzymes such
as (CYP) inhibition models. Our investigations revealed estrogenic character for most of the
predicted metabolites and have confirmed earlier reports of potential CYP3A4 and CYP1A2
inhibition.
Compilation of such data is essential to gain a better understanding of the efficacy/safety
of licorice extracts used in various botanical formularies. This approach with the involved
cheminformatic tools has proven effective to yield rich information to support our understanding
of traditional practices. It also can expand the role of botanical drugs for introducing new
chemical entities (NCEs) and/or uncovering their liabilities at early stages.
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CHAPTER I
INTRODUCTION
I.1

Natural product research remodeling: Medical research and clinical practice
perspectives
The inherently complicated nature of an herbal remedy usually precludes the full

understanding of its activity or safety. The polypharmacology represented by modulation of a
network of targets and the infeasibility of the experimental testing of every reported secondary
metabolite denotes the major hurdles in botanical research. This is coupled with the natural
products chemical complexity, which imposes vast difficulties regarding their supplementation
and progression in medical research. Therefore, in the past few decades, we have witnessed a
biased investment into focused small molecule libraries generated by combinatorial chemistry as
the mainstream for drug development. Unfortunately, the results were seemingly
contradictory.1-5
The clinical attrition of the vast majority of the new chemical entities was devastating and
described as “productivity crises.”6-7 In part, this situation has been correlated to the phasing out
of NPs from the drug discovery pipeline.8 On the other hand, one analysis revealed that 60% of
the registered chemical entities in 1981 to 2010 are either natural products or natural products
related molecules including NP derivatives or NP synthetic mimics.9 Undeniably, natural
products are the ideal primary resource of new chemical entities by natural selection. The
interactive environment in which these natural products have evolved should have indulged them
with exceedingly incomparable therapeutic potentials. Therefore, they are predicted to harbor
1

chemical pharmacophores with preferred interactions toward surrounding biological
targets.10-11 One interesting example is the blockbuster drug rosuvastatin, which is used for
hypercholesteremia. This drug is considered as a synthetic mimic of mevastatin, a natural
product from Penicillium citrinum fungus but with a less intricate scaffold for chemical synthesis
(Figure 1).12
In addition to the above, NPs are still used as a basic therapeutic option side by side as
traditional medicine worldwide. In general, there was a global drift towards the use of natural
products supplements, which was driven by the perception that they are safe and efficacious.13
Correspondingly, the sales of these supplements peaked to $7.45 billion in 2016.14 The current
cliffs where both the medical research and clinical practices stand has created a chain reaction in
the natural product field. At this moment, it became a requisite to understand the drawbacks of
the existing strategies and practices in this field, and to improve their competences. For instance,
although coupling the biological assays to the chemical investigation of the NP was meant to
rationalize the process of isolation in this field, but soon it was clear that it failed to prove their
efficacy in the clinical trials in many occasions.15-16 In fact, these practices were incomplete to
draw the complete picture of how these systems operate. Some of the reasons behind these
failures are summarized in Figure 2.17-18
These concomitant conclusions in both fields pointed out to the necessity of
understanding the mechanism of action of NP or herbal remedy as to a priority to prove their
efficacy and safety in the clinical practice and to eliminate the difficulties that undermined their
engagement into the pipelines of the medical research. In silico investigation of natural products
provides a versatile toolbox to deal with its complexity.4 In the past few decades, virtual
screening (both structure-based and ligand-based approaches) has been utilized as a basic tool to
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capture novel scaffolds out of diverse chemical libraries against known pharmacological targets.
19-20

Additionally, the growing field of genome mining, chemogenomics and molecular
networking constitute a promising avenue to approach novel and effective NPs leads by
application of multiple sophisticated computational tools.21 Nevertheless, in this context, natural
product libraries are only partially and passively integrated into this procedure. However, to
enrich their engagement in the process they should be treated separately before their direct
employment. Creating this shortcut will inspire drug design and development effectively by
capturing NP hits or generating natural product fragment libraries as fingerprints of active
motifs, specifically, with the accumulating knowledge and computational tools to predict the
pharmacodynamics and pharmacokinetic properties of molecules along with the growing
numbers of NP entries in the databases. Moreover, it would also help us to explore novel
candidates as natural-product-lead-structures in a time and cost-effective manner
(Table 1.).4, 12, 22

Figure 1. Natural products as a source of NCEs: Application of novel
methodologies to upgrade sustainable resources
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However, searching for lead compounds from NP origin is not the sole application of in
silico procedures and virtual screening. They should be utilized for understanding the
multi-targeted (polypharmacology) and off-targeted effects (toxicity) of the known plant therapy,
defining the best components, which are capable of interacting with specific targets including
enzymes involved in drug metabolism. The prediction of macromolecule targets for molecules of
natural origin (reverse pharmacognosy), might solve the long lasted debate about the efficacy of
herbal remedies. These concepts came along with the growing paradigm of reverse virtual
screening or inverse docking, which is a direct consequence of thousands of accumulating solved
protein crystal structures into data banks. Other approaches explored feature and similarity
searches for target fishing.23-24

Figure 2. An overview of BGF drawbacks that might lead to sub-clinical significance of
intended NP therapeutics
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In the context of plant therapy, this would achieve the ultimate goal of defining a
spectrum of potential activities and spotting the possible natural products candidates behind
them. Conversely, it might predict or explain in early stages why such therapies end up with
controversial conclusions when extrapolating to in vivo settings. For instance, adapting such
methodologies have unveiled both peroxisome proliferator-activated receptor gamma and
cyclooxygenase-2 as the main targets of Meranzin. Interestingly, the latter molecule was shown
to have a potency comparable to their conventional drug therapies, rosiglitazone, and
indomethacin.20 By the application and benchmarking of such methods, we should be able to
define and rationally prioritize the targets, which should be screened.
The diverse nature of plant secondary metabolites and their natural resources
inconsistency has also dampened the study of their pharmacokinetic interaction with
conventional therapeutics. They are the major contributors to why these effects are left
underestimated and thus understudied. Although several HDIs are well known in the literature,
the study of these events is still retrospective. This is quite concerning as one study showed that
4 out of 10 adults in the US engage alternative and complementary medicines in their life.
Around 20% of these are natural products.25-28 Moreover, concerning the HDI, it became clear
that the NP entities play a complex role at the molecular level. Besides the direct interaction with
the metabolizing enzymes and transporters, recent studies uncovered the significant role played
by PXR mediating or exaggerating these effects.13
The recent development of a systematic approach by the FDA to prioritize the natural
supplements with the high-risk potential of precipitating an HDI is still dependent on the ranking
and scoring of gathered information. However, there is a clear basic need for adapting
prospective methodologies.25 In this context, the in silico oriented approaches, which try to
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tackle the human-xenobiotic disposition system should take the lead. This trend has been
motivated by the low-cost and the efficiency of such approaches, and it is aggravated by the
clinical attrition of drug candidates in the clinical trials. In fact, the latter events along with
several cases of FDA “approved drugs” withdrawals (because of CYP enzymes related drug-drug
interaction) have escalated the need to screen for drug safety at an early stage of any drug
development. This situation has created a surge of in vitro data measuring different metabolic
endpoints such as metabolic stability or inhibition for thousands of chemical entities. In addition,
the last few years have witnessed crucial advancements in the knowledge of metabolic pathways
and their regulation as well as the structural and functional understanding of their operating
machinery.29-30
In all, these events have created a momentum to develop multiple computational models
to screen for different metabolic endpoints. Similar to the efficacy predictions, these
computational approaches are also classified as ligand-based and structure-based models. On the
grounds of reality, metabolism is among the most complex properties to predict. Unlike
conventional targets, metabolic processes recruit a variety of enzymes with multiple isoforms
and transporters, which are created to process a diverse group of chemical structures known as
“xenobiotics”.
Table 1: Selected natural product databases and number of entries
Database
Dictionary of
Natural products

NPs entries

Content

40,000

NPs found in the literature

SymMAP

19,595

SuperNatural II
Zinc 15
CheMBL
MarinLit

326,000
80,617
>75,000
26,490

NPs from listed in Chinese medical texts with target
prediction
NPs with the description of toxicity and target prediction
NPs found in the literature with a purchasable list
NPs structures from the literature
Marine NPs found in the literature
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Hence, making them usually larger, more flexible and promiscuous.31 Additionally, their
expression is further regulated by several chemical, genetic and environmental factors.
Nevertheless, assessing these properties is vital for developing NCEs as well as for herbs in order
to avoid drug-drug or HDI that may lead to suboptimal dosing of accompanying drugs or even
adverse effects.
Thus, the best rationale in such a scenario is “to divide and conquer.” Incorporation of
multiple computational models including the CYP enzymes and their regulators such as PXR or
CAR, which are most involved in drug disposition, would be a better practice. Particularly the
CYP enzymes, where multiple models can measure different aspects of the process such as
substrate/inhibition properties, substrate selectivity, regioselectivity (the site of metabolism the
expected metabolites), and the rate or extent of metabolite generation or inhibition. The vast
majority of metabolism occurs via CYP enzymes, particularly, CYP3A4, which is solely
responsible for the metabolism of nearly half of the prescription drugs.31-33
As a direct result of this discussion and to approach the pharmacokinetic and metabolism effects
of herbal drug therapy with a known multicomponent system, the in silico models offer a good
starting point to untangle the complexity of the situation.
I.2

Cheminformatic approaches to unravel the biological functions and potential safety
issues associated with herbal drugs.
Application of cheminformatics to solve the complexity of an herbal remedy is enticing.

Cheminformatics offers a diverse set of tools, which includes physics-based models comprising
both quantum chemistry and molecular dynamics simulations. In addition, it encompasses the
machine learning approaches that apply certain algorithms to recognize similar patterns and to
find mathematical relationships between empirical observations. This could be applied to small

7

molecules in order to predict their properties (chemical, physical or biological). Furthermore,
these techniques can be classified into structure-based and ligand-based approaches depending
on the experimental design. Some of the commonly applied approaches include docking,
pharmacophores, quantitative structure-activity relationships, similarity searches, and machine
learning.
In fact, such approaches have proven to be effective in multiple research areas in
medicine and drug design, which emphasizes the expansion of these terms to the phytochemical
field in various applications such as activity profiling, mechanism of action and ADMET
prediction including safety issues and HDI. The exponential increase in computational power
represented by speed, accuracy, and cost, reinforces the importance of such techniques in every
project agenda.
The following will be a brief overview of the implemented approaches in our study.
I.2.1

Structure-based approaches: Molecular Docking
The three dimensional and structural information extracted from biological targets forms

a fundamental aspect of the structure-based approaches, which mainly includes molecular
docking, virtual screening, and molecular dynamics. Exploring the transient interactions between
small molecules and their targets became more and more feasible with the increasingly
accumulating solved protein crystal structures in the databases. Moreover, the prediction of these
interactions became sufficiently accurate with the advent of more sophisticated algorithms and
scoring functions.34
The process of docking is a multistep procedure that will predict the posing of the ligand
by defining specific conformation and orientation within the binding site of a certain target. The
aim of this process is to predict a correct pose and to estimate the binding energy of the small
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molecules toward their targets. Docking procedures involve three premises. The first one is the
flexibility of small molecules. The second premise is the flexibility of the protein followed by the
scoring method.35 Small molecules usually have multiple degrees of freedom.
The conformational sampling algorithm will provide a multi-conformer database to find the best
conformation, which matches the binding site. The sampling procedure could be systematic, but
most often it is stochastic to comply with the high throughput nature of the docking virtual
screening. This ligand sampling procedure could be a separate step, or it can be embedded within
the docking protocol.
However, protein flexibility is a bit more challenging issue due to its huge nature and
complexity. Docking procedures differ in the degree of freedom allowed for the binding site
flexibility which could be advantageous in multiple occasions, especially where the key and lock
principle fails to explain the protein-ligand interaction. Accordingly, the docking procedure
could be rigid, or semi-flexible. In the first case, the protein is restricted to one conformation
while in the second case the protein is treated as a soft body by relaxing the potentials of the van
der Waals radii, or by considering a rotamer library for the protein side chains. In fact, these
protocols may or may not adequately select a true or active conformation of the protein.
An alternative approach that we have adopted in this research is to consider multiple rigid and
known active conformations of the protein-ligand complexes, which is known as ensemble
docking.23, 35-36
For the third premise of the docking procedure, the direct evaluation and comparison
between various ligand conformers inside the protein pockets are required. Most docking
programs generate potential energy grids. In this context, grid points are set as reference points
to store information about the binding site such as steric, electrostatic and van der Waals
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potentials that will be used for scoring the ligand pose using atomic pair-wise interactions.
However, the overall success of the docking procedure does not end by identifying the correct
binding conformation. Rather, it will be judged for the correct pose prediction, differentiating
between actives and inactives and the correct estimation of the binding energy. In fact, the latter
aspect is not easily achieved in the regular setting, which relies on the scoring functions solely.
Most often, the scoring function is inherently deficient for oversimplification of the energetic
terms.35, 37-39 Accordingly, to achieve true binding energy calculations both enthalpy and entropy
terms such as desolvation, translational and rotational entropy of the binding process should be
considered. Alternatively, quantum mechanics or mixed approaches might be adapted.
Nonetheless, the scoring methods are usually sufficient to rank the small molecules according to
their simplified predicted energies.35
I.2.2

Ligand-based approaches: Quantitative structure-activity relationships (QSAR)
Although it is reasonable to think of the protein’s 3D structure as a straightforward way

to get information about the ligand-binding process, this technique comes to the sheer
complexity of multi-factorial drawbacks. These are related to the X-ray crystal structure itself,
the nature of the target protein or to the interactive binding process. For instance, some of the
major problems of crystallographic structures are their explicit waters, their resolution and other
artifacts related to the crystallization process. Hence, the computational chemist should decide
which waters to keep and which ones to discard.
Moreover, the inherent limitation of their resolution makes them blind to the hydrogen
atoms. Then, it becomes problematic to decide if the ionizable groups inside the pocket are in
their ionized form or not. Nevertheless, careful treatment and examination of these drawbacks in
the structure-based approach will increase their rate of success. However, the docking process

10

could become more and more challenging with proteins, having large binding sites or greater
flexibility. Experimentally, proteins could be heterogeneously expressed with different ligands or
they could bind to multiple ligands at the same time. In addition, some of them have multiple
isoforms, which mostly will create selectivity challenges.40
In such cases, considering single conformation of the protein, especially in a highly
flexible one, would certainly undermine the dynamic process of a ligand interacting with a
protein. In fact, there are multiple proposed solutions for such problems such as considering
multiple protein structures, the soft docking, or by considering rotamer libraries of the protein
side chains. On the other hand and as we have envisaged in this research with regards to the
critical targets, combining an orthogonal approach along with the above mentioned would
increase the true positives and decrease the false positives rates.36, 41
The ligand-based approaches provide an alternative solution to reach out for the best
understanding of ligand-target interactions in the absence of the experimental structure of a
protein or in the case of a challenging protein. Even though both approaches are divergent, they
serve the same role of finding a true binder. The building blocks of ligand-based approaches are
the QSAR and pharmacophore models. Emanating from the concept that actives should share
common features or physicochemical properties that would yield similar bioactivity.
Furthermore, better solutions (potent ligands) could be found in the neighborhood of good
solutions (actives). Thus, a QSAR model is simply the mathematical representation that discerns
and correlates the best physicochemical properties or “the descriptors” that can explain the
affinity of ligands toward a biological target.
The first step in this method is data mining. The availability of diverse and reliable
experimental data is a fundamental step in this method. After which, energy minimization and
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calculation of diverse structural and physicochemical descriptors should take place.
Consecutively, the researcher should find the best combination of descriptors that can explain the
variation in the biological activity followed by the statistical examination of the model power in
predicting the activity of an external testing set. This approach uses 2D and 3D information
embedded in the ligands. For instance, it could be coupled to a pharmacophore model which can
enrich the 3D conceptual match of how active molecules could bind to their targets. A
pharmacophore is defined as “the 3D spatial orientation of various features, such as hydrogen
bond donors or acceptors, which are essential for the desired biological activity”.40, 42
There are two general classes for the derivatization of structure-activity relationships, the
linear and the nonlinear methods. In fact, there is no method superior upon the other; it is more
related to the researcher choice and preference. Linear methods include multiple linear
regression and partial least squares while the non-linear includes mainly the support vector
machines and artificial neural networks.
I.3

Cheminformatic approaches to understanding the efficacy and safety of herbal
remedies - Licorice plant as a proof of concept
The licorice plant is among the most popular medicinal plants that are marketed in the

U.S. to alleviate multiple ailments, including cough, asthma and menopausal complaints, etc. In
addition, it is recognized as one of the most studied herbs in the contemporary alternative
medicine. Nevertheless, significant research gaps are still found. For instance, there is no definite
explanation or even an appropriate recommendation of either its efficacy or safety. This includes
its use as an alternative medicine for hormone replacement therapy, and as a chemopreventive
agent, or adjuvant therapy in cancer treatments.17, 25In addition, consumed licorice supplements
are prepared from different mixed species. Every species has its distinctive chemical profile,
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which will yield a diverse spectrum of biological effects. This situation warrants the use of more
sophisticated methods to empower and delineate activity endpoint detection in clinical trials or to
detect pharmacokinetic liabilities as well.
I.3.1

Licorice plant origin and medicinal use
Licorice plant was recognized as a medicinal plant since the genesis of early civilization.

The use of licorice is predated to the ancient Assyrians, Chinese and Egyptians and documented
as a folk remedy in both Greek and Roman empires. The name Glycyrrhiza is a combination of
two Greek words, which means the sweet (glycos) root (rhiza). In addition to its healing
properties and as the name indicates this plant has been used as a sweetener, which was usually
mixed with other bitter therapeutic herbs. This herbaceous, perennial herb is native to the
Mediterranean region but it is also found in other parts of the world such as China, Russia, and
India. The Glycyrrhiza genus belong to the family Fabaceae and consist of more than 28 species.
However, three clinically relevant species are employed in the pharmacopeias namely
Glycyrrhiza glabra L., Glycyrrhiza uralensis Fisch. and Glycyrrhiza inflata Batal.
The roots and rhizomes are the most widely used parts in both industry and therapeutic
settings.43 Traditionally, the roots are used to treat cough, diabetes, stomachache, ulcers, and
tuberculosis. In addition to the fresh leaves were used to treat wounds. In the past few decades, a
variety of pharmacological activities have been described for licorice or its secondary
metabolites such as antioxidant, anti-inflammatory, antitussive and expectorant, antimicrobial,
antiviral, anti-carcinogenic, neuroprotective, estrogenic and antidepressant. The astonishing
diverse spectrum of activities is not surprising since more than 400 compounds have been
isolated from different species of Glycyrrhiza.44-45

13

I.3.2

The licorice secondary metabolome: a vast interspecies diversity
The secondary metabolites of medicinal herbs comprise a large reservoir of bioactive or

toxic compounds.11 Generally, a substantial group of compounds might be shared between
closely related species. However, their abundances would not be the same. In addition, different
species usually express species-specific or marker compounds.46 As a result, a variation in
therapeutic effect is expected when different species are used. In fact, it is of great importance to
address the dissimilarities between plant species to assure safe and efficacious delivery of their
therapeutic effects.
Licorice species are among the richest and diverse plants in terms of secondary
metabolites, producing triterpene saponins and a variety of phenolic compounds such as flavons,
flavonols, isoflavones, isoflavenes, coumarines, and chalcones, and others.47-48 Multiple species
are, usually, mixed and used without discrimination in the preparation of licorice based herbal
supplements. For instance, G. uralensis, G. glabra, and G. inflata are used in Europe and China
interchangeably as licorice. Whereas, in the United States and Japan only G. uralensis and G.
glabra are used. The identity of the constituents is directly correlated to the efficacy or safety of
the supplement, which emphasizes the significance of understanding the secondary metabolite in
each species, the correct labeling of the herbal supplements and the standardization of the
botanical to their active components rather than to their marker compounds. Fortunately, the
licorice metabolome has been vigorously investigated by both targeted and untargeted
analysis.46-47, 49-53 One recent study, analyzed 95 plant samples of the three species of licorice (G.
uralensis, G. glabra, and G. inflata) and targeted 151 pure compounds known for licorice, has
identified 12 and 13 species-specific marker compounds in both G. uralensis and G. glabra.54 In
addition, they have deduced characteristic biosynthetic pathways in each kind. Based on their
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findings, the 3-aryl-5-methoxyl coumarins, the isoprenyl isoflavanes and the 2’-H chalcones
were expressed discriminatively in G. uralensis, G. glabra, and G. inflata respectively. This
interspecies diversity can remarkably affect the intended medicinal use (Figures 3 and 4).54

Figure 3. Species-specific chemical markers of G. glabra
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Figure 4. Species-specific chemical markers of G. uralensis
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I.3.3

Licorice plant for woman health
There is a growing tendency among women to consume botanical supplements for a

variety of reasons.17 This trend is predominant in older women for the chemoprevention or the
relief of postmenopausal symptoms such as vaginal atrophy, hot flashes, bone loss, and
cardiovascular and metabolic functional changes. Popular opinion drifted to natural sources after
the findings that pharmaceutical hormone replacement therapy (HRT), represented by estrogen
pills or the available selective estrogen receptor modulators, may induce or exacerbate already
existing uterine or breast cancer.55 Moreover, several other studies encouraged the use of
botanicals for their chemopreventive properties or protective effects against osteoporosis.
However, none of these herbal treatments was carefully studied for their safety.17, 56-58
Glycyrrhiza is commonly encountered in herbal supplements intended for
postmenopausal symptoms relief in the United States. Many studies detected the estrogenic
behavior of the clinically relevant licorice plant as well as for other defined phenolics isolated
from them.17, 55, 59-63 In one recent study, G. inflata was shown to have the maximum efficacy for
hERα activity in Ishikawa cells followed by G. uralensis and G. glabra respectively. On the
other hand, G. uralensis was ranked first for the maximum efficacy toward hERβ followed by G.
inflata and G. glabra.62
Liquiritigenin, a ubiquitous and major component in different licorice species was shown
to produce weak estrogenic activity. However, several other compounds were also characterized
by mixed estrogenic and anti-estrogenic behavior. Apparently, the estrogenic behavior of these
species is a blend of multiple factors and can be traced back to many compounds that show a
diverse estrogenic selectivity and functionality.55
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A direct comparison between these species is intricate. Nevertheless, rigorous
identification of these compounds is critical and further evaluation of their long term interaction
with the estrogenic receptors is required in order to guarantee the safety of their use.
I.4

Overall aims
The grand challenges in botanical research starting from efficacy issues (how effective

are extracts, marker compounds, and potent active constituents?) or safety issues (off-target
effects, toxicity, HDIs, and other adverse effects) warrant the implementation of new strategies
such as physiologically-based models and informatics. The analysis of multicomponent herbs
using cheminformatics logic may be one of the effective, innovative tools that could be used. An
approach that includes identification of active component(s) with computational tools, validation
with cell-based methods will facilitate the identification of component(s) that could explain the
activity of the botanical drugs. Such an approach could lead to a method to provide a mass
comparison between multiple plant species.
In view of the above discussion, we have envisaged that licorice plant would serve as the
perfect demonstration in how to deal with a botanical issue of different levels or multiplicities. In
this research, we have investigated the utility of cheminformatics methodologies as new
strategies to identify the pool of the possible chemicals that could be attributed for certain
activities or safety issues related to a plant species.
1. Deconvolution of Estrogenic Potential of PhytoSERMs in Licorice (Chapter II)
2. Synthesis of Unique Chemical Entities and their Estrogenic Activities (Chapter III)
3. Activation of PXR by Licorice Compounds (Chapter IV)
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Scheme 1. General representation of the proposed research methodology
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CHAPTER II
DECONVOLUTION OF ESTROGENIC POTENTIAL OF
PhytoSERMs IN LICORICE
II.1 Introduction
II.1.1 PhytoSERMS: Chemoprevention vs endocrine disruption
The recent term of “PhytoSERMs” came after two consecutive serendipities. The first
one was the red clover disease, which was reported in the 1940s. Remarkably, a “botanical”
estrogenic behavior was inferred from the observed infertility of the sheep grazed on grasslands
that had the red clover.57 The second one was the discovery of tamoxifen in the 1960s, upon
which the concept of “SERM behavior” was born. Tamoxifen had transformed from a failed
contraceptive to the gold standard of the targeted chemotherapy of breast cancer in that era.56
The estrogenic behavior of tamoxifen was puzzling; it showed different agonistic/antagonistic
behaviors depending on the analyzed specific tissue. It has triggered antagonism and agonism in
the breast and bone tissue respectively.64 The main underlying mechanisms behind this nonclassical activity involved the presence or absence of certain coactivators/corepressors proteins
as well as the abundance of specific estrogen receptor isoform in the targeted tissue.56, 65
In fact, SERM tissue selectivity serves a multi-targeted therapy by antagonizing the
estrogen-driven carcinogenesis in the breast tissue, while at the same time mimicking and
maintaining the beneficial bone health. However, large-scale studies showed later that tamoxifen
and other synthetic SERMs have detrimental effects on the uterine and endometrial tissues,
which might lead to carcinogenesis. Consequently, to solve this estrogen paradox, the search for
20

alternatives SERMs with improved profiles was commenced. Finding novel SERMS with
unique downstream expression events is extremely important, especially for the genes distinctly
regulated by unique estrogen isoform.66-67
Over time, phytoestrogens were recognized as a vital source of natural estrogens and
multiple studies have verified their SERM behavior. Many of the first generation phytoestrogens
belong to the isoflavonoids and flavonoids classes, but other structural types such as lignans,
coumestans, and stilbenes or their prenylated congeners share the same properties.56 The
significance of these phytoSERMS has grown immediately after the epidemiological studies
among the Asian women. These studies found an interesting correlation between the
phytoestrogen-rich diets and the diminished incidence of breast cancer as compared to the typical
western women (These events have encouraged the western community to consume isoflavonerich diets in addition to other nutraceuticals prepared for this purpose (Figure 5).68 Presently, the
debate about the efficacy and safety of these trends is still going on. The clinical studies
conducted were controversial and most likely they were designed only for short spans.69-70

100,000

American

Asian

Breast

Prostate

Breast

Prostate

96

95

29.1

9.4

Figure 5. Comparison of the incidence of breast and prostate cancer
among the Asian and American people.

21

A recent study has shown that isoflavones -like genistein- are capable of inducing
proliferation in cancer cells by altering the NFkβ (nuclear factor kappa-light-chain-enhancer of
activated B cells) and AKT (Protein Kinase B) pathways in addition to hERs. This study
revealed that they are capable of upregulating the gene expression associated with tumor
proliferation via hERs.71 Conversely, many other studies concluded appealing results, where they
recommended their use in both pre and post-menopausal women.68, 72 Taken together, there has
been a steady conceptual buildup that phytoSERMs have the potential to act as chemopreventive
agents, or as an estrogen surrogate to relief the vasomotor complications and to avoid
osteoporosis.73
Since then, the targeted population has free access to these phytoSERMs nutraceuticals
and herbal preparations without any rigorous attention. This situation has undermined the safety
of these products, where they might behave as endocrine disruptors. In addition, it underscores
the potential harms of transforming these products from regular diets to every day pills. It
ignores the fact that these products are mixtures of chemicals with high capability of
manipulating the estrogenic receptors and their various gene expression responses. Actually, the
short-term and small-sized studies are incompetent to rule out any possibilities. Moreover,
although the FDA divines the potentials of these therapies, it recommends people and special
population to take some precautions when consuming such products.74 On the other hand, these
botanicals are considered as reservoirs of estrogens or estrogenic scaffolds each with a unique
matrix of tissue, coregulator, gene, and isoform selectivity. A demanding requisite here is the
detailed investigation of these components to unravel their potentials or harm spectrums.
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II.1.2 The Human Estrogen Receptors
The first step to capture novel phytoSERMs from botanicals, which will aid in designing
better SERMs, is to understand their mechanism of action. The estrogenic receptors belong to the
nuclear receptor family, which are described as gene transcription regulators. Estradiol is the
native ligand, which is responsible for triggering a cascade of gene transcriptional events that
control the growth, proliferation, differentiation and the function of different tissues.75 There are
two isoforms of estrogen receptors (hERα and hERβ); both are widely distributed in our bodies
and both can be stimulated by estradiol. Higher hERα ratios found in the breast, ovarian,
endometrial and hypothalamus tissues. On the other hand, higher hERβ ratios are found in the
heart, kidney, lung, bone, brain, prostate, intestine and endothelial tissues.56, 75-76
Additionally, unique tissues selectively express the specific type or concentration of
coregulator proteins, which could act as coactivators or corepressors. hERβ has been shown to
exert regulatory functions over hERα, while at the same time, they are both triggered by estradiol
and share many target genes, indicating high similarity.76-77 Similar to other nuclear receptors, it
consists of five main domains but the most important ones in terms of transcriptional activity are
the N-terminal (DNA-binding Domain, DBD) and the C-terminal domain (ligand-binding
domain, LBD).
The LBD consists of 12 helices (H) and 4 β sheets, where the core layer that is in direct
contact with the ligand is formed by H5, H6, H9, and H10. Three polar residues are established
for receptor activation, in one side E353 (305 in hER β) and R394 (R346) and on the other side
H524 (475). Generally, to fulfill the best H-bond network required for activation, the ligand
should have a hydrophobic scaffold flanked with two polar sides separated by 11 Å. The amino
acids lining the LBD of both hERs isoforms are almost identical except for two residues.77-81
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Only two residues among those that line the binding pocket are found to be different: L384
(hERα) vs. M336 (hERβ) and M421 (hERα) vs. I373 (hERβ).82-83
Interestingly, ligands, which interacts with hERs, can direct the function of these
receptors toward their active or inactive states. Previous experimental data correlated the
conformation of the LBD of hER crystal structures to the ligand-induced activity. They can
modulate the flexible helix H12 (one part of the active functional region 2 (AF-2) in the LBD),
which allows variant conformations to take place as shown in Figure 6. Of note, the agonist,
partial agonist and the antagonist conformations which will determine whether or not and which
type of coregulator (coactivator or corepressor) might be hosted in the hydrophobic groove found
in the AF-2.75
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Figure 6. (Upper right) Open conformation of hER in brown cartoon (PDB: 2P15)
with helix 12 in maroon. (Bottom left) Open conformation of hER in grey cartoon
(PDB: 1L2J) with helix 12 in light pink. (Upper right) Helix 11 flexibility as shown
by different orientations of the key residue histidine H524 (475). (Bottom right) Open
and closed conformations overlaid.
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II.1.3 Available cheminformatic information for the prediction of estrogenicity.
Since the discovery of hERs in the 1960s up to date, the estrogenic behavior of synthetic
and natural compounds became a hot topic in the scientific arena. This has been further
aggravated by the emergence of the endocrine disruptors.84 Essentially, the world has witnessed
an increasing number of exogenous chemicals that can interfere with the human endocrine
system and induce adverse effects.
This group of heterogeneous compounds includes many pesticides, herbicides, and fuel
combustion by-products. This high burden of thousands of chemicals emerging has created a gap
that exceeds the capacities of the regulatory agencies and the industrial sectors to follow and to
evaluate their endpoint toxicities. Hence, to address this issue, the incorporation of multiple in
silico and cheminformatic-based techniques have been created for the prediction of estrogenicity
as well as other toxicity endpoints.85-87
Among the list, there are two commercially available models viz., ADMET Predictor™
and MetaDrug™, and other open access sources viz., the free docking software the Endocrine
Disruptome.88-90 Other free QSAR-based models are VEGA (Virtual models for property
Evaluation of chemicals within a Global Architecture)91 and OCHEM (Online Chemical
Environment).92 The first two models were generated from the same data set; the DSSTox
database (Distributed Structure-Searchable Toxicity).93 In addition, they both offer a qualitative
and a quantitative assessment for the estrogenic activity built by QSAR models of nonlinear
analysis such as ensemble neural networks or recursive partitioning algorithms, respectively. The
OCHEM model was generated using a different dataset; the CERAPP database (Collaborative
Estrogen Receptor Activity Prediction) which involved a diverse set of estrogenic activity
endpoints that could not be modeled using regular linear methods.94 Instead, they have applied a
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network modeling with two-dimensional hierarchical clustering to get a consensus decision for
their assessment, which provides both qualitative and quantitative measures. The VEGA model
is only a classification model, which has applied the CART algorithm (Classification and
regression tree) on a data set published from the Japanese Ministry of Economy, Trade, and
Industry database.
The last free tool is the Endocrine Disruptome, which offers a structure-based solution
rather than a QSAR based analysis. This tool provides a free platform for the assessment of
potential activity toward fourteen nuclear receptors including the estrogenic receptors. It is a
classification model that provides the illustration of the docking protocols and the data sets used
for building the model, in addition to the sensitivity thresholds that would be applied for
identification.85
One recent study has compared the performance of these five tools against the CERAPP
database. As expected, the performance of OCHEM was the best since it has been trained with
the same data set. However, the predictability of all models was described as convenient for
selecting high priority chemicals that could alter the ERs. Even though they have shown low
sensitivity (ratio of the true positive rate ~ 0.50), a higher specificity (ratio of the true negative
rate ~ 0.80) was accomplished. The reason being that they were trained using imbalanced
training sets that have incorporated more inactives. However, the addition of applicability
domains would enhance the reliability and appropriateness of use according to the chemical
structure similarity to the training set. The study concluded that these models would have more
power to identify inactives and the combination of multiple models will be more advantageous to
enhance the true positives rates.85
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II.1.4 Ensemble docking technique
Docking and virtual screening are increasingly engaged in multiple processes of drug
discovery, design and development. To speed up the docking processes, the flexibility of the
protein is overlooked or partially considered.36 However, the proteins are intrinsically dynamic
structures that experience perturbations between high and low energy levels expressed as
multiple conformations.
Apparently, in this environment, the ligand-binding event itself could not be explained by
the key and lock model anymore; instead, a conformational selection or induced fit model will
take place. In fact, overlooking a profound characteristic as protein flexibility will definitely
compromise the predictability of the 3D model under consideration. On the other hand,
implementing these properties will sensitize the performance of the model and permit the
exploration of novel chemospheres for potential target-ligand pairs. The applicability of these
models exceed the classic task of hit identification; it has open the doors to explore toxicity,
selectivity profiling, target fishing, polypharmacology and drug repurposing.95
To overcome the limitations of rigid docking, multiple receptor docking or “ensemble
docking” has been proposed. An experimental sampling of protein-ligand complexes will track
back true active or inactive snapshots among the infinite number of possible protein
conformations.96 Furthermore, molecular dynamics offer another source of probable relevant
conformations.97
One addition in this area is the “Pocketome” search engine. This engine is a collection
(3313 entries in the last update in 2018) of conformational ensembles of druggable protein
pockets for major biologicals targets pathways such as kinases, nuclear receptors family,
CYP340 family, G-protein coupled receptor 1 family, etc. Treatment of protein flexibility within
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the context of conformational ensembles has proven effective.23 In one benchmarking study, the
applicability of the conformational ensembles libraries for virtual screening was investigated by
utilizing thirteen nuclear receptors (66 structures) and a focused library of known nuclear
receptors modulators (157 structures).98 The selectivity of active ligands was found to be high,
where the area under the receiver operating characteristic curve (ROC curves) averaged to 85%
and peaked to 99%. Compared to single receptor mode, there were major improvements in
specific cases such as the estrogen receptors or at least keeping a high-level of detection.
Specifically, the ensemble docking mode has increased the docking accuracy from 78% to 89%
as measured by the selection of the near-native pose as one of the top three (out of a list of scored
and ranked poses). This study concluded that the application of the ensemble strategy would
enhance the performance of docking and virtual screening by careful selection of a limited
number of distinctive conformations.98
For the assessment of licorice compounds for their estrogenic potential, we have
incorporated the docking technique, which was elaborated with the ensemble of available
receptors of both ER isoform. Additionally, we have investigated the commercially available
QSAR model “estro-model” that is found in (ADMET Predictor™) to empower the performance
of our predictions.
II.1.5 PhytoSERMs in licorice: A case study
Licorice (Radix Glycyrrhizae) is one of the herbs endowed with estrogenic character.
Indeed, it is increasingly used both as a natural substitute for endogenous estrogens in case of
menopause or as a chemopreventive agent.17 However, licorice extract is derived from various
species of Glycyrrhiza. Yet, most often, the identity of the botanical material in the licorice
herbal product is not well characterized. The most common variety of licorice is Glycyrrhiza
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glabra, commercially cultivated throughout the US and Europe, but other varieties are often used
in various regions, such as G. glabra var. glandulifera (Russian and southwestern Asian), G.
echinata (Russian licorice) and G. uralensis Fisch. Ex DC. (Chinese licorice/Manchurian
licorice).49 In addition to the presence of species-specific secondary metabolites, different
licorice species demonstrate a wide spectrum of chemovariation. Metabolic profiling of multiple
licorice species has shown widely heterogeneous chemical profiles. These distinct chemical
patterns are expected to elicit variable biological responses. To date, more than 20 triterpenoids
and 300 flavonoids have been isolated from different Glycyrrhiza species.46, 52-53, 99
A common phytoestrogen to all licorice species is liquiritigenin, which displays weak
estrogenic activity with moderate selectivity for hERβ.55 Previous studies have shown
significantly higher concentrations of liquiritigenin and its analogs; liquiritin or isoliquiritin in G.
uralensis as compared to those found in G. glabra or G. inflata.63 Species-specific compounds
are also identified, such as glycycoumarin in G. uralensis, glabridin in G. glabra, and
licochalcone A in G. inflata.100 To elucidate the estrogenic behavior of these plant species, many
researchers compared their efficacy for stimulating an estrogenic response in cell-based assays.
One recent study showed that the estrogenic activity decreased in the order G. uralensis > G.
inflata > G. glabra with a higher preference toward hERβ.62, 101
This study and several previous ones encouraged researchers to carry out the bioactivityguided fractionation to identify the compounds responsible for this estrogenic activity. Besides
liquiritigenin, researchers identified other phytoestrogens in licorice such as (glabridin, glabrene,
vestitol, calycosin, methoxychalcone, vestitol, glyasperin C, glycycoumarin, and glicoricone)
demonstrating the estrogenic activity with moderate ERβ selectivity (Figure 7). Screening the
estrogenic activity of the latter compounds via transcriptional assays in breast cell lines (MCF-7)
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and liver cancer cell lines showed a unique mixed agonist/antagonist character for each
compound in different tissue/target gene subsets, indicating a selective estrogen receptor
modulating (SERM) behavior toward hERs.55, 59, 102
However, there is enough evidence in the literature that crude plant extracts have greater
estrogenic activity compared to the isolated constituents at an equivalent dose. In many cases,
there is evidence of synergy including pharmacodynamics interactions, but the exact mechanisms
have not been elucidated. Several mechanisms may also be operating in parallel.55 Generally,
phytoestrogens are estrogen mimics capable of interacting with the estrogenic receptors (hERα
and hERβ) but in a discriminative fashion. They were shown to be hERβ selective in multiple
levels of action including binding affinity, co-regulators recruitment, and gene transcription. The
licorice SERM activity can be explained by the distinct ability of its components to stabilize the
different conformation of hERs, which will preferentially recruit different types of
coregulators.101
Nevertheless, none of the individual identified components matches the activity of the
extract. From the above discussion, it is clear that only a few licorice components were tested for
their estrogenic behavior mostly due to their minor presence in the fractions. Likewise, they
might have different unique phytoSERMS profiles and they could be involved in the observed
activity. The aim of this study was to dissect the estrogenic behavior of licorice components by
the application of comparative ensemble docking study. Hence, validating an exciting
methodology to identify active compounds in complex mixtures and to understand the
mechanism of action behind an herbal remedy.
By the application of such a method, we anticipate circumventing some of the
shortcomings accompanied by the classic bioactivity-guided fractionation. Particularly, when the
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tested fraction includes multiple compounds with potential paradoxical estrogenic effects or in
the opposite scenario where you have the additive effect of multiple weakly active components.
Furthermore, selecting the right measures of certain activity for screening would certainly
influence the results. For instance, if the screening assay seeks activation of certain function
controlled by ER that means it is incompetent to detect antagonists.
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Figure 7. Selected universal known phytoestrogens from licorice and other botanical sources.
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Alternatively, the application of new techniques of cheminformatics will shed light onto
new phytoestrogens with unique profiles that would not be detected by the classic methods. To
demonstrate the utility of ensemble docking for the deconvolution of active compounds in a
complex mixture, two species of commonly used licorice, Glycyrrhiza glabra and Glycyrrhiza
uralensis, were selected. Using several computational tools along with crystal structures of two
isoforms of human Estrogen Receptors (hERs), phytochemicals from Glycyrrhiza were probed
for their isoform preference along with their putative functionality as agonists/antagonists of
estrogen receptors.
II.2 Results
II.2.1 Ensemble docking
II.2.1.1 Validation
Initially, we have explored the binding site of six distinct hER conformations using
sitemap calculation in order to evaluate their diverse characteristics as shown in Table SI 1,
Figure 8, and Figure 9. In general, the pocket of hER receptors is highly hydrophobic with few
polar residues at the sides of the binding site. Obviously, the active (closed) and the inactive
(open) conformations of hERs differ widely in the total surface area. This is modulated by H12
perturbation when it binds to an antagonist or a SERM, which will result in releasing one side of
the binding site. One exception is 2P15 that has a large total surface area but it is still active,
indicating that hERα can accommodate larger hydrophobic compounds by adopting a unique
conformation. On the other hand, hERβ in its active form (4J24) exhibited the least surface area
indicating its preference for smaller ligands. Next, we have considered an internal and external
validation test as a measure of the accuracy of the docking procedure. The Glide SP docking
protocol was reliable enough to reproduce the poses of the co-crystallized ligands with low
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RMSD values. We also found that the ensemble docking approach was able to correctly pick the
parent crystal structure for each native ligand as shown in Table SI 2. Regarding the focused
library of known estrogenic compounds, the SP docking scores and the isoform preference are
compared to the results of their actual experimental data as summarized in Table 2. Ten out of
twenty listed compounds are licorice components that have been already tested toward hERs. We
found that the active compounds score below −10 kcal/mol generally. This protocol had 85%
efficiency in the functional selectivity task (ER (+) for agonist vs ER (−) for the antagonist), but
it had lower efficiency in isoform selectivity (65%). In fact, this is expected since it is already
established that ER selectivity is hard to gain because of the high similarity between the two
isoforms.

Figure 8. Co-crystallized ligands in the crystal structures used for the ensemble docking.
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ER (+)
ER (+)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
ER (+)
ER (−)
ER (−)
ER (−)
ER (−)
ER (−)
−9.81
*
−11.37
−11.92
−10.55
−10.51
−10.33
−10.50
−10.23
−10.19
−11.15
−10.23
−10.68
−10.92
−10.34
−9.04
−9.40
−9.76
−9.67
−10.85

h ER (+)
−10.91
−14.44
*
−11.17
−10.06
−9.98
−9.86
−9.93
−9.12
−9.94
−10.98
−9.58
−9.37
−10.72
−11.04
−8.87
*
−8.94
−10.8
−9.50

Predicted
Selectivity
α
α
α
β
β
β
β
β
β
β
β
β
β
β
α
β
β
β
α
β

h ERβ SP
Score
−10.81
*
*
−11.92
−10.55
−10.51
−10.33
−10.50
−10.23
−10.19
−11.15
−10.23
−10.68
−10.92
−10.34
−9.04
−9.40
−9.76
−9.67
−10.85

h ERα SP
Score
−10.91
−14.44
−11.37
−11.17
−10.06
−9.98
−9.86
−9.93
−8.94
−9.94
−10.98
−9.29
−9.09
−10.72
−11.04
−8.87
−7.70
−8.94
−10.8
−9.50

h ERβ
Pharmacology
ago
ago
Ant
Ant
m
m
ago
ago
ago
*
ago
m
m
m
Ant
m
Ant
m
NA
NA

h ERα
pharmacology
ago
ago
Ant
ago
m
m
ago
ago
ago
*
ago
m
m
m
Ant
m
Ant
m
Ant
Ant

Prefered ER
α
α
β
β
β
β
β
β
β
*
α
β
β
NA
β
α
β
β
β
β

Selectivity
index
1
NA
1.9
6
324
4
8
93
6.25
*
0.33
13
2.6
NA
2.28
0.6
1.2
2.7
2.4
11.1

RBA
h ERβ
100
NA
339
144
6.8
0.04
1.66
4.3
0.5
*
6.5
0.013
0.013
NA
0.0032
0.039
0.091
0.027
0.019
0.111

RBA
h ERα
100
223
178
23
0.021
0.01
0.2
0.046
0.08
*
19.46
<0.001
0.005
0.22
0.0014
0.062
0.075
0.01
0.008
0.01

Ligand Name.

Estradiol
TFMP-Estradiol
Tamoxifen
R,R-THC
Genistein
Daidzein
Equol
Dehydroequol
Naringenin
6-Prenyl Naringenin
8-Prenyl Naringenin
Liquitrigenin (G10)
Isoliquitrigenin (G125)
Glabrene (38)
Glabrol (G3)
Vestitol (G128)
Glabridin (G35)
Calycosin (G122)
Glicoricone (G127)
Glyasperin C (G175)

Prediction
h ER (−)

Experimental data

Table 2. Experimental affinity (RBA in nM) and isoform selectivity toward both hERα and hERβ for the external testing set
compared to predicted SP docking score in isoform hER (α and β) ensemble and functional hER ensemble (ER (+): agonist
or ER (−): antagonist)

Predicted
Conformation

E353

E353
R394

E353
R394

R394

H524

H524

E305

D351

H524

E305

R346
R346

R346
E305
H475

H475

H475

Figure 9. A) Binding sitemaps of hERs with co-crystallized native ligands ((upper) hERα
PDBs, left: 1GWR, middle: 2P15, right: 3ERT, (lower) hERβ PDBs, left: 4J24, lower middle
1X7J, and lower right 1L2J). Hydrogen-bond acceptor sites are indicated by red color,
hydrogen-bond donor sites are indicated by purple color and hydrophobic sites are indicated by
yellow color. Key residues are shown in green.
II.2.2 Docking of Glycyrrhiza compounds library into the ER ensembles
As described in the Experimental, we were interested in the identification of Glycyrrhiza
compounds that might modulate the estrogenic activity, as we believed that correlation of their
estrogenic activity to a couple of compounds is an oversimplification for the plant estrogenicity.
Hence, a library of 368 compounds reported from both Glycyrrhiza species (glabra and
uralensis) was docked to six hER crystal structures. Apart from the known estrogenic modulators
reported from licorice and evaluated in our validation test, this study has uncovered a larger
group of phenolic compounds (78 structures), which have the same potential and yet has not
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been explored. Firstly, to compare the predicted estrogenic compounds in both species we have
plotted the highest glide score among the whole ensemble of six hERs crystal structures for each
compound against the preferred crystal structure (Figure 10). For Glycyrrhiza glabra, 49
compounds out of 177 scored above 10 and 65% of them preferred hER beta isoform.

Figure 10. Ensemble SP docking scores in kcal/mol for the secondary metabolites of both G.
glabra (triangles) and G. uralensis (circles) against six different crystal structures. For hERα:
1GWR in green, 2P15 in blue and 3ERT in yellow. For hERβ: 1L2J in red, 1X7J in grey and
4J24 in orange
For G. uralensis, 43 of the compounds out of 191 scored below −10 and 63% of them
preferred hERβ crystal structures. Our data suggest the preference of isoform β for both species.
The analysis of such results revealed at least 50 compounds in each species that bear the
potential of interfering with both hERs α and β in different modes of action. Secondly, for the
search of novel phytoSERMS candidates, we also challenged the compounds by following
various methods described in the experimental section. The top twenty compounds along with
their docking results, which are nominated by this model, belong to several classes as
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summarized in Figure 11, Figure 12, and Figure 13.
II.2.3 The qualitative and quantitative estimation of the estrogenic character of licorice
secondary metabolites via Estro-model (QSAR model from ADMET Predictor™
software)
It has been established that the estrogenic activity is one of the complex bimolecular
events that involve multiple levels of small molecule-protein-protein-DNA interaction. However,
this process is sparked by the ligand (the small molecule-protein) interaction. To enhance our
prediction of such an intricate system, we decided to test the licorice components with the
orthogonal ligand-based model provided by ADMET Predictor™. Hence, we fed all the
collected compounds from both species in the estro_filter model to calculate many atomic and
molecular descriptors and eventually gain a consensus vote by the neural network that this model
provides for classification. The compounds, which were selected as estrogenic, have been
submitted to affinity estimation model (the estro_RBA model). The top 20 nominated estrogenic
compound in each species are summarized in Table SI 7. Interestingly, many of the top
compounds were shared in both models indicating a high chance of interference with this nuclear
receptor.
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G86
hERα: −10.79
hERβ (−): −11.35

G138
hERα: −10.54
hERβ (−): −10.74

G38
hERα: −10.72
hERβ (−): −10.92

G28
hERα: −10.43
hERβ (−): −10.54

G112
hERα: −10.40
hERβ (−): −10.34

G3
hERα: −11.04
hERβ (−): −10.34

G40
hERα: −10.83
hERβ (−): −10.43

G174
hERα: −10.84
hERβ (−): −10.64

G156
hERα: −10.38
hERβ (−): −10.34

G106
hERα: −10.54
hERβ (−): −9.31

Figure 11. Top scoring compounds of G. glabra nominated by ensemble docking (structures
highlighted in red are: top scoring compounds which belong to DHS class, identifiers in blue
are those in agreement with top scoring compounds identified by the QSAR model)

40

U77
hERα: −11.045
hERβ (−): −10.474

U16
hERα: −8.866
hERβ (−): −11.35

U22
hERα: −10.263
hERβ (−): −9.862

U15
hERα: −11.487
hERβ (−):−9.652

U191
hERα: −10.841
hERβ (−): −9.011

U78
hERα: −10.194
hERβ (−):−10.061

U25
hERα: −9.918
hERβ: −9.014

U86
hERα: −9.094
hERβ (−): −10.581

U23
hERα: −8.246
hERβ (−):−11.135

U42
hERα: −10.39
hERβ (−): −9.039

Figure 12. Top scoring compounds of G. uralensis nominated by ensemble docking (structures
highlighted in red are: top scoring compounds which belong to DHS class, identifiers in blue
are those in agreement with top scoring compounds identified by the QSAR model)
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1GWR

α-ensemble
3ERT

2p15

1L2J

β-ensemble
1X7J

4j24
0
-9.99
-9.88
-7.43
0
0
0
-11.08
-10.3
0
-10.2
-9.85
-10.1
0
-9.99
0
0
-9.98
-9.63
0

1GWR
-11.88
-8.23
-10.96
0
-8.11
-8.09
0
0
-10.31
-10.28
0
0
-6.75
0
-8.5
-9.94
-9.66
-9.63
0
0

α-ensemble
3ERT
-5.63
-8.11
-8.18
-6.48
-7.42
-7.42
-5.34
-5.98
-5.76
-6.88
-6.78
-6.25
-7.68
-5.69
-3.91
-8.56
-5.23
-7.21
-5.32
-5.31

2p15
-10.33
-11.49
-11.15
-11.05
-10.95
-10.84
-10.66
-10.39
-9.63
-10.01
-10.26
-10.19
-10.12
-10.02
-9.95
-9.92
-9.92
-9.78
-9.76
-9.7

1L2J
-9.89
-9.65
-10.49
-10.47
-9.94
-9.01
-10.3
-8.66
-9.99
-9.9
-9.86
-10.06
-9.73
-10.08
-9.12
-7.96
-8.8
-9.46
-10.47
-8.41

β-ensemble
1X7J
-9.07
0
-8.64
0
-9.51
0
0
-9.04
-9.63
-10.23
0
0
-9.24
0
0
-10.09
-7.77
0
-6.49
0

G6
G50
G38
G174
G40
G47
G127
G163
G138
G106
G108
G33
G21
G28
G112
G176
G156
G30
G171
G154

0
-9.91
-10.35
-8.48
0
0
-8.04
-10.39
-9.81
-8.86
-10.27
-10.45
-10.17
0
-9.84
-10.41
-9.59
-10.37
-10.33
-7.76

0
0
0
-6.55
-6.19
-7.23
0
-8.21
-7.23
-8.26
-5.71
-8.51
-8.45
-8.27
-7.55
-8.34
-8.86
-7.44
-7.38
-6.86

-11.04
-10.95
-10.87
-10.84
-10.83
-10.82
-10.8
-10.79
-10.55
-10.54
-10.53
-10.49
-10.47
-10.43
-10.41
-9.58
-10.38
-10.06
-10.2
-10.32

-10.34
-10.59
-10.52
-10.64
-10.43
-10.3
-9.67
-11.35
-10.01
-9.31
-10.39
-8.94
-9.43
-10.54
-9.72
-10.71
-10.34
-8.99
-9.93
-8.8

0
-10.74
-10.92
-9.47
0
-8.55
0
-10.84
-10.75
0
-10.42
-9.82
-10.4
-8.41
-10.34
0
0
-9.43
-10.88
0

4j24
-10.25
0
-10.23
0
0
0
0
0
-9.3
-10.1
0
0
-9.11
-7.18
-8.84
-9.18
-9.01
-10.08
0
0

U63
U15
U66
U77
U106
U191
U127
U24
U89
U105
U22
U78
U177
U99
U189
U190
U25
U61
U115
U2

G158
G163
G100
G99
G38
171
G60
G170
G138
G50
G75
G176
G125
G174
G111
G28
G2
G40
G108
G144

0
-10.39
-9.7
-9.64
-10.35
-10.33
0
0
-9.81
-9.91
-9.43
-10.41
-9.09
-8.48
-8.33
0
0
0
-10.27
-9.68

-6.51
-8.21
-8.13
-7.06
0
-7.38
0
-7.99
-7.23
0
0
-8.34
-7.34
-6.55
-7.7
-8.27
0
-6.19
-5.71
-8.61

-9.93
-10.79
-9.88
-9.84
-10.87
-10.2
0
-10.3
-10.55
-10.95
-10.08
-9.58
-8.8
-10.84
-10.03
-10.43
-9.84
-10.83
-10.53
-8.83

-11.73
-11.35
-10.42
-11
-10.52
-9.93
-10.83
-10.75
-10.01
-10.59
-9.7
-10.71
-9.17
-10.64
-10.58
-10.54
-10.45
-10.43
-10.39
-9.01

0
-10.84
-11.06
0
-10.92
-10.88
0
-8.46
-10.75
-10.74
-10.74
0
-10.68
-9.47
-8.8
-8.41
0
0
-10.42
-10.42

0
-11.08
-9.61
0
-9.88
-9.63
0
0
-10.3
-9.99
-9.89
0
-9.37
-7.43
0
0
0
0
-10.2
-9.4

0
0
0
0
0
-9.02
0
-9.68
-10.96
0
0
0
0
0
-11.88
-10.28
0
0
0
-9.94

-5.36
-7.45
-7.54
-3.37
-5.1
-5.97
-6.08
-9.44
-8.18
-6.48
-5.32
-6.07
-5.34
-8.17
-5.63
-6.88
-6.18
-7.78
-5.73
-8.56

-8.25
-8.87
-8.9
-9.5
-8.41
-9.18
-9.09
-9.61
-11.15
-11.05
-9.76
-8.7
-10.66
-7.52
-10.33
-10.01
0
-8.83
-7.57
-9.92

-11.14
-11.03
-10.91
-10.85
-10.72
-9.28
-10.58
-9.6
-10.49
-10.47
-10.47
-10.33
-10.3
-10.29
-9.89
-9.9
-10.22
-9.08
-10.15
-7.96

0
0
0
0
0
-10.59
-6.05
-10.49
-8.64
0
-6.49
0
0
0
-9.07
-10.231
0
-10.15
0
-10.09

0
0
0
0
0
-9.69
0
-9.56
-10.23
0
0
0
0
0
-10.25
-10.1
0
-8.98
0
-9.18

U23
U16
U117
U175
U88
U69
U86
U165
U66
U77
U115
U176
U127
U39
U63
U105
U57
U119
U62
U190

Figure 13. Top 20 compounds (white color) by SP docking scores in hERα ensemble
compared to all crystal structures to visualize selectivity (G. glabra: upper left, G. uralensis
upper right). Top 20 compounds by SP docking scores in hERβ ensemble (G. glabra:
lower left, G. uralensis lower right)
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II.2.4 ADMET Metabolite prediction and estrogenic evaluation via QSAR models
The data revealed a small number of bio-activated metabolites (Figure 14). This is
exemplified mostly by O-demethylation and/or hydroxylation processes. This is not surprising
since most of the compounds are oxygenated phenolic structures. Nevertheless, the data suggest
an estrogenic character for the majority of these metabolites. This preliminary investigation
should be complemented with physiologically based pharmacokinetic models and secondary
phase metabolism models to evaluate the effect and time of exposure of each route.
II.3 Discussion:
Licorice (Glycyrrhiza spp.) is well known for its wide spectrum of estrogenic activity,
which presumably adds to the beneficial effects of this plant. Both species of licorice– G. glabra
and G. uralensis are commonly used in the marketed botanical products without any respect to
their soundly different chemical composition. Many studies tried to identify the phytoestrogens
found in these plants. Some compounds, which belong to the classes of flavonoids, isoflavonoids
or chalcones, such as liquiritigenin, vestitol, calycosin and isoliquiritigenin have demonstrated
estrogenic activities. Others, such as glabrene, glabridin, glyasperin C, glabrol, glicoricone,
showed antagonism or partial agonism of estrogenic activities. By contrast, compounds like
hispaglabridin A and hispaglabridin B have no activity to either estrogen receptors. In fact,
licorice plant provides a versatile and powerful SERM toolbox. The advent of ESR1 mutations
that lead to (30-50%) resistance of the available therapies call for an urgent search for novel
hERα partial antagonists or SERMs of highly favorable kinetics profiles.67 Paradoxically, in the
case of highly estrogen-deprived tissue such as in case of exhaustive and long endocrine
treatment of breast cancer or in the case of menopause, recent studies revealed the clinical
efficacy of estradiol as an anticancer or antiproliferative agent through hERα.103
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Open: Metabolites
Red: Bio-activated
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Figure 14. Comparison of ADMET QSAR Predicted RBA for both parent compounds
and their putative metabolites originated from G. uralensis (up) and G. glabra (down)
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As a result, a new-targeted SERM category with hERα partial agonistic effects in cancer
tissue but devoid of proliferative activity elsewhere is highly acquired. In this study, we were
interested in understanding the estrogenic potential of two licorice species by the application of
multiple cheminformatic techniques such as molecular docking and QSAR analysis. In addition,
our attempt sought the validation of these tools as a basic approach for cheminformatic-guided
investigation of herbal remedy. hERs are nuclear receptors that are known for having a flexible
ligand-binding domain. Moreover, the ligand-directed transcriptional activity of hERs is
correlated to the conformation of this particular region of the protein. Careful analysis of the
conformational space of hERs suggests variable degrees of H12 flexibility leading to different
states of open and closed conformation.75, 104
Obviously, this suggests variable geometric and electronic features of the binding site in
each specific conformation. That was evidenced by our analysis of the LBD pockets using
sitemap calculations. To compensate for this flexibility for both hERα and hERβ and to avoid
misleading information guided by one rigid receptor we have considered an ensemble docking
with multiple protein conformations. To avoid any bias in the ensemble docking protocol and to
improve the predictability, the same compounds were also evaluated using a readily available
QSAR model from ADMET Predictor™ software for both qualitative and quantitative estimation
of estrogenic nature.105 In the latter approach, the ‘hits’ which scored above 70% confidence
level in ADMET model were included for comparison and confirmation purposes.
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II.3.1 Validation
Modeling the estrogenic activity of multicomponent systems such as licorice extracts that
are targeting a physiologically versatile target such as hERs is not straightforward.
This situation warrants a careful use of the precise computational methods to address more
complicated protein features such as flexibility. In our modeling, we have considered six hER
protein structures and we have drawn out four ensembles to target both hER isoform selectivity
(α vs β) and conformation preference (active (hER+) vs inactive (hER−)). Cognate ligands were
redocked using flexible SP protocol, which was able to reproduce the binding geometry of each
ligand. By considering the focused library, the application of ensemble docking allowed us to
detect SERM ligands that cannot fit into the agonist conformation but instead they prefer the
inactive conformation. In this manner, Glycyrrhiza compounds such as (glabridine, glabrol,
glicoricone, and glyasperin C) could be detected where they have achieved relatively high scores
(−9.40, −10.34, −9.67, and −10.85 kcal/mol respectively) in at least one of the inactive
conformations
Moreover, our ensemble model showed high recognition of the isotype-selective ligands
by considering the simple SP raw scores. This model could not identify 8-prenyl-naringenin and
vestitol as hERα selective. Maybe this is due to the low selectivity index of these two compounds
(0.5-0.6). On the other hand, all hERβ selective agonists or partial agonists, which show better
selectivity (genistein, daidzein, equol, dehydroequol, liquiritigenin, isoliquiritigenin, calycosin,
and glabrene) and the antagonist (glabridin), were classified correctly as hERβ selective.
Interestingly, both isoform ensembles were able to rank the known phytoestrogens compounds in
agreement with their experimental binding affinities. For instance, previous studies have shown
that 8-prenyl-naringenin is the most estrogenically active phytoestrogen.106
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In addition, hERα agonistic activity declines in the order: 8-prenyl-naringenin>
liquitrigenin> isoliquitrigenin> calycosin> vestitol when tested under identical assay
conditions.55, 63 By considering the docking results in the hERα ensemble, we can notice a very
similar trend. Moreover,
both binding affinity assays; the relative binding affinity (RBA) and efficacy assays; the
concentration at the half maximum efficacy (EC50) toward hERβ showed a higher activity for the
isoflavone genistein (13, 6 nM) followed by dehydroequol (4.3, 7.2nM) > equol (1.66, 74 nM) >
(0.04, 100 nM).107 hERβ ensemble SP scores have also similar ranking. Of note, our docking
algorithm did not yield any favorable docking pose for either hispaglabridin A or hispaglabridin
B, which is in agreement with the previously reported cell-based data.59, 79
II.3.2 Estrogenicity of Glycyrrhiza secondary metabolites via hER ensembles and
estro_filter
Computational tools provide a versatile knowledge about the interactions of small
molecules with their target proteins. For this purpose, we have analyzed 368 known secondary
metabolites in licorice plant against ensemble hER crystal structures of both isoforms. Our model
suggests hERβ selectivity for both G. glabra and G. uralensis extracts, where more than 60% of
the highest scoring compounds (those scored higher than the cut-off −10.0 kcal/mol) preferred
hERβ sites. Interestingly, these results are consistent with the recent analysis, which showed that
both G. glabra and G. uralensis extracts have similar potencies and both preferring hERβ.
The top 20 compounds out of 368 are summarized in Figure 13. The model was able to
identify many known phytoestrogens that are part of licorice in agreement with the reported
literature. Among the top 20 compounds, known compounds were present such as glabrene
(G38) the isoflavene and glycerol (U86) the 6-prenyl coumestrol, which are documented for their
high experimental binding affinity toward hERα (RBA of 0.22 and 0.11 respectively).108 As
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anticipated, most of the top scoring compounds are tethered with at least one prenyl group. This
is due to the hydrophobic nature of the LBD, which will increase the value of the hydrophobic
terms in the SP scoring function.
In fact, the experimental data in the validation set supports this prediction, where we
noticed multiple prenylated compounds (G3, G35, G38, G127, and U175) that show sufficient
RBA to exert hER activity. However, the prenylation of isoflavonoids is known to change their
pharmacology.109 Although they show high affinity for hER receptors in the binding affinity
assay, these compounds show hER inhibition response at least in one specific cell-based assay, a
behavior that suggests a SERM activity. This is true for the monoprenylated isoflavones at 8, 6,
5’ positions found in glabridine (G35), glyasperin C (U175) or glicoricone (G127)
respectively.55 On the other hand, prenylation at 3’ position in flavonoids such as apigenin and
liquiritigenin or a di-prenyl at 3’ and 5’ position such as breviflavone A and B kept their
estrogenic character in the range of other known phytoestrogens.110
However, in our results, we found several compounds, which belong to the
dihydrostilbenoid (DHS) class appended with prenyl groups at various positions, to be an
interesting group of compounds that has not been studied for their estrogenic activities. In
addition, the model suggests that these prenylated DHS are amenable to occupying available
chemical space composed of L346, T347, L354, W383, and L540, hence had the potentials to
tightly interact with hERs. Interestingly, some of the bis-prenylated DHS U15 and U16 have
been reported to be unique to G. uralensis. Not only these compounds scored high (< −11
Kcal/mol), but also the position of the prenylation is predicted to change their selectivity, where
U15 preferred hERα in the active form, while U16 selectively preferred hERβ in the inactive
form (Figure 15 and Figure 16). As shown in the figures, the bad interactions between the
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prenyl group of U16 and H524 in the closed form might be the main reason behind this predicted
selectivity. Both compounds showed interactions with the key amino acids E353, R394, and
H524.
The present computational study revealed interesting features that might be gained with
the introduction of prenyl groups onto the stilbenoid and dihydrostilbenoid scaffold. As
described in the next chapter, we sought to synthesize this representative class of compounds
including various prenylated constitutional isomers to analyze their structure-activityrelationships and their activation against both isoforms of hERs. The number and the position of
the prenyl groups might also influence their estrogenic activity.

49

H475

H524

F356
F404
R346

U16

R394

U15
E353

E305

H475: 1L2J
U15
U16
8-prenyl
Naringenin

H524: 1GWR
and 2P15

Figure 15. (Up left) Docking pose of U16 (yellow ball-and-stick) in the LBD of PDB:ID: 1L2J
(grey cartoon). (Up right) Docking pose of U15 (green ball-and-stick) in the LBD of PDB:ID:
2P15 (grey cartoon) both showing major interactions with key residues (brown tubes). (Bottom
middle) The docking poses of U16 (yellow) and U15 (green) and 8-prenyl-naringenin (grey)
overlaid in PDB structures (1L2J in cyan, 2P15 in orange and 1GWR in light pink), the position
of prenyl group in U15 showing bad interactions with H524 of 2P15 and 1GWR.
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Figure 16. Docking pose of U15 in PDB 2P15 (green ball-and-stick) and U16 in PDB 1L2J
(yellow ball-and-stick) overlaid with the protein crystal structures (up) and showing different
positions of H12 (magenta in 2P15 and pink in 1L2J) (lower left and right).
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II.3.3 In silico evaluation of estrogenic activity for the predicted metabolites
It is now established and supported by literature reports that metabolism changes the
parent compounds to a set of metabolites that might have their own spectrum of bioactivities.111112

A classic example is a phytoestrogen, daidzein. The intestinal microflora converts daidzein

into two different metabolites. One of them is equol, which has stronger estrogenic activity,
while the other one is O-desmethylangolensin, which is devoid of estrogenic activity compared
to the parent compound, daidzein. It is obvious that inactive chemicals that bear a possible
estrogenic metabolite would not be detected in a regular in vitro set up.113 Consequently, it is
significant to pre-screen for metabolite estrogenicity.114 Thus, application of cheminformatic
techniques such as QSAR models should be implemented in any early drug discovery programs.
In the present study, we utilized an integrated in silico approach linking metabolite prediction
with qualitative and quantitative assessment of estrogenic activity of both the parent and the
predicted metabolites.
ADMET Predictor™ provides both qualitative and quantitative models related to
estrogenic activity. Only the compounds classified as estrogenic with “estro_filter” (compounds
with a high likelihood to bind to the estrogenic receptors) were submitted to the second model
“estro_RBA”.105 The endocrine regression models developed to estimate the numerical values of
receptor binding affinity in ADMET Predictor™ were trained using U.S. EPA's Distributed
Structure-Searchable Toxicity (DSSTox) database. Competitive binding assays in rats were used
as the quantitative measures for building the model. As such, running the calculation for the
provided molecule would estimate the degree of binding to the estrogenic receptors expressed as
the relative binding affinity %RBA (100%*(IC50 for 17β-estradiol/IC50 for the query
compound). Higher predicted %RBA value indicates higher affinity. The qualification test of
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estrogenicity using ADMET Predictor™ would provide the output data with confidence
estimation. The output of the metabolite estrogenic character was further filtered according to the
provided confidence ratios. Only those that scored > 70% confidence were further sorted and
ranked for their predicted %RBA.
By carrying out this model using our licorice generated libraries, we found that most of
the selected estrogenic metabolites with a high level of confidence for estrogenicity are coming
from estrogenic parents. While we could not detect a high number of bio-activated compounds,
we learned that phase 1 metabolism is not going to inactivate them.
II.4 Experimental
II.4.1 Datasets
The known secondary metabolites of two licorice species, G. glabra (179 compounds)
and G. uralensis (189 compounds) were retrieved from several scientific databases, such as the
Dictionary of Natural Products (DNP) and several other publications by a text search in
SciFinder Scholar.115 For the external validation, a focused library of twenty compounds was
considered, which included seven known phytoestrogens along with eleven compounds isolated
from Glycyrrhiza that were already tested for their estrogenic activity. In order to validate the
efficiency of incorporating multiple rigid protein crystal structures in our docking procedure, we
have considered a diverse group of SERMS and phytoestrogens in the focused library. In
addition to the co-crystalized ligands, we have considered hERα selective agonists based on their
binding affinity assays (8-prenyl-naringenin, vestitol), or hERβ selective agonists or partial
agonists (genistein, daidzein, equol, dehydroequol, liquiritigenin, isoliquiritigenin and calycosin,
glabrene), or hERβ selective antagonists (glabridine, glabrol, glicoricone and glyasperin C).
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II.4.2 Ligand preparation
The structure libraries were sketched using ChemDraw software and were saved as
spatial data files (SDF) using Chem3D. After which, they were imported by Maestro
(Schrödinger, LLC) for ligand preparation and data curation. Tautomeric and ionization states
were generated at target pH7.4. The chirality of the molecules was determined from the 3D
structure input.
II.4.3 Protein preparation
The following protein crystal structures were downloaded from the RCSB protein
database. For hERα ensemble, we have considered the following structures: the agonist
conformation, estradiol, bound to LBD (PDB:1GWR) 116 , the antagonist conformation or
SERM, 4-OH tamoxifen, bound to LBD (PDB: 3ERT), 77 and the hydrophobic agonist
conformation, ortho-trifluoromethylphenylvinyl estradiol, bound to LBD (PDB: 2P15).80 For
hER beta ensemble, the structures included the agonist conformation, estradiol, bound to LBD
(PDB:4J24) 117, the antagonist conformation, (R,R)-5,11-cis-diethyl-5,6,11,12tetrahydrochrysene-2,8-diol, bound to LBD (PDB: 1l2J), 118 and the partial agonist conformation,
genistein bound to LBD represented by (PDB: 1X7J)119. For each protein crystal structure, only
one monomeric form was kept and prepared by the protein preparation wizard in Maestro.
Hydrogen atoms were added after deleting the original ones. The protein was checked for
missing residues and loop segments that were added using Prime. Water molecules with no
hydrogen bond were removed. The protonation state and tautomeric state of protic amino acids
were adjusted to match a pH 7.4. Possible orientations of side chains were generated and
checked in the binding site to match the reported protein-ligand interaction. Finally, the proteinligand complex was subjected to geometry refinement for hydrogens only, using an OPLS2005
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force field. 120
II.4.4 Sitemap protein binding site analysis
The PDB crystal structures were further studied using sitemap module in Maestro to
explore the surface-type characteristic of each LBD.120 Through the protein analysis panel, the
evaluation of a single binding site region was selected to encompass the native ligand in each
crystal structure plus 3Å buffer. The binding site examination was set to require at least 15 points
with the application of a more restrictive definition of the hydrophobicity and utilizing a standard
grid.
II.4.5 Ensemble Docking
For each crystal structure, the grid was calculated using Glide, (Maestro, 10.3.015;
Schrodinger).120 The binding site of each grid was defined by the native ligand with no
constraints. The prepared ligands of both species were docked flexibly into the six generated
grids of the rigid protein of the ensemble with the help of the virtual screening workflow in
Maestro. For each compound, only one docking pose was kept against each crystal structure and
scored by Glide SP (standard precision) score. Out of six protein structures, we have mainly
considered two ensembles. The first ensemble inclined for active conformation (1GWR, 2P15,
and 4J24) or inactive conformation (3ERT, 1X7J, and 1L2J). The highest docking score was
considered to assign the preferred conformation in each ensemble. The second ensemble inclined
for isoform selectivity. For each compound, only the highest score was kept for each isoform to
determine the preferred isoform. To identify the best binders in each species we reviewed the key
interactions known for activity and we have computed the simulated binding energy for the top
20 scoring compounds in each isoform ensemble by the molecular mechanics − generalized born
surface area model (MM-GBSA). Forty compounds for each species were ranked upon their
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MM-GBSA energy allowing the challenge of isoform selectivity to take place. Of note, the top
30 compounds were kept for each species (Table SI 5 and SI 6). Similarly, the top 20
compounds ranked by the predicted RBA values are shown in (Table SI 7).
II.4.6 Metabolite prediction and estimation of estrogenic activity via Estro-model
A commercially available software, ADMET Predictor™ 9.0 (Simulations Plus Inc.),
provides a friendly interface with a robust prediction environment. Molecular descriptor values
are calculated and used to generate independent mathematical models by application of nonlinear
machine learning techniques.105 The built-in trained QSAR models allow the prediction of
metabolic oxidation sites mediated by various CYP enzymes. In this work, a pool of primary
putative metabolites based on nine cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP3A4, CYP2A6, CYP2B6, CYP2C8, and CYP2E1) were generated. To launch the
metabolite generation in this QSAR package, compounds from licorice were imported as the
basic 2D SMILES (simplified molecular-input line-entry system) notations.
Curation of the data included removal of duplicate structures to get the unique
compounds for each species as well as sugar hydrolysis using the MedChem Designer module.
As such, the number of compounds from G. glabra and G. uralensis were refined to 146 and 158
respectively. Upon execution of the program with the above parameters, a total of 601 and 708
metabolites were generated for both glabra and uralensis, respectively. The generated
metabolites were used as input for estrogenic activity prediction to analyze the importance of
bio-activation as well as for comparison between the two species. ADMET Predictor™ provides
both qualitative and quantitative models related to estrogenic activity.
Only the compounds classified as estrogenic with “estro_filter” (compounds with a high
likelihood to bind to estrogenic receptors) were submitted to the second model “estro_RBA”.
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Consequently, the output of the metabolite estrogenic character was further filtered according to
the provided confidence ratios. Only those that scored > 80% confidence were further sorted and
ranked for the %RBA.
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CHAPTER III
SYNTHESIS OF UNIQUE CHEMICAL ENTITIES
AND THEIR ESTROGENIC ACTIVITIES
III.1 Introduction
The previous in silico study of licorice against hERs, selected prenylated stilbenoids and
DHS as potential components capable to interact differentially with the estrogenic receptors. In
fact, plant secondary metabolites tethered with isoprenoids appendages provide an immensely
rich diversity of biological activities that captured the interest of many scientific communities.121123

The vast number of research papers on the chemistry and the biology of many compounds

have reflected this impact in the past two decades. From an evolutionary and functional
perspective, the interplay between the plants and the surrounding harsh environment has
amazingly selected the simplest methods, which coin for diverse effects. The addition of the
iconic five carbon units on phenolics or alkaloids systems display the effects of a
physicochemical change such as increased hydrophobicity. From a pharmacological point of
view, this is usually accompanied by changes in pharmacokinetics and pharmacodynamics of the
parent molecule.112
Undeniably, the prenylated stilbenoids isolated from a variety of plant sources, have been
described as phytoalexins, which show antibacterial, antifungal and antioxidant effects, are
indispensable for the plant survival under stressful situations. In fact, these isoprene motives are
not exclusive for plant, bacteria or fungi phylogenies, but also they are known to exert vital
cellular processes roles in mammals via prenyl transferases.124 Unsurprisingly, this underpins the
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viable crosstalk of prenylated plant secondary metabolites across the living organism.
Many prenylated stilbenoids occur in the coniferous species such as Morus species, Rheum,
Abies, Picea, pine, Rheum, and Juniperus but also found in many other plants.125 Stilbenoid
produced in this line may differ in the number, position, and the type of the prenyls attached
(furan and pyran type).126 Since the prenylated compounds were shown to have profound effects
influencing their activity, potency, selectivity, and functionality compared to their parent
molecules, the chemical installation of these units is a valued investment.
We have identified the prenylated stilbenoids and prenylated dihydrostilbenoids, (Figure
17) found in licorice species as one of its major components that are capable to interact
differentially with the estrogenic receptors. To validate our computational data as well as to
explore the influential aspects of these appendages to the stilbenoid scaffold, we have envisioned
a regiodivergent chemistry that provides multiple isomers in a one-pot reaction. Despite the fact
that a regiocontrolled synthesis is preferred, it has proven challenging and multi-step process,
usually with low yields. However, in the early stage of pharmacological evaluation of such
constitutional isomeric constructs, the straightforward regiodivergent installation of the alkyl
group is a viable option. Interesting observations are found in the literature, in how these
positional variants may profoundly affect the activity or selectivity of the compounds.
A well-known example is the 8-prenyl naringenin. The presence of the prenyl group at
the 8-position converted the flavanone from estrogenically inactive molecule into a highly
estrogenic one. The same prenyl group added at 6 position acquired anticancer and androgenic
characteristics.106, 127 On the other hand, the presence of the prenyl group at 8-position
transformed the estrogenically active isoflavone or isoflavan structures, genistin and glabridin,
into antagonists.55, 109
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Figure 17. Examples of stilbenoids and DHS reported in different licorice species.

Furthermore, the displacement of the prenyl group from position 3 to 6 in one of the
pawhuskin A methylated analog has changed the selectivity of the compound from kappa opioid
receptor to a selective delta antagonist.128 In this study, we report the regiodivergent prenylation
of the stilbenoid resveratrol and its dihydro-analog including multiple chemical strategies such as
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Friedel-Crafts, ortho-metallation alkylation or the bio-inspired alkylation. During the course of
this work, we have identified the plausible analogs in each reaction including major and minor
products as well as the new analogs.
III.2 Chemistry
To append/tether a prenyl group on the stilbene scaffold, a flexible synthetic scheme was
envisioned to accomplish the synthesis of a diverse set of prenylated stilbenes and
dihydrostilbenes starting from commercially available resveratrol.
Access to such analogs is expected to provide ample information on the number of prenyl groups
necessary along with the preferred regioisomeric positions related to a specific estrogenic
activity along with the isoform selectivity.
III.2.1 Initial attempts: O-alkylation & Claisen rearrangement and ortho metalation
alkylation
The presence of the phenolic group in stilbenes makes them amenable to carbonylation
via the carbonate exchange reaction, which could potentially afford several isomeric mono or
multiple ether alkyl adducts as precursors for Claisen rearrangement. As shown in (Scheme 2),
the readily available propargyl alcohol was converted to the carbonate with Buli and methyl
chlorformate. Trans-etherification of the carbonate with the O-anion of resveratrol, followed by
partial reduction with Lindlarl’s catalyst would have resulted in allyl ether.129 Microwaveassisted Claisen rearrangement of allyl ether would have furnished the prenylated resveratrol.
However, we were not able to prepare initial O-alkylation with carbonate, which prompted us to
search for an alternative synthetic route.
Our second attempt was to employ the nucleophilic addition with ortho metalation, which
was inspired by chiricanine A synthesis.130 The protection of the phenolic moiety in stilbene with
methoxymethyl is anticipated to increase the selectivity and stability of the resulting anion under
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basic condition. Next, the addition of the prenyl bromide (24) will trap the generated anion to
furnish the prenylated stilbene. As depicted in scheme 3 route I, the hydrogenation of
resveratrol under condition (a) proceeded with excellent yield (92%).
The emerged dihydroresveratrol was treated with methoxymethyl chloride (MOM) in the
presence of the hydride anion (NAH) or triethyl amine (TEA) to gain access to the tri-protected
product. Unfortunately, our attempts failed; it gave only a slight amount of the required product
with NAH and only the mono-protected product was noticed with TEA. Similarly, only trivial
amounts of the tri-protected version were detected in the interchange of MOM chloride with
methoxyethoxymethyl (MEM) chloride.

Scheme 2. Reagents and conditions: (a) nBuLi, anhyd. THF, 0 oC (b) CuCl2, DBU, THF at r.t.
(c) H2, Lindlar cat (d) µ-wave, DMF, 180 oC (e) Pd/H2, EtOH, r.t.
Alternatively, in route II, we started with the stilbene 1 directly to forge the tri-MEM protected
product 23 in good yield (70%). Next, Product 23 was subjected to catalytic hydrogenation to
afford the intermediate 25 (tri-MEM protected dihydroresveratrol) in 90% yield. Next, the prenyl
donor was added under condition c or d to get the final product.
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Unfortunately, the reaction did not proceed in either case.

Scheme 3. Reagents and conditions. (a) Pd/H2, EtOH, r.t. (b) MOMCl/MEMCl/, HNa/DMF or
TEA/DCM, RT, 12 hrs. (c) Prenyl bromide, nBuLi, anhydrous THF, −70 to r.t. °C (d) Prenyl
bromide, HNa, anhydrous THF, 0 to r.t. °C.

III.2.2 Optimized regiodivergent synthesis of prenylated resveratrol and
dihydroresveratrol.
In order to get the target compounds, we have applied both biomimetic and semisynthetic
prenylation methods either via electrophilic or nucleophilic additions starting with resveratrol.
As depicted in Scheme 4. (Condition b), heating resveratrol (1) or dihydroresveratrol (2) with
prenyl alcohol (26) in acidic conditions led to a regio, divergent installation of the prenyl group
at C2, C4 or C6 in different ratios but in low yields. The bio-inspired reaction takes place in
acidic aqueous solution through the emerged allylic cation. This reaction resulted in a complex,
most diverse set of prenylated analogs along with the corresponding tetrahydropyrano analogs
due to harsh, low pH conditions. Formation of the latter analogs is inevitable in this reaction,
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where the decrease in time or temperature of the reaction will end up only with the monoprenylated isomers in low yield. Nevertheless, two new diprenylated (C2 and C4) resveratrol
analogs (compounds M8 and M9) were generated under these conditions with a mixed pattern of
linear prenyl chain (C2) and cyclized tetrahydropyran products (C4). The generated compounds
differ in the mode of cyclization, where compound M8 dehydrated with C3 hydroxy and
compound M9 is dehydrated with C5 hydroxy as shown by HMBC and NOESY spectra (Table
4, Figure 20, and Figure 21).
Alternatively, the Lewis acid-catalyzed “electrophilic addition” (Friedel-Crafts
alkylation) was explored as a milder condition (c). As anticipated, the addition of 2,2dimethylbutenol (27) to 1 or 2 at 0 oC in the presence of BF3.OEt2 led to the formation of
multiple mono- and di-prenylated analogs (with substitution onto positions C2, C4, and C6).
This route provided higher yields compared to the previous one and did not lead to cyclization
products (tetrahydropyrans moieties). An improved product selectivity was observed as we
changed the (substrate: reagent) ratio. Of note, a major C2 monoprenylated product (compound
M2) was observed at (1:1) ratio. On the other hand, we were pleased to see higher ratios of
diprenylated product M6 (C2, C4) followed by M7 (C2, C6) preferentially produced at higher
ratios as (1:3) or (1:4). As an alternative to electrophilic addition, and to reduce the number of
prenylated products, the nucleophilic substitution was explored as outlined in condition d. We
noticed from the prelude reactions in our initial attempts that we can approach the nucleophilic
addition without protection. Thus, direct nucleophilic prenylation of 1 and 2 were investigated
under multiple basic conditions including DBU, NaH and basic alumina (Al2O3) but they ended
up with O-prenylation or an inseparable complex mixture.
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However, deprotonation with n-butyl lithium at low temperature followed by the addition of
prenyl bromide resulted in mono-prenylated or di-prenylated products.

Scheme 4. Reagents and conditions: (a) Pd/H2, EtOH, r.t. (b) Prenyl alcohol,
EtOH, pH 2.6, 120 °C, 7 hrs. (c) 2,2-Dimethylbutenol, BF3.OEt2, dioxane, 0
o
C, 12 hrs. (d) Prenyl bromide, nBuLi, anhydrous THF, −40 °C.
Interestingly, this route showed higher selectivity profiles compared to the previous ones
as the diprenylated resveratrol M7 (C2, and C6) emerged in higher amounts. Along with the
required C-alkylation products, easily separable O-alkylated products and cyclized products were
also noticed under this condition but in very low yields. However, starting with 2 under these
conditions, the mono-tetrahydropyran versions (compounds M14 and M15) and a minor double
tetrahydropyran dihydroresveratrol became a major product (compound M18) upon purification.
Overall, 16 different analogs of both resveratrol (M2-M10) and dihydroresveratrol (M12-M18)
were prepared; five of them were synthesized for the first time (Figure 18 and Figure 19). The
overall yields and selectivities are summarized in Table 3.
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−40-25 24h
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r.t., 24h

115, 7h

−40-25, 24h

r.t., 24h

r.t., 24h

120, 24h

100, 24h

115, 7h
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-

-
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-

-
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Table 3. Summarized reaction yields and conditions
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Figure 18. Synthesized resveratrol derivatives M2-M10
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Figure 19. Synthesized dihydro-resveratrol derivatives M12-M18
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Figure 20. Energy-minimized structures M8 (cyan tubes) and M9 (green tubes) with the
measured distances between the olefin proton of the straight chain prenyl and the methyl proton
of the neighboring THP ring (3.66 and 8 Å, respectively)

M9

M8

Figure 21. Lack of NOE correlation between olefin proton and the methyl group on
the THP ring in M9 compared to M8
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Table 4. NMR data for compounds M8 and M9

C/H no
δC
1
2
3
4
5
6
a

135.39, C
117.43, C
152.62, C
108.10, C
152.65, C
105.51, CH
123.69, CH

b

129.00, CH

1′
2′

129.84, C
127.75, CH

3′

115.48, CH

4′
5′

157.13, C
115.48, CH

6′

127.75, CH

1″

24.49, CH2

2″

124.3, CH

3″
4′′
5′′
1‴

129.66, C
17.21, CH3
25.00, CH3
17.53, CH2

2‴

32.17, CH2

3‴
4‴
5‴

72.80, C
25.99, CH3
25.99, CH3

δH,
(JHz)

M9
mult. HMBC

6.63 (s, 1H)
7.20 (d, J =
16.1 Hz, 1H)

a, 2, 4, 5
b, 2, 6

6.93 (d, J =
16.1 Hz, 1H)
7.44 (d, J =
8.5 Hz, 2H)
6.86 (d, J =
8.5 Hz, 2H)
6.86 (d, J =
8.5 Hz, 2H)
7.44 (d, J =
8.5 Hz, 2H)
3.49 (d, J =
6.6 Hz, 2H)

1.30 (s, 6H)
1.30 (s, 6H)

134.84, C
118.69, C
153.31, C
107.93, C
152.29, C
102.33, CH
124.07, CH
128.63, CH

b, 1′, 4′, 5′

129.66, C
127.63, CH
115.38, CH
157.21, C
115.38, CH
127.63, CH

1 ,2, 2″

5.14 (t, J = 6.7
Hz, 1H)
1.83 (s, 3H)
1.67 (s, 3H)
2.71 (t, J = 6.8
Hz, 2H)
1.83 (t, J = 6.8
Hz, 2H)

δC

24.11, CH2
124.52, CH

2′′′, 3′′′, 3, 4

128.72, C
17.30, CH3
25.07, CH3
17.27, CH2

3′′′, 4

31.88, CH2

2′′′, 3′′′

73.27, C
26.16, CH3
26.16, CH3
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M8
δH,
mult.
(JHz)

HMBC

152.29, C

6.71 (s, 1H)
7.24 (d, J =
16.1
Hz,
1H)
6.84 (d, J =
16.3
Hz,
1H)

a, 2, 4
6, 2, 1′

7.40 (d, J =
8.6 Hz, 2H)
6.85 (d, J =
8.6 Hz, 2H)

6′, 4′

6.85 (d, J =
8.6 Hz, 2H)
7.40 (d, J =
8.6 Hz, 2H)
3.41 (d, J =
7.0 Hz, 2H)

1, 2′, 6′

4′

1, 2, 3, 2″,
3″

5.12 (t, J =
7.0 Hz, 1H)
1.83 (s, 3H)
1.65 (s, 3H)
2.68 (t, J =
6.9 Hz, 2H)
1.79 (t, J =
6.9 Hz, 2H)
1.32 (s, 6H)
1.32 (s, 6H)

1″, 4″, 5″
2″, 3″
2″, 3″, 4″
2‴, 3‴, 4, 5
1‴,4 , 3‴
3‴, 2‴,1‴
5‴, 3‴
4‴, 5‴

III.3 Experimental
III.3.1 Conformational analysis of compounds M8 and M9
The conformational search was applied with MacroModel (Schrodinger, LLC) utilizing
advanced search with Low-frequency-Mode and OPLS2005 for energy minimization. The
probability of TORS/MOLS steps was set to 0.5 with a maximum number of steps was equal to
1000. The energy window for saving a structure was set to 5.02 kcal/mol to eliminate the higher
energy conformations that could be generated. The maximum deviation between conformers was
set to a cutoff of 0.5Å to eliminate the redundant structures. The number of structures generated
by this method was 1387 structures, out of which 888 were successfully minimized. The sampled
conformational populations were assembled based on the Boltzmann potential energy-weighted
populations (relative Potential-Energy-OPLS-2005 in KJ/mol at 298.15 K).
III.3.2 General experimental procedures
All the reactions were monitored using thin layer chromatography. All the chemicals and
reagents were purchased from Sigma Aldrich (MO, USA). Agilent 630 FTIR (Agilent
Technologies, CA, USA) was used to record the IR spectra. 1H and 13C NMR spectral data were
recorded on Bruker (400 and 500 MHz; Bruker AU III, MA, USA) spectrometers and chemical
shifts were expressed as p.p.m. Agilent UHPLC 6200 series (Agilent Technologies) was used to
acquire Mass spectra. Column chromatography was performed on (Merck, MA, USA) silica gel
60 and Sephadex LH20 (sigma). Flash silica gel (40μm, 60 Å, J. T. Baker) and reversed phase
RP-C18 silica (Polarbond, J.T. Baker). Preparative-TLC plates were used for extra purification
(20 cm × 20 cm, 500μm).
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III.3.3 Chemistry
Condition b: Biomimetic prenylation of stilbenoids and dihydrostilbenoids using prenyl
alcohol
The stirred solution of resveratrol (500 mg or 2g) or dihydroresveratrol (250 mg or 500
mg) in ethanol was adjusted to pH 2.6 using 500 mg of citric acid dissolved in 5 ml of water,then
prenyl alcohol (2 or 4 equivalents) was added. The reaction mixture was heated up to 120 °C
gradually in a sealed vessel using silicon oil bath for 7 or 24 hours. The reaction mixture was
quenched with aqueous NaHCO3 and the water layer was extracted three times (15 ml) with ethyl
acetate. The combined organic layer was dried over MgSO4 and concentrated under reduced
pressure. Column chromatography (SiO2, EtOAc−Hex = 15:85 to 50:50) provided compounds
M2-M10 and M12-M15.
Condition c: Prenylation of stilbenoids and dihydrostilbenoids via electrophilic addition
(Friedel-Crafts alkylation)
To an ice cooled solution of resveratrol or dihydroresveratrol in dry dioxane was slowly
added BF3.Et2O followed by (2-methyl-but-3-en-2-ol). The reaction mixture was stirred at r.t.
overnight. The reaction mixture was evaporated under vacuum and partitioned between H2O (35
ml) and EtOAc (3x15). The combined organic layers were washed with H2O (1x15), dried over
MgSO4, and concentrated under reduced pressure. Flash chromatography (SiO2, Acetone-Hex =
5:95 to 75:25) provided compounds M2, M3, M6, M7, M12, M13, M16 and M17.
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Condition d: Prenylation of stilbenoids and dihydrostilbenoids via nucleophilic substitution
using prenyl bromide and n-BuLi
To a stirred solution of resveratrol (300mg) or dihydroreveratrol (1g, 750mg) in dry THF
at −40 °C was added dropwise n-BuLi. After 20 min the reaction was allowed to reach −20 °C, at
which 3,3-dimethylallyl bromide was added slowly and left to stir for 3 hrs. Then the reaction
temperature was raised gradually to the room temperature and was stirred for an additional 12
hrs. The reaction mixture was quenched with saturated aqueous NH4Cl and the water layer was
extracted three times EtOAc (15 ml). The combined organic layers were dried over Na2SO4 and
concentrated under with reduced pressure. Column chromatography (SiO2, EtOAc−Hex = 15:85
to 50:50) provided compounds M2, M3, M6, M7, M10 and M12-M18.
III.3.4 Spectral data
M2
IR: 3339.7, 1587.8, 1353.0, 1444.3, 1244.9, 1131.2, 821.9. 1H NMR (400 MHz, MeOD):7.33 (d,
J = 8.6 Hz, 2H, H-2’, H-6’), 7.14 (d, J = 16.1 Hz, 1H, H-α), 6.84 (d, J = 16.1 Hz, 1H, H-β), 6.78
(d, J = 8.7 Hz, 2H, H-3’, H-5’), 6.57 (d, J = 2.4 Hz, 1H, H-6), 6.25 (d, J = 2.4 Hz, 1H, H-4), 5.13
(m, 1H, H-2”), 3.39 (d, J = 6.8, 2H, H-1”), 1.81 (s, 3H, H-4”), 1.69 (s, 3H, H-5”). 13C NMR (100
MHz, MeOD) δ 156.85 (C-4’), 155.64 (C-5), 155.33 (C-3), 138.29 (C-1), 129.50 (C-1’), 129.31
(C-β), 129.00 (C-3”), 127.30 (C-2’, C-6’), 124.28 (C-2’), 123.93 (C-α), 117.69 (C-2), 115.08 (C3’, C-5’), 102.88 (C-6), 101.20 (C-4), 24.56 (C-4”), 23.84 (C-1”), 16.74 (C-5”). HRMS (ESI)
calcd for C19H20O3 (MH+), 297.1485; found 297.1484.
M3
IR: 3281.9, 1509.6, 1425.7, 1161.1, 1041.8, 965.4. 1H NMR (400 MHz, MeOD) δ 7.34 (d, J = 8.6
Hz, 2H), 6.92 (d, J = 16.3 Hz, 1H), 6.76 (d, J = 16.3 Hz, 1H), 6.78 (d, J = 8.6 Hz, 2H), 6.48 (s,
1H), 5.26 (m, 1H), 3.30 (d, J = 7.1 Hz, 2H), 1.78 (s, 3H), 1.68 (s, 3H). 13C NMR (100 MHz,
MeOD) δ 156.75, 155.62, 155.24, 138.38, 129.58, 129.47, 129.10, 127.39, 124.22, 123.97, 117.86,
115.14, 103.04, 101.29, 24.64, 23.91, 16.83. HRMS (ESI) calcd for C19H20O3 (MH+), 297.1485;
found 297.1486
M4
IR: 3339.7, 1582.3, 1442.5, 1166.7, 1019.4, 836.8. 1H NMR (400 MHz, acetone-d6) δ 7.47 (d, J
= 8.6 Hz, 2H), 7.18 (d, J = 16.1 Hz, 1H), 6.96 (d, J = 16.1 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 6.71
(d, J = 2.4 Hz, 1H), 6.20 (d, J = 2.4 Hz, 1H), 2.78 (t, J = 6.8 Hz, 2H) 1.82 (t, J = 6.8 Hz, 2H), 1.30
(s, 6H). 13C NMR (100 MHz, acetone-d6) δ 157.31, 156.30, 155.05, 137.95, 129.79, 129.37,
127.96, 122.87, 115.53, 110.21, 104.11, 103.06, 73.06, 32.73, 25.98, 19.51. HRMS (ESI) calcd
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for C19H20O3 (MH+), 297.1485; found 297.1488.
M5
IR: 3308.0, 1547.8, 1511.4, 1422.0, 1116.3, 1053.0, 834.9. 1H NMR (400 MHz, acetone-d6) δ
7.42 (d, J = 8.6 Hz, 2H), 7.00 (d, J = 16.3 Hz, 1H), 6.86 (d, J = 16.3 Hz, 1H), 6.85 (d, J = 8.5 Hz,
2H), 6.60 (d, J = 1.4 Hz, 1H), 6.49 (d, J = 1.3 Hz, 1H), 2.67 (t, J = 6.8 Hz, 2H), 1.80 (t, J = 6.8 Hz,
2H), 1.31 (s, 6H). 13C NMR (100 MHz, acetone-d6) δ 157.13, 155.62, 155.16, 136.88, 129.21,
127.72, 127.72, 127.45, 125.93, 115.51, 115.51, 108.03, 106.50, 103.89, 73.40, 32.07, 26.07,
26.07, 17.05. HRMS (ESI) calcd for C19H20O3 (MH+), 297.1485; found 297.1487.
M6
IR: 3369.5, 1578.5, 1431.3, 1168.5, 1034.3, 838.1. 1H NMR (500 MHz, acetone-d6) δ 7.39 (d, J
= 7.9 Hz, 2H), 7.20 (d, J = 16.0 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 6.79 (d, J = 16.1 Hz, 1H), 6.76
(s, 1H), 5.26 (t, J = 7.0 Hz, 1H), 5.13 (t, J = 6.1 Hz, 1H), 3.48 (d, J = 6.6 Hz, 2H), 3.44 (d, J = 6.9
Hz, 2H), 1.82 (s, 3H), 1.79 (s, 3H) 1.67 (s, 6H). 13C NMR (125 MHz, acetone-d6) δ 157.11, 153.57,
153.36, 135.19, 130.85, 129.97, 129.56, 128.79, 127.66, 127.66, 124.26, 124.11, 123.11, 118.07,
115.52, 115.52, 114.66, 104.12, 25.03, 24.99, 24.70, 22.56, 17.24, 17.09. HRMS (ESI) calcd for
C24H28O3 (MH+), 365.2111; found 365.2110.
M7
IR: 3317.3, 1589.7, 1442.5, 1151.7, 1086.5, 903.5. 1H NMR (500 MHz, acetone-d6) δ 7.38 (d, J
= 8.5 Hz, 2H), 6.98 (d, J = 16.7 Hz, 1H), 6.87 (d, J = 8.4 Hz, 2H), 6.44 (d, J = 16.6 Hz, 1H), 6.45
(s, 1H), 5.20 (dt, J = 8.4, 4.2 Hz, 2H), 3.35 (d, J = 4.7 Hz, 4H), 1.65 (s, 6H), 1.63 (s, 6H). 13C
NMR (100 MHz, acetone-d6) δ 157.06, 153.44, 153.44, 139.55, 133.30, 129.53, 128.95, 128.95,
127.46, 127.46, 124.90, 124.90, 124.21, 117.55, 117.55, 115.45, 115.45, 101.43, 25.95, 25.95,
25.08, 25.08, 17.31, 17.31. HRMS (ESI) calcd for C24H28O3 (MH+), 365.2111; found 365.2111
M8
IR: 3261.4, 1578.5, 1422.0, 1159.2, 1072.2, 821.9. 1H NMR (400 MHz, acetone-d6) δ 7.40 (d, J
= 8.6 Hz, 2H), 7.24 (d, J = 16.1 Hz, 1H), 6.85 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 16.3 Hz, 1H), 6.71
(s, 1H), 5.12 (t, J = 7.0 Hz, 1H), 3.41 (d, J = 7.0 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H), 1.83 (s, 3H), 1.79
(t, J = 6.9 Hz, 2H), 1.65 (s, 3H), 1.32 (s, 6H). 13C NMR (100 MHz, acetone-d6) δ 157.08, 153.31,
152.27, 134.89, 129.61, 128.96, 128.53, 127.65, 124.48, 124.04, 118.85, 115.52, 107.93, 102.33,
73.36, 31.84, 26.13, 25.06, 24.04, 17.34, 17.27. HRMS (ESI) calcd for C24H28O3 (MH+),
365.2111; found 365.2110.
M9
IR: 3380.2, 15559.9, 1429.4, 1157.3, 1094.0, 838.7. 1H NMR (500 MHz, acetone-d6) δ 7.44 (d, J
= 8.5 Hz, 2H), 7.20 (d, J = 16.1 Hz, 1H), 6.93 (d, J = 16.1 Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.63
(s, 1H), 5.14 (t, J = 6.7 Hz, 1H), 3.49 (d, J = 6.6 Hz, 2H), 2.71 (t, J = 6.8 Hz, 2H), 1.83 (t, J = 6.8
Hz, 2H), 1.83 (s, 3H), 1.67 (s, 3H), 1.30 (s, 6H). 13C NMR (125 MHz, acetone-d6) δ 157.13,
152.63, 135.79, 129.79, 129.63, 129.02, 127.73, 127.73, 124.31, 123.72, 117.45, 115.50, 115.50,
108.11, 105.46, 72.88, 72.88, 32.16, 25.98, 25.98,25.00, 24.50, 17.55, 17.25. HRMS (ESI) calcd
for C24H28O3 (MH+), 365.2111; found 365.2108
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M10
IR: 3360.2, 1559.9, 1429.4, 1157.3, 1094.0, 838.7. 1H NMR (400 MHz, acetone-d6) δ 7.41 (d, J
= 8.6 Hz, 2H), 6.96 (d, J = 16.6 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 6.53 (d, J = 16.7 Hz, 1H), 6.27
(s, 1H), 5.22 (tdd, J = 5.4, 2.9, 1.4 Hz, 1H), 3.38 (d, J = 6.7 Hz, 2H), 2.67 (t, J = 6.7 Hz, 2H), 1.74
(t, J = 6.7 Hz, 2H), 1.66 (d, J = 1.5 Hz, 3H), 1.65 (d, J = 1.5 Hz, 3H), 1.29 (s, 6H). 13C NMR (100
MHz, acetone-d6) δ 157.18, 154.08, 152.54, 138.50, 133.60, 129.36, 129.06, 127.52, 127.52,
124.84, 123.53, 118.34, 115.45, 115.45, 110.40, 102.36, 72.81, 33.10, 26.11, 26.1, 1 25.75, 25.02,
21.25, 17.27. HRMS (ESI) calcd for C24H28O3 (MH+), 365.2111; found 365.2130.
M12
IR: 3295.0, 1593.4, 1448.1, 1131.2, 11131.2, 779.0. 1H NMR (400 MHz, acetone-d6) δ 7.07 (d, J
= 8.5 Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 2.5 Hz, 1H), 6.26 (d, J = 2.4 Hz, 1H), 5.13
(tdd, J = 5.4, 2.8, 1.5 Hz, 1H), 3.31 (d, J = 6.6 Hz, 2H), 2.75 (s, 4H), 1.74 (d, J = 1.3 Hz, 3H), 1.66
(d, J = 1.5 Hz, 3H). 13C NMR (100 MHz, MeOD) δ 155.65, 155.11, 154.96, 142.01, 133.03,
129.16, 128.88, 128.88, 124.58, 117.64, 114.64, 114.64, 107.23, 99.95, 36.59, 35.44, 24.54, 23.88,
16.71. HRMS (ESI) calcd for C19H22O3 (MH+), 299.1642; found 299.1643
M13
IR: 3233.5, 1589.7, 1438.8, 1115.5, 1034.3, 980.3. 1H NMR (400 MHz, acetone-d6) δ 7.03 (d, J
= 8.4 Hz, 2H), 6.75 (d, J = 8.5 Hz, 2H), 6.28 (s, 2H), 5.31 (ddt, J = 7.2, 5.8, 1.4 Hz, 1H), 3.34 (d,
J = 7.2 Hz, 1H), 2.81-2.63 (m, 4H), 1.77 (d, J = 1.3 Hz, 3H), 1.65 (d, J = 1.4 Hz, 3H). 13C NMR
(100 MHz, acetone-d6) δ 155.80, 155.80, 155.40, 140.47, 132.75, 129.53, 129.21, 129.21, 123.80,
115.01, 115.01, 112.21, 106.93, 106.93, 37.85, 36.69, 25.07, 22.02, 17.05. HRMS (ESI) calcd for
C19H22O3 (MH+), 299.1642; found 299.1642
M14
IR: 3285.8, 1513.3, 1444.3, 1136.8, 1012.0, 834.9. 1H NMR (400 MHz, MeOD) δ 6.95 (d, J = 8.5
Hz, 2H), 6.68 (d, J = 8.5 Hz, 2H), 6.23 (d, J = 2.5 Hz, 1H), 6.06 (d, J = 2.5 Hz, 1H), 2.77 – 2.69
(m, 4H), 2.48 (t, J = 6.8 Hz, 2H), 1.72 (t, J = 6.8 Hz, 1H) 1.25 (s, 6H). 13C NMR (100 MHz,
MeOD) δ 155.56, 155.04, 154.53, 141.47, 132.68, 129.04, 129.04, 114.63, 114.63, 110.50, 108.01,
101.25, 73.09, 35.84, 34.67, 32.76, 25.53, 25.53, 18.87. HRMS (ESI) calcd for C19H22O3 (MH+),
299.1642; found 299.16.14.
M15
IR: 3360.33, 1514.68, 1120.1, 1057.36, 830.69. 1H NMR (500 MHz, acetone-d6) 7.05 (d, J = 8.4
Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 1.6 Hz, 1H), 6.19 (d, J = 1.5 Hz, 0H), 2.82 – 2.73
(m, 2H), 2.72-2.66 (m, 1H), 2.63 (t, J = 6.8 Hz, 2H), 1.76 (t, J = 6.8 Hz, 2H), 1.28 (s, 6H). 13C
NMR (125 MHz, acetone-d6 δ 155.40, 155.27, 154.85, 141.01, 132.79, 129.25, 129.25, 115.06,
115.06, 108.40, 106.19, 105.99, 73.21, 38.01, 36.72, 32.20, 26.15, 26.15, 16.86. HRMS (ESI)
calcd for C19H22O3 (MH+), 299.1642; found 299.1642.
M16
IR: 3390.0, 1591.6, 1425.7, 1170.4, 1041.8, 827.5. 1H NMR (400 MHz, acetone-d6) 7.05 (d, J =
8.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 1H), 6.35 (s, 1H), 5.26 (dddd, J = 7.1, 5.6, 2.9, 1.5 Hz, 1H), 5.09
(tq, J = 5.0, 1.5 Hz, 1H), 3.40 (d, J = 7.3 Hz, 2H), 3.34 (d, J = 6.6 Hz, 2H), 2.72 (s, 4H), 1.78 (d, J
= 1.3 Hz, 3H), 1.75 (d, J = 1.3 Hz, 3H), 1.67 (d, J = 1.5 Hz, 6H). 13C NMR (100 MHz, acetone75

d6) δ 155.48, 153.49, 153.41, 138.57, 132.91, 130.57, 130.12, 129.13, 129.13, 124.50, 123.45,
117.63, 115.06, 115.06, 112.79, 108.19, 36.76, 35.55, 25.04, 24.96, 24.72, 22.39, 17.21, 17.07.
HRMS (ESI) calcd for C24H30O3 (MH+), 367.2268; found 367.2267
M17
IR: 3546.6, 1513.3, 1436.9, 1149.9, 825.6. 1H NMR (400 MHz, acetone-d6) 7.11 (d, J = 8.4 Hz,
2H), 6.80 (d, J = 8.4 Hz, 2H), 6.39 (s, 1H), 5.17-5.10 (m, 2H), 3.37 (d, J = 6.6 Hz, 4H), 2.85 – 2.74
(m, 2H), 2.68 (dd, J = 11.5, 5.1 Hz, 2H), 1.75 (s, 6H), 1.65 (s, 6H). 13C NMR (100 MHz, acetoned6) δ 155.51, 153.56, 153.56, 140.31, 133.24, 129.13, 129.13 129.02, 129.02, 125.27, 125.27,
117.69, 117.69, 115.18, 115.18, 100.71, 36.19, 32.04, 25.05, 25.05, 24.77, 24.77, 17.33, 17.33.
HRMS (ESI) calcd for C24H30O3 (MH+), 367.2268; found 367.2260.
M18
IR: 3349.0, 1584.1, 1459.3, 1157.3, 1105.2, 827.5. 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 8.4
Hz, 2H), 6.79 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 2.86-2.79 (m, 2H), 2.73 – 2.67 (m, 2H), 2.65 (t, J
= 6.8 Hz, 2H), 1.80 (t, J = 6.8 Hz, 2H), 1.31 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 153.85,
153.25, 153.25, 138.75, 134.20, 129.44, 129.44, 115.23, 115.23, 111.39, 111.39 103.55, 73.14,
73.14, 34.31, 33.29, 33.29, 31.18, 26.70, 26.70, 26.70, 26.70, 19.77, 19.77. HRMS (ESI) calcd
for C24H30O3 (MH+), 367.2268; found 367.2270
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CHAPTER IV
ACTIVATION OF PXR BY LICORICE COMPOUNDS
IV.1 Background
The common perception that a label of ‘natural’ ensures safety, the unpleasant episodes
and side effects associated with pharmaceutical (synthetic) drugs, along with the long history of
usage of botanicals as medicines have resulted in an upsurge of herbal medicines in Western
healthcare. Passage of the education act further fueled the utility of botanicals in drugs, dietary
supplements, cosmetics or personal care products. As a result, herbal ingredients became part of
various formularies and the trend shows a strong inclination of consumers to self-medicate with
botanicals.26 Due to this rapid growth of the market, consumer use in many cases has outpaced
adequate scientific understanding of the products, opening the door for potential adverse effects.
Although the efficacy of some botanical drugs has been documented, there is a concern
regarding the perceived safety of herbal products, particularly with respect to the knowledge of
botanical drug interaction potential with conventional prescription drugs and its clinical
significance. Moreover, herb-drug and induced-herb-drug interactions have generally been
inadequately studied. With the burgeoning use of botanicals, some reports of serious drug
interactions are appearing in the literature. 131-135 A further risk for consumers, which will
exacerbate the problems associated with botanical ingredients, is that self-medication might
delay or prevent a patient from seeking appropriate medical treatment. Botanical drugs comprise
a plethora of bioactive constituents and often exist as very complex mixtures. Several reports
indicate that herbal constituents could alter the pharmacokinetics of prescription drugs via direct
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or inductive pathways.13, 28, 136 This is critically important when it comes to drugs of a
narrow therapeutic index such as immunosuppressants or chemotherapeutic agents or with those
intended for a chronic or life-threatening diseases. The incidence of such events has been
reported and led to therapeutic failure.
For instance, St. John’s Wort concomitantly used with cyclosporine
(immunosuppressant) or contraceptives led to the failure of therapy. Other reports described the
inefficacy of efavirenz (antiviral) consumed with Ginkgo supplements. Direct modulation of
metabolizing enzymes is one route recognized for the pharmacokinetics interactions between
conventional drugs and other xenobiotics. This includes CYPs inhibition, both as transient and
irreversible inhibition. However, these models could not explain the inductive effects acquired
by consumption of some herbs. Later on, researchers have identified the pivotal role played by
nuclear receptors in regulating the gene-expression of drug metabolizing enzymes and
transporters.137-138 The Pregnane X Receptor (PXR), as one of the newly defined nuclear
receptors, is considered as the master regulator of drug metabolizing enzymes. This includes
induction of cytochrome P450s and multiple other phase-I and phase-II enzymes and
transporters.
Several botanicals and their constituents have been recognized as inducers of PXR such a
St. John’s Wort, Kava Kava and Gugulipids, Gan Cao.13 Further investigations revealed a wide
variety of molecules responsible for initiating PXR machinery, which indicates the broad
substrate acceptability. In conformity with the above, herbal constituents can interact with PXR
ligand binding domain and have the ability to modulate principal metabolic enzyme and some of
the energy expenditure checkpoints.139 This situation has raised a huge campaign inclined to
unveil the potential risk/benefit of intentional long-term herbal consumption.
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IV.1.1 The role of Pregnane X receptor
One major discovery in the nuclear receptors field has occurred in 1998. The discovery of
PXR has outlined a new era into understanding the regulatory mechanisms behind xenobiotic
detoxification as a primary defense mechanism in our bodies. Initially, it was classified as one of
the orphan receptors “a receptor without a characterized endogenous ligand”, but soon it was
found to bind a family of diverse chemical subtypes.140 This includes a set of endobiotics such as
the pregnane steroids as well as other therapeutic drugs. This nuclear receptor (NR1I2) belongs
to the nuclear receptor subfamily 1 group I, which also includes the vitamin D receptor (VDR)
and the constitutive androstane receptor (CAR). Similar to the other nuclear receptors, it
functions as a ligand-induced transcriptional factor, where the binding of a ligand can trigger a
conformational change of the protein that will switch on a cascade of events leading to a
controlled and specific genetic induction.137
It is well established that PXR has a paramount role as a xenosensor, where it regulates
the expression of many metabolic enzymes and transporters responsible for drug or
“xenobiotics” disposition. In addition, it has viable but less studied roles in endobiotics synthesis,
metabolism and homeostasis including bile acids, lipids, glucose, bilirubin, vitamins and other
steroid hormones. This highlights the diverse and crucial roles of PXR implicated into both drug
metabolism (efficacy, toxicity, drug interactions, and drug resistance) and disease (metabolic
syndrome, cancer, and inflammation).141-142 In fact, PXR ligand-activation is paradoxically
important, in a way to sense these xenobiotics and to dispose them. Alternatively, they may
influence the systemic or tissue exposure of the other drugs in case of concurrent consumption
with the PXR activators. In fact, PXR versatile role is reflected by its vast control upon many
metabolic enzymes and transporters. So far, it is shown to control the target genes of phase-I

79

CYP450 (CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A1, CYP3A4, CYP3A5,
CYP3A7, CYP4F12, CYP24, and CYP27A1), phase II uridine diphosphate (UDP)glucuronosyltransferases (UGT1A1, UGT1A3, UGT1A4, UGT1A6, and UGT1A9),
sulfotransferases (Sult2a1), glutathione S-transferases (GSTA2, GSTA4). In addition to the
carboxylesterases and phase III P-glycoprotein (MDR1/ABCB1), multidrug resistance-associated
protein 1 (ABCC1), multidrug resistance-associated protein 2 (ABCC2), multidrug resistanceassociated protein 3 (ABCC3), and organic anion transporting polypeptide 2 (OATP2).13
However, induction of PXR is not the ultimate event. Also, it is not necessarily translated
into the genetic pool of susceptible enzymes and transporters. Instead, responses are selective
and gradient in nature, which rather come as a result of multiple other dimensions including
specific tissue, coregulators, epigenetics, and post-translational modifications, specific response
elements, and other NRs.143 In addition to its roles as a xenobiotic sensor, many studies have
unveiled the kinetics behind its uncanonical roles. Hence providing the evidence of its function
as a mediator of chemo-genetics interplay, which delineates the etiology of the environmentally
induced diseases such as the cardiometabolic disease.
This can be explained by upregulation or inhibition of vital checkpoints proteins
(enzymes or factors) in specific diseases networks. One example is the hyperglycemic effects
corroborated with PXR induction, where PXR induction was found to downregulate the glucose
transporter 2 and other vital kinases related to gluconeogenesis (glucokinase, dehydrogenase
kinase isozyme 2, and phosphoenolpyruvate carboxykinase 1).142, 144 Moreover, PXR
polymorphism, and PXR variants have been correlated to multiple diseases and malignancy such
as Crone’s disease, colon cancer and adenocarcinoma.138
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4.A.2 The Pregnane X receptor structure
PXR shares the common features of other NRs required for the transcriptional machinery.
It consists of five main domains among which the DNA-binding domain (DBD) and the ligandbinding domain (LBD) are the most important. The former recognizes specific response elements
that flank the genes controlled by PXR. The ligand-binding domain mainly comprises the
binding site for ligands in addition to the protein-protein surface interaction. Nevertheless, PXR
is unique among other NRs by having a large spherical and flexible binding pocket.
Gene induction is triggered by the ligand-binding event, which will induce a
conformational change that will release corepressors already bound to PXR in the AF-2 region.
After ligand activation, PXR heterodimerization with retinoid X receptor (RXRα) will take
place, which will further stabilize the coactivator binding in the AF-2 region and selectively
recognizes DNA response elements of specific genes.145 The adopted structural features upon
ligand binding dictate the following genetic responses by stabilizing and recruiting different
coregulators and factors and vice versa.
PXR has a large and flexible hydrophobic pocket wrapped between 12 α-helixes and a
short region of 5 β-strands. Compared to other NRs, PXR has a wider surface of β-sheets since it
has an extra two β-strands. The ligand binding site volume can vary between apo and ligandbound crystal structure from 1280-1600 Å3, which is substantially larger than any other NRs.
The region comprised of residues 198 and 212 can be completely disordered to fit very large
structures such as Rifampicin. This further explains its promiscuous behavior and the lack of
direct antagonists through its ligand-binding site. Thus, it can accommodate a wide variety of
structures with varying molecular weights (300-800 Daltons). The diversity of the amino acids
lining this pocket explain the hospitality of such receptor (ten hydrophobic, four polar and four
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charged amino acids).146-149 Compliance with diversity is essentially one feature that is required
for its function as a xenobiotic sensor, which allows the detection of a versatile set of chemicals
that may differ in size or electronic features.150
However, aside from this sophisticated behavior, several computational studies have
deduced global features as the primary requirements needed for PXR activation. For instance,
larger hydrophobic molecules have a better chance to interact with PXR; this includes a
molecular weight, which is larger than 300 Daltons and hydrophobic features that allow multiple
hydrophobic interactions and π-π interactions with a list of recognized hydrophobic amino acids
mainly, those occupying the aromatic sub-pocket surrounded by F288 and W299. Further studies
recognized S247, Q289, and H407 as indispensable residues for the PXR induction.149, 151-153
Thus, at least one hydrogen bond interaction with one of the key amino acids is considered as a
basic requirement for PXR activation.
The existence of multiple crystal structures of PXR with different ligands has allowed the
recognition of the characteristic flexible side chains at the binding site. The AF-2 region is
stabilized via ligand binding, especially by the direct interaction with S247. This region
recognizes a family of peptides with the LXXLL motif, which is further stabilized by a charge
clamp interaction with conserved charged amino acids K259 and E427 (Figure 22).149 Although
many inducers of PXR have been identified, antagonists were more resilient.142 However, more
recently, the indirect allosteric modulation was recognized as one pathway for PXR
antagonism.154
The coregulator site at the AF-2 region constitutes the plausible site for this modulation.
This key intervention will prevent the coactivators from binding. Ketoconazole among other
azoles is the representative ligand for PXR antagonism.155 Other naturally occurring and plant-
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derived compounds have been discovered, viz. coumestrol, sesamine and resveratrol.156-157
IV.1.2 An overview of the applied computational techniques to predict PXR activation
It is increasingly important to screen for drug interaction early in the process of drug
development to eliminate hits with a high propensity for inducing adverse effects through the
drug metabolizing enzymes. In fact, computational methods provide a significant research axis
for pre-screening of hit libraries. In the realm of drug metabolism and excretion, PXR has the
major influence upon expression of the vital CYPs enzymes and transporters.158-159 However,
indirect PXR screening is very challenging. It has species-specific selectivity, where animal
models cannot exclusively tell us about the possible interaction that could happen. For instance,
rifampicin, which is a potent PXR activator in human, does not induce PXR in rodents.
Moreover, PXR in vitro models suffer from high variability among different cell lines
and can lead to contradicting results. The reasons behind this could be related to the cell viability
or the presence or absence of different transporter machinery that will affect the permeabilities
and concentrations of the tested compound. Moreover, the origin of the cell-line plays a
fundamental role in the expressed corepressors/coactivator ratios. For instance, Hela or HepG2
(cancer cell line) have higher corepressor concentrations compared to normal hepatocytes.
Hence, extrapolation should be highly dependent on the targeted population. Application of in
silico models of both structure-based and ligand-based methods not only would provide
alternative routes but also would fine-tune the screening of the existing methods.160This will
salvage some of the costs and would keep the more expensive screenings methods such as
hepatocyte cell-lines or the transgenic mice models (expressing human PXR) for those highly
alerting compounds.
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Q272
L694
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L693
L276

I689
F264
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L690
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L276
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Figure 22. (Left) Interaction of SRC-1 (the coactivator peptide in a purple cartoon) with the
hydrophobic groove in the 1NRL crystal structure. (Middle) the LXXLL motif in SRC-1 is
buried in the groove with the charge clamp lock with K259 and E427. (Right) Antagonist
ketoconazole (green sticks) and fluconazole (grey sticks) and coumestrol (pink sticks) docked
to the SRC-1 site
However, the challenge is not inevitable when applying in silico screening. The
promiscuity and flexibility of PXR represent the major obstacle. Nevertheless, previous studies
have encouraged the application of these approaches coupled to in vitro methods. Most of the
studies have focused on the ligand-based approaches. For example, one study has applied
machine-learning methods to predict PXR active ligands and the best predictive ability has
reached 80% accuracy by applying the support vector machine (SVM) method.161 Other QSAR
models have employed the pharmacophore modeling, which comprised of hydrophobic and
hydrogen bonding features similar to the features found in PXR crystal structures.162 Predictions
based on the LBP and docking have performed well, where one study has used Gold scores to
classify the compounds from the ToxCast database. They were able to correctly identify 8 out of
12 agonists and 7 out of 16 PXR non-agonist.160
Taken together, the application of pre-clinical screening of PXR will significantly reduce
the costs and can enhance our knowledge about the behavior of such compounds in the presence
of a very challenging defense mechanism. There is no straightforward method that can give the
perfect answer. Nevertheless, combining in silico and in vitro screens together will enhance the
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performance of these models. In this study, we have utilized the structure-based approach
screening coupled to in vitro analysis to screen a library of Glycyrrhiza compounds. We
envisaged that docking (compared to the other mentioned in silico methods) would give us direct
insights for ligand interaction with PXR; a method, which will cope better with the highly
variable chemical space of PXR activators. Particularly, the number and the class of compounds
preconceived in the training set for ligand-based methods are usually insufficient to avoid the
bias. In addition, ligand-based and machine learning approaches are more susceptible to the
inhomogeneity that is typically encountered within PXR in vitro data.
IV.1.3 Glycyrrhiza and Herb-drug interaction: An in silico approach
Induction of PXR is identified as one of the major mechanisms for triggering HDI.
Multiple clinically significant pharmacokinetic interactions between herbs and prescription drugs
have been reported via PXR. Direct CYP/transporter inhibition is another vital mechanism,
although not mutually exclusive, but rather a competitive route under in vivo conditions.13, 28, 136
Licorice herb has been used for centuries in traditional medicine in different parts of the world,
where it has been found in 85% of the traditional Chinese medicinal prescriptions. Moreover, it
is increasingly used in the US and Europe as a standardized total extract to alleviate multiple
ailments, including postmenopausal symptoms. It is also consumed for its chemoprevention and
hepatoprotective properties.
Recently, there is more scientific and preclinical experimental evidence, which confirmed
the efficacy of these ethnobotanical remedies.17, 63, 163 However, these commercialized freely
accessible herbal supplements have infiltrated the health systems without a rigorous
understanding of its possible side effects. This situation has triggered an urgent call for more
rigorous studies of HDI.26 In addition, natural products are indispensable resources for NCEs,
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where the optimization of their pharmacokinetics and their drug metabolism properties are at the
top priority for their success.9 Recent studies have raised the concerns for licorice induced PXR
activity, and they pointed out to its glycyrrhizin component as the source of induction.164-165
However, only weak PXR activation has been detected with the in vitro reporter gene assays for
glycyrrhizin as compared to rifampicin (the positive control).
Moreover, Glycyrrhiza has been prioritized by the FDA as one of the high-risk herbal
constituents for inducing the adverse effects.166 The objective of this study is to screen the
components of different Glycyrrhizae species against potential PXR induction or CYP inhibition
by application of multiple computational methods. The components with high interaction
potentials will be further confirmed with cell-based in vitro assays for the assessment of PXR
induction and the elucidation of the susceptible target genes. The activation of PXR will be
determined in HepG2 cells that are transiently transfected with the expression vector of PXR and
the reporter plasmid.
By the application of such methods, we anticipate bypassing some of the inconveniences
coupled to the direct in vitro analysis, including interference of endpoint measurements and the
inadequate supply of the purified diverse component systems. To fill the gaps into our
knowledge of the possible HDI that could be induced by the secondary metabolites of licorice,
we have utilized a tandem scheme of both in silico and in vitro risk assessment models. To roll
out the privileged ingredients with a high propensity for triggering HDI, two clinically relevant
Glycyrrhiza species (G. glabra and G. uralensis) have been docked to the LBD of PXR crystal
structure to prioritize their potential interaction. Furthermore, in silico risk assessment of CYP
enzyme inhibition models commercially available in ADMET predictor have been applied to the
unglycosylated structures of several secondary metabolites reported in both species.
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IV.2 Results
IV.2.1 Docking
The top docking scores for licorice compounds are summarized in Tables SI 8 and SI 9.
Redocking of the cognate ligand in both crystal structures has reproduced the binding mode in
the native protein structure with relatively good precision (RMSD for SRL and hyperforin were
found to be 1.0751Å and 1.1987Å, respectively). The docking scores for a group of
experimentally active compounds were used as a control group to estimate the cut-off value
(Figure 23 and Table 5). Thus, both SP and XP glide scores were evaluated for a set of active
known compounds (highly active, moderate and weak) into two different crystal structures,
1NRL and 1M13. The XP docking scores against 1NRL were capable of reflecting the
experimental gradient activity of the control group and thus they were used for our screening
purposes.
The calculated scores of the known compounds in the control group showed that
moderately active ones scored in the range of (−9.0 to −9.5 kcal/mol), while high activators
scored below (−10 kcal/mol). However, earlier studies showed that potent PXR induction
correlates successfully with a transient transfection assay when the compound (<10 µM)
achieves (70%) maximum induction relative to (10 µM) rifampicin.167 Thus, in order to reflect
these observations onto our docking results, we decided to consider the compounds with glide
scores < −9.5 kcal/mol. In this present study, the docking scores against the LBD suggested a
high number of licorice components having the potential of inducing PXR activation. According
to our predefined threshold of PXR agonist, around 60 phenolic compounds in G. glabra and 50
compounds in G. uralensis have scored below −9.5 kcal/mole. Interestingly, most of these
compounds belong to the isoflavonoid classes with a higher order of prenyl groups. Moreover,
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all the prenylated dihydro stilbenoids reported in both licorice species scored very high, due to
favorable ligand-protein interactions.

Figure 23. Naturally occurring PXR inducers and 1NRL native ligand SR12813

The visual inspection of the isoflavonoids docking poses revealed the vital hydrophobic
and π-π interactions of both prenyl groups or their tetrahydropyran (THP) counterparts (the
cyclized prenyl appendages found in many top-ranked compounds) with the hydrophobic subpocket comprised of F288 and W299 (Figure 24). Representative examples of each category are
shown in
Figure 25 (flavonoids and isoflavonoids), Figure 26 (DHS), and Figure 27 (other
miscellaneous components). In addition, several compounds were also able to interact with at
least one key residue in the LBD via hydrogen bonding. On the other hand, the docking poses of
the prenylated stilbenoids did not show a certain pattern of interaction since they have a more
freely rotatable scaffold and can adopt a variety of conformations. Other prenylated
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miscellaneous compounds classes (coumarins, chalcones, and pterocarpans) have shown the
similar potential of interacting with PXR. Examples of the docking pose of some representative
compounds interacting with PXR LBD is shown in Figure 28.

Table 5. SP and XP glide scores (kcal/mol) for a set of known PXR active compounds (highly
active, moderate and weak)
Name

SP-Score

XP-Score

SP-Score

XP-Score

1NRL

1NRL

1M13

1M13

Hyperforin
4-OHII
Tamoxifen
III
Enterolactone
IV
Hypericin
V
Quercetin
VI
Genistein
VII Physcion
VIII SR12813

−8.44

−8.15

−9.60

−11.71

a

High activator

−9.82

−10.54

−9.17

−10.15

a

High activator

−7.99
NA
−6.93
−6.66
−6.94
−10.82

−9.34
NA
−8.70
−8.10
−7.71
−12.34

−7.22
−7.55
−6.76
−7.72
−6.54
−8.14

−8.71
−10.02
−9.50
−6.58
−7.22
−9.68

b

No.
I

Activity

Moderate activator
Moderate activator
c
Weak activator
c
Weak activator
c
Weak activator
a,d
High activator
b

a) >70% maximum induction relative to 10 µM Rifampicin according to transient transfection assay.
b) 30-70% maximum induction relative to 10 µM Rifampicin according to transient transfection assay.
c) <30% maximum induction relative to 10 µM Rifampicin according to transient transfection assay.
d) One of the most potent activators with Kd value of 40 nm.

Q285

F281

F288
S247

H407
W299
Figure 24. Docking pose (PDB:1NRL) of a number of representative isoflavonoids and
flavonoids compounds (orange sticks) in the top scoring list of G. glabra and G. uralensis
showing similar preferable π-π interactions (blue dotted lines) with W299 and F288
(magenta balls and sticks) with their dihydro THP or phenolic groups.
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Figure 25. Group 1 (flavonoids and isoflavonoids) of top-scoring compounds from both G.
glabra and G. uralensis species against PXR LBD (PDB:1NRL)
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Figure 26. Group 2 (dihydrostilbenoids) of top-scoring compounds from both G. glabra and G.
uralensis species against PXR LBD (PDB: 1NRL)

Figure 27. Group 3 (miscellaneous) of top-scoring compounds from both G. glabra and G.
uralensis species against PXR LBD (PDB: 1NRL)
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G33

G90

G35

U35

U79

U16

U15

G71

G30

G53

U54
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5
9
Figure 28. Docking pose of representative top scoring compounds in PDB: 1NRL binding
site (group 1 in magenta sticks, group 2 in green sticks and group 3 in yellow sticks)
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IV.2.2 In vitro testing
Based on in silico assessment of licorice secondary metabolites, prenylated stilbenoids
have been identified as one of the top scoring components with a high propensity for PXR
activation. A library of 18 stilbenoids rich with diverse prenylation patterns (0.78-25 µM), where
incubated with HepG2 cells transfected with the pSG5‐hPXR (25 µM) and the PCR5 (25 µM)
plasmid DNA with and without the positive control rifampicin (3.125-25 µM)
After incubation for 24 hours with the pretreated cells, resveratrol (parent compound) and
several compounds of both the stilbenoids and the DHS series (M7-10 and M13-18) were able to
induce PXR with multiple fold induction in a dose-dependent manner (Figure 29, Figure 30 and
Table 6). Interestingly, compounds M9-M10, M15-M18 showed strong activity, where they
were evenly or slightly more efficacious than the positive control, rifampicin. The maximum fold
induction surpassed the positive control (3.8) for compound M10 (4.37 folds), M15-18 (4.225.25 folds) at the same concentration (12.5 µM). Moreover, potent PXR induction was observed
at the sub-micromolar range for compounds M9, 10, 15, 17 and 18, which maintained at least
two-fold induction at low concentration as 0.78 µM.
Furthermore, the significant increase of CYP3A4 mRNA expression of the compounds
M1, 7, 10, 12, 15, 17, and 18 validates the PXR activation assay (Table 7 and Figure 31).
Compounds M7, M10, and M15 were able to increase the mRNA levels up to 6 folds with M10
having the most potent activity. It maintained the 6 fold induction at 1µM concentration.
Additionally, to exclude any antagonist allosteric modulation of PXR, known for resveratrol,
select compounds, viz M7, 10, 12, 15, 17, 18 including resveratrol were subjected to competitive
experiments with rifampicin. None of these compounds were able to antagonize the rifampicin
activated PXR in the range of 10.0-0.6 µM.
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Figure 29. PXR fold induction in transfected HepG2 cells for
stilbenoids derivatives M1, 7, 8, 9 and 10. The compounds were tested
at concentrations of 25, 12.5, 6.25, 3.13, 1.56 and 0.78 μM.
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Figure 30. PXR fold induction in transfected HepG2 cells for DHS
derivatives M11, and M13-M18.
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Table 6. PXR activation in HepG2 cells treated with prenylated stilbenoids and DHS for 24 hr.
The data is included as the means ± standard deviation of three independent experiments
Fold induction
Compounds 25
12.5
(µM)
1.20 ± 0.02
1.71 ± 0.14
M1
3.16 ± 0.08
2.37 ± 0.01
M7
1.62 ± 0.03
2.54 ± 0.07
M8
3.10
±
0.00
3.67 ± 0.16
M9
4.80 ± 0.01
4.37 ± 0.44
M10
1.54
±
0.07
0.94 ± 0.07
M11
1.96 ± 0.21
1.04 ± 0.15
M13
3.16
±
0.14
1.98 ± 0.16
M14
4.85 ± 0.39
5.15 ± 0.78
M15
4.91
±
0.15
4.67 ± 0.51
M16
5.27 ± 0.28
5.24 ± 0.25
M17
4.91
±
0.32
4.22 ± 0.15
M18

6.25

3.13

1.56

0.78

1.75 ± 0.01
1.39 ± 0.14
2.68 ± 0.01
3.74 ± 0.27
4.48 ± 0.08
0.99 ± 0.02
1.05 ± .07
1.64 ± 0.22
5.37 ± 0.05
3.64 ± 0.11
4.60 ± 0.04
4.05 ± 0.12

0.92 ± 0.05
1.06 ± 0.08
2.20 ± 0.03
3.17 ± 0.22
3.40 ± 0.05
0.86 ± 0.07
1.07 ± 0.10
1.44 ± 0.15
4.35 ± 0.26
2.71 ± 0.01
3.56 ± 0.05
2.98 ± 0.12

0.90 ± 0.12
0.98 ± 0.08
1.76 ± 0.01
2.60 ± 0.17
2.60 ± 0.59
1.07 ± 0.02
1.26 ± 0.02
1.49 ± 0.07
2.71 ± 0.02
1.73 ± 0.22
2.47 ± 0.20
2.80 ± 0.18

0.73 ± 0.01
0.86 ± 0.01
1.44 ± 0.04
1.87 ± 0.13
2.22 ± 0.21
0.96 ± 0.11
0.92 ± 0.06
0.77 ± 0.09
1.95 ± 0.13
1.26 ± 0.11
1.55 ± 0.20
1.84 ± 0.16

Table 7. Increase in the mRNA expression of CYP3A4 in HepG2 cells by the
synthesized prenylated stilbenoid and DHS derivatives at three different concentrations.
Compounds (µM)
M1
M7
M10
M12
M15
M17
M18

Fold induction
10

3

1

1.66 ± 0.03

1.76 ± 0.20

2.79 ± 0.20

6.37 ± .053

4.96 ± 0.31

4.64 ± 0.21

3.96 ± 0.34

5.65 ± 0.29

6.62 ± 0.13

2.38 ± 0.33

3.46 ± 0.23

2.54 ± 0.22
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Figure 31. Increase in the mRNA expression of CYP3A4 in HepG2 cells by the synthesized
prenylated stilbenoid and DHS derivatives. The compounds were tested at concentrations of
10 (left), 3 (middle), and 1 (right) μM. Rifampicin (10μM, yellow) was used as a positive
control. The data is represented as mean ± standard deviation calculated from three
independent experiment.
IV.2.3 In silico risk assessment of CYP enzyme inhibition models commercially available in
ADMET predictor
Phytochemicals from both G. glabra and G. uralensis have been evaluated through
QSAR models utilizing commercially available software product, ADMET Predictor™ 9.0
(Simulations Plus Inc.) for potential inhibitors of CY1P450s. These models include general
inhibition models for five recombinant CYPs (1A2, 2C9, 2C19, 2D6, and 3A4). As a result, we
have classified and compared the putative components in licorice that might influence CYP
inhibition at the level of the enzymes. The analysis unveiled the risk potential upon licorice
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consumption amongst two major CYPs, 1A2 and 3A4, where many compounds in both species
(Table 8) were shown to qualify for CYP inhibition with high confidence level (> 79%).
Table 8. Compounds predicted to have CYP enzyme inhibition with a high confidence level in
five different CYP inhibition models (CYP3A4, CYP1A2, CYP2C9, CYP2D6, and CYP2C19)
available in ADMET predictor
G. glabra

G. uralensis

CYP3A4_Inh

1 (80%), 28 (80%), 29 (80%), 67 (80%), 83
(80%), 108 (80%), 140 (80%), 146 (80%), 158
(80%), 170 (80%)

15 (80%), 16 (80%), 17 (80%), 20 (80%),
32 (80%), 51 (80%), 53 (80%), 55 (80%),
56 (80%), 61 (80%), 66 (80%), 77 (80%),
79 (80%), 85 (80%), 111 (80%), 121 (80%),
122 (80%), 171 (80%), 186 (80%)

CYP1A2_Inh

1 (84%), 8 (95%), 9 (95%), 17 (95%), 18 (95%),
20 (84%), 24 (95%), 31 (79%), 34 (95%), 36
(95%), 43 (84%), 45 (95%), 48 (95%), 53 (95%),
54 (95%), 55 (95%) , 56 (95%), 62 (95%), 71
(95%), 72 (95%), 74 (95%), 76 (95%), 77 (95%),
88 (95%), 92 (84%), 95 (95%), 101 (84%), 104
(95%), 106 (84%), 120 (95%), 122 (95%), 130
(95%), 136 (79%), 139 (95%), 140 (95%), 147
(84%), 148 (84%), 149 (95%), 160 (95%), 166
(95%)

2 (84%), 3 (95%), 5 (79%), 6 (84%), 38
(95%), 39 (79%), 42 (95%), 60 (95%), 61
(79%), 64 (84%), 66 (79%), 70 (95%), 85
(79%), 91 (84%), 108 (95%), 111 (79%),
114 (95%), 118 (95%), 124 (95%), 148
(95%), 149 (95%), 157 (84%), 158 (95%),
159 (95%), 161 (95%), 162 (95%), 179
(79%)

CYP2C9_Inh
CYP2D6_Inh
CYP2C19_Inh

94 (70%)

5 (77%), 14 (77%), 19 (77%), 20 (77%), 22
(77%), 24 (77%), 47 (77%), 54 (77%), 57
(77%), 70 (77%), 83 (77%), 88 (77%), 113
(77%), 119 (77%), 133 (77%), 149 (77%),
152 (77%), 161 (77%), 164 (77%), 180
(77%), 181 (77%)
50 (70%), 54 (70%)

21 (78%)

94 (77%)

19 (77%), 22 (77%), 37 (77%), 52 (77%), 54
(77%), 112 (77%), 129 (77%)

IV.3 Discussion
Earlier reports showed weak PXR activation related to its glycyrrhizin component. Many
manufacturers provide deglycyrrhizinated licorice (DGL licorice) supplements, which are
labeled to be safe and effective since it avoids the hypertensive crises that could be triggered by
glycyrrhizin. However, this does not mean that these DGL supplements are void of HDI. In this
manner, underestimation of a plant material, which can potentially produce hundreds of
compounds, might be responsible for potentiating HDI. PXR plays a pivotal role in the ADME
properties of the co-ingested conventional drugs that might change its metabolism, distribution,
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and elimination.
To better understand the pharmacokinetic interaction potential of the licorice plant
constituents, we have utilized a dual approach by applying integrated in silico structure-based
PXR screening followed by in vitro testing. The molecular docking into PXR LBD can capture
the global features, which might later turn on the activation cascade of the target genes. This
approach is anticipated to increase the efficiency of the in vitro screening for preclinical studies.
In this work, we have revealed multiple licorice components that essentially possessed high
docking scores together with excellent interaction with the key amino acids such as S247, W299,
and H407. A large group of isoflavonoids and stilbenoids common in licorice attained such
features similar to the known activators. All of the top ranking ligands are prenylated with at
least one prenyl group, which indicated the highly favorable hydrophobic interactions for PXR.
This initial result also suggests the vital role of these prenylation patterns as a fingerprint for
PXR recognition. It also demonstrates the bi-faceted nature that these prenylated patterns might
bear, since they were shown in previous reports to increase the activity, selectivity, and the
bioavailability as compared to their unprenylated congeners.
However, they appear to be a source of liability and should be dealt with caution. In this
study, we sought to explore the validity of our in silico predictions by the application of in vitro
screening of a home-designed resveratrol and dihydroresveratrol prenylation products archetypal
of stilbenoids and dihydrostilbenoids present into different licorice species. Interestingly, these
experiments manifested the ability of these compounds to induce PXR as predicted. Given the
fact that PXR activation is highly sensitive for the hydrophobic features, one can surmise that the
addition of prenyl groups can enhance the interactions with the LBD. The in vitro screening has
supported this postulate with some of the compounds far more active than the unprenylated
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counterparts. Some rudimentary SAR could be withdrawn from these results. Both unprenylated
compounds, resveratrol, and DHR, had very weak but comparable activity against PXR at 25 µM
concentration in accord with their low docking scores, with resveratrol having better ability in
maintaining this activity at lower concentrations (6.25 µM). The abolished rigidity in the
dihydroresveratrol M11 had dramatically affected the pose prediction in the LBD as compared to
resveratrol M1, which adopted more cis-like conformation to allow multiple polar interactions
(Figure 32).

F281
Q285
H407

F288
W299

F288

Q285

F281

S247
S247
W299

H407

Figure 32. (Left) The docking pose of M1 (grey sticks) and M11 (purple sticks) in PDB:1NRL
(white cartoon). (Right) The docking pose of M15 (green sticks) in the same crystal structure. ππ interactions are shown in blue dotted lines and H-bonds in red dotted lines.
Nevertheless, these interactions failed to increase the docking score (~ −6.5) or the
activity of the compound as compared to the trans-resveratrol, most likely due to the increased
entropy experienced with the increase in the number of the rotatable bonds. None of the monoprenylated M1 derivatives at positions C2 and C4 (as a straight chain or the cyclized THP),
namely M2, M3, M4, and M5 were able to induce PXR. The docking scores (−7.43, −8.563,
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−9.922, −8.262

respectively) generally indicated a lower chance of activation but failed to sense

the slightly active ones, which is acceptable as we indicated in the validation experiment.
Compounds M3 (arachidin 2) and its cyclized congener M4 showed cell toxicity in accord with
previous reports. In contrast, all the mono-prenylated DHS (M12, M13, M14, and M15) were
active at the 25 µM concentration.
Interestingly, the more constrained mono-prenylated DHS (the cyclized versions) M14
and M15 were able to show salient multiple fold activation in the reporter gene assay (up to 4
folds at 25 µM). Moreover, M15 showed at least 6-fold induction in CYP3A4 mRNA expression
levels, which has further supported the PXR induction observed in the reporter gene assay.
According to our cut-off value, these compounds are classified, as moderate activators. Although
they were not well differentiated as compared to their resveratrol cyclized mono-prenylated
mates, we noticed that the direction of the docking poses of these compounds were opposite
(Figure 32, Right). We assumed that the free phenyl moiety of DHS (unprenylated side), which
resides in the hydrophobic sub-pocket of both F288 and W299 acquire firm π-π interactions
compared to the benzo-tetrahydropyran side (with the less aromatic character) of the stilbenoid
posed at the same site. Of note, this might not be the case for some of the natural compounds
found in licorice where they have a benzo-dehydropyran moiety, which pertains aromatic
character in both ring systems. We have also examined the double prenylated derivatives
represented with different patterns. Those compounds have their prenylation in a straight chain
(M6, M7, M16, and M17), mixed patterns of straight prenyl and cyclized (M8, M9, M10) and
the double cyclized (M18). Amazingly, as predicted by their higher scores, all the double
prenylated compounds are PXR actives as verified by their 4-5 fold induction in the reporter
assay. In addition, these compounds activated the luciferase reporter gene at very low
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concentrations indicating a higher potency. Moreover, all the tested double prenylated
compounds were also capable of inducing CYP3A4 mRNA expression.
F281

F281

Q285

H407

Q285

F288 S247

F288 S247
L234
L209

W299

F281

L234
L209

H407

Q285
F288

W299

H407

S247
L234

W299

L209

Figure 33. Docking pose of M10 in green tubes (Left up), M7 in aqua blue (left down) and
M17 in bluish green tubes (Right up) in PDB: 1NRL (maroon cartoon) showing π-π bonds (blue
dotted line) with W299 and P288 (orange ball and sticks). (Right down) M7 and M10 overlaid
docking pose.
However, high levels of mRNA expression are noticed for the tested compounds M7,
M10 and M15 (up to 6 folds). M7 and M10 have secured π-π interactions with the key residues
F288 and W299 as shown in Figure 33. These compounds are prenylated at the same positions,
but the cyclization of one of the prenyl group (M10) did not affect the activity. In contrast, the
rigidity of the compound seems to have a prominent role at these positions (based on mRNA
levels), which is apparent by comparing M7 and M10 (stilbenoids) with M17 (DHS).
It is also of vital importance to screen for allosteric antagonist activity since some of the
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compounds might have a preferred interaction and selectivity toward the AF-2 region rather than
the LBD especially in the presence of other agonists. Ketoconazole is the prototype of an
allosteric PXR modifier, which was proposed to interact with the AF-2 region precluding the
coactivator from binding. Other natural products were also described such as coumestrol and
resveratrol. However, for resveratrol, controversial conclusions were drawn from different
studies about its allosteric antagonistic character. To evaluate the ability of resveratrol and the
other tested compounds to act as pure agonists or allosteric antagonists, selected representative
compounds of different prenylation patterns were screened in the reporter assay together with
rifampicin. Our findings revealed that resveratrol and the other derivatives failed to antagonize
the rifampicin induced PXR in HepG2 cells at the tested concentration range, suggesting that
these stilbenoids including DHS might be binding at allosteric site.
These tested synthesized compounds resonated with the DHS present in the licorice
species except that the latter have the piceatannol as a precursor rather than resveratrol. It is wellestablished that piceatannol is a direct metabolite of resveratrol with one extra hydroxy group
permitting an extra hydrogen bond. Hence, they have achieved higher scores in the initial
screening. Some of the alerting “in silico identified” compounds found in licorice are speciesspecific. For example, the diprenylated DHS U15 and U16 found in Glycyrrhiza uralensis.
Others belong to the cycloprenylated isoflavenes, which are species-specific markers of G.
glabra. Moreover, multiple moderately active compounds may synergistically activate PXR and
dispose of a higher risk for HDI.
IV.4 Experimental
IV.4.1 Docking experiments
Both proteins crystal structures PDB: ID 1NRL and 1M13 were prepared using the
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Protein Preparation Wizard (PrepWizard, Schrodinger 10.3). For both structures, hydrogen atoms
were added after the deletion of original ones, and the bond orders were assigned. The protein
structure was checked and the missing residues or loop segments were added using Prime. Nonhydrogen- bonding water molecules were removed. Only chains B and D for 1NRL and chain A
for 1M13 were included in the current study. The protonation and tautomeric states of H, Q, S, T,
and E were adjusted to match a pH of 7.4. Possible orientations of side chain were generated and
checked. Active site water molecules beyond 5.0 Å from the ligand were deleted. Then, the
protein-ligand complex was subjected to geometry refinement using an OPLS2005 force field,
and restrained minimization. The convergence of heavy atoms was set to an RMSD of 0.3 Å.
Docking grids for both 1NRL and 1M13 were generated with the default settings in Glide using
the co-crystalized ligands to define the center of the grid box (20 x 20 x 20Å). No constraints
were included during grid generation. The generated databases of both G. glabra and G.
uralensis (described in Chapter II) in addition to the generated library of positive controls (Table
5), which includes known potent ligands (hyperforin and 4-hydroxytamoxifen) as well as a
moderate inducer (hypericine and enterolactone) and the weak activators (genistein and
physcion) were prepared using LigPrep module. Initially, the 2D structures of these molecules
were sketched using ChemDraw, converted to 3D structures, and then saved as SD files before
they were exported to Maestro.
After 3D structures were loaded, OPLS2005 force field and charges were used in all
ligand preparation steps. Possible protonation states and ionization states were explored for each
ligand using Epik at a pH of 7.4. Chirality was determined from 3D structures and compared
with reported literature. Tautomeric states were generated for chemical groups with possible
prototrophic tautomerism. Only the lowest energy conformer was kept for each ligand. For
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validation and comparison purposes, the positive controls were docked in the generated grids of
both 1NRL and 1M13 using flexible ligand protocol of both SP and XP glide docking. For
screening of the generated licorice libraries, they were docked into 1NRL using XP flexible
docking. The compounds, which scored below −9.5 kcal/mol, were kept for further analysis.
IV.4.2 PXR activation
IV.4.3 Reporter gene assay
PXR activation by the synthesized compounds was measured in HepG2 cell lines
transiently transfected with 25 μg of pSG5‐hPXR (the expression vector was provided by Dr.
Steven Kliewer, University of Texas Southwestern Medical Center) and 25 μg of PCR5 plasmid
DNA (the reporter plasmid was provided by Dr. Christopher Liddle, University of Sydney) by
electroporation as described earlier. The 96‐well plates were seeded with cells at a density of
50,000 cells per well. When the cells reach > 90% confluency after 24 hrs, the synthesized
compounds and the positive control were added at 25, 12.5, 6.25, 3.13, 1.56 and 0.78 μg/mL.
Subsequently, the media was aspirated after incubation with the test compounds for 48 hrs, and
40 μL of luciferase reagent (Promega Corporation, Madison, WI, USA) was added to each well.
After which, the luminescence was measured on Spectramax M5 plate reader (Molecular
Devices, Sunnyvale, CA, USA). The activation of luciferase in the treated cells was calculated in
comparison with vehicle-treated cells.
IV.4.4 RT‐PCR analysis of CYP3A4
CYP3A4 primers qHsaCID0012316 (both the forward and reverse primers) were
purchased from Bio‐Rad Laboratories (Hercules, CA, USA). HepG2 cells transfected (> 90%
confluency) as described above, were implanted into 6‐well plate (5 × 105 per well) and they
were allowed to grow for 24 hrs. Subsequently, cells were treated with three different
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concentrations of test samples (10, 3 and 1 µM; 10μM for rifampicin (the positive control) for 48
h. The RNA was extracted using the Quick‐start protocol (Qiagen®) after washing the cells with
PBS. The concentration of RNA was calculated using a BioTek Take3 plate, which uses the
A260/A280 ratio to assess the purity. The template used in BioRad's iScript Reverse
Transcription kit was RNA equal to 0.5μg/ml for initial strand complementary DNA synthesis.
The resultant complementary DNA strand was fed as the template into BioRad's iTaq Universal
SYBR Green supermix. RT‐PCR was performed in a 96‐well plate employing a CFX connect
real-time PCR detector system (Bio‐Rad). The housekeeping gene HPRT1 (qHsaCID0016375)
was used to normalize the quantification of expressed CYP3A4 genes. The fold induction in
mRNA expression post-treatment was measured in comparison with the vehicle as described
earlier.168
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
The biodiversity offered by NPs and the successful records achieved in the drug
discovery based on NPs underline their significant roles in this area. Marked therapeutics of
anticancer, anti-infective, lipid-lowering, antimalarial, and immunosuppressant are either NPs or
NPs derivatives. Despite the vast developments in the analytical and screening techniques, the
activity and risk assessment of plant-based therapy is still challenging. The extensive challenges
of an NP-based discovery made them less present in the pharmaceutical industry paradigms.
However, the decline in the vital drugs registered or approved by the FDA has changed their
outlook for screening programs. Although it is an extremely intricate situation, yet
cheminformatic techniques can offer a variety of solution models to deal with the complexity of
NPs. Of note, the application of medicinal chemistry roles for filtration of virtual libraries would
avoid most of the NPs structural features since they break many regular rules practiced in other
disciplines.
However, the unique structural features of NPs evolved to recognize natural target
motives in living systems. The application of in silico tools to search for these untapped NPs
might unveil unprecedented activities. Moreover, the increase in consumption of herbal
supplements to alleviate various ailments have outpaced the understanding of their safety or
efficacy. This situation has created a knowledge gap in the herbal remedy assessments and
revealed the deficiency for a fit of purpose methodology that could deal with complex mixtures
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of an herbal supplement. For instance, the preference of a reputable herbal remedy to
alleviate menopausal symptoms is encouraged by the failure of therapeutic estrogens to
demonstrate adequate safety under different dosage forms, route of administration, or
formulations. This trend is further stimulated by the pertained polypharmacology and the
perceived safety of herbal treatments. One characteristic plant in this category is licorice. Similar
to other herbal remedies, licorice offers digestive relief, antioxidant, anti-inflammatory, antiviral,
antibacterial, and chemopreventive properties in addition to its estrogenic nature. However, the
rise in licorice consumption and self-medication together with prescription drugs and/or over the
counter medication is a major concern for metabolic disruption as well as HDI. In particular,
licorice is consumed as an adjuvant therapy together with conventional drugs, and it is present in
70% of the TCM herbal prescriptions, where it is described as a guide drug. Moreover, many
medical practitioners believe that it has powerful chemopreventive and antitumor effects.
Whereas, some of these co-administered drugs are narrow-indexed therapeutics, which are
commonly consumed by the targeted population of elderly women for chemoprevention in a
high-risk of breast cancer or with anticancer agents themselves. Hence, there is a great potential
of unrecognized HDI that could be attributed to other improper causes, which often raise
questions with no specific rational answers.
To evaluate the applicability of cheminformatic methods in such a situation, we have
utilized a platform of ensemble docking and QSAR techniques to study its estrogenic activity.
Our results allocated a multitude of potential estrogenic components found in licorice diverse
phenolic metabolome. Many of them are present with different prenylation patterns that could
alter both hER isoforms. The connection of the plant estrogenic activity to a single entity is an
oversimplification, which undermines its safety. Deconvolution of the phenolic metabolome of
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both G. glabra and G. uralensis revealed around 50 unique compounds in each species that
potentially could alter the hER pathways in different manners of agonism or antagonism, which
ultimately might lead to endocrine disruption by its chronic use.
This situation implies the significance of characterization and purification when needed
for potential phytoalexins or phytoSERMs that might be involved in such activity. The
application of these techniques was successfully validated by the identification of the already
known hER active compounds from licorice. After receiving favorable results thus far, we
decided to focus onto one of the top scoring components based on both ensemble docking and
QSAR analysis that have not been yet rigorously explored. The DHS, tethered with different
prenylation patterns, showed favorable interactions in both hERs structures that were dependent
on the position of the prenyl group. To further analyze the effect of the prenylation pattern on
DHS activity, we aimed to synthesize a small library of prenylated DHS archetypal of those
found in licorice. Fortunately, a diverse set of prenylation patterns could be achieved in one pot
reaction as we described in chapter III. For initial screening purposes, we have found that the
divergent installation of the
prenyl group is convenient to provide sufficient quantities for biological testing. Two
series of stilbenoids (M1-M10) and DHS (M11-M18) were synthesized. Multiple structures
were synthesized for the same time (M8, M9, M14, M15, M17, and M18). Having this library of
compounds in hand, the in vitro analysis of estrogenic activity is ongoing and the results will be
reported in the near future to verify what these patterns might reveal as a unique SERM activity.
These results would also help us to comprehend the estrogenic activity of licorice plant by
validation of these methods. Particularly, some of these diprenylated DHS are species-specific
for G. uralensis.
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Licorice plant was described to have high potential for exerting HDI. However, different
mechanisms could be involved in this behavior. Having the induced herb-drug interaction of
licorice supplements via PXR less studied; we ventured to analyze the potential PXR activation
by the application of in silico tools. We have coupled the molecular docking experiments with
the in vitro testing to verify PXR agonists. We have identified many compounds, which are
potentially capable of triggering PXR; some of these compounds belong to a specific licorice
species. Interestingly enough, the prenylated DHS was one of the identified alerting classes for
PXR activation. As a proof of concept, we have further validated our approach by screening the
DHS synthesized library with the cell-based in vitro luciferase reporter gene assay. As a result,
this study has unveiled prenylated stilbenoids and DHS as a potential source of PXR activation.
Furthermore, these results were confirmed by the CYP3A4 mRNA expression, which was
susceptible to 6 fold activation by multiple tested compounds, especially those of cyclized and
diprenylated ones similar to glabridin-like metabolites. This situation raised some questions
about higher prenylation patterns, ubiquitous in nature or intended for lead optimization, as a
PXR phenotypic alerts.
To verify other mechanisms of HDI, we have screened the licorice components against
multiple available QSAR CYP inhibition models. This initial analysis has provided us with a list
of potentially problematic compounds that might participate in the precipitation of some risks
upon licorice consumption such as HDIs. Two out of five CYPs, namely CYP3A4 and CYP1A2
were predicted as a major concern for direct CYP inhibition in both licorice species under
investigation. However, G. uralensis is predicted to have a higher burden against CYP2C9. It is
important to note that these predictions are void of pharmacokinetics predictions, and further
physiologically based models are required to evaluate the in vivo reliability of the predicted
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inhibition.
Taken together, the application of cheminformatic tools can provide us with immense
information that could be the key to untangle the complex mixtures of herbal remedies and their
activity or safety profiles. Furthermore, there is a continuous need to find new drugs for reluctant
ailments or resistant therapeutics. NPs are sustainable resources that can supply us with
compelling untapped structural activities by the application of the appropriate techniques.
Finally, with the versatile plausible mechanisms of hER interruption that could be exerted
by the phenolic content of licorice, in addition to the different HDI mechanism discussed in this
research, we find many concerns regarding licorice plant as a safe surrogate of estrogen. Further
validation models of endocrine and metabolic disruption should be evaluated. Moreover, our
research results trigger many questions: Is hERβ antagonism capable of turning on proliferation
effects via deletion of its negative feedbacks against hERα? Does higher prenylation patterns
found in many licorice phenolic metabolome exert antagonism against hER-β similar to its
capacity of counteracting hERα? And if it does what would be the end result in tissues populated
with both hERs isoforms? Which, if any, of those predicted compounds have preferable SERM
characteristics? Have our bodies already developed the tools to recognize these prenylation
patterns and made them self-limiting? Is it the induction rather than inhibition route of HDI to
take over in in vivo setting? Faced with all these overwhelming questions, we have more
endeavors to explore and find the answers in the future.
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APPENDIX I.
List of SI tables
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SI 1. Sitemap surface type criteria
1GWR

ACCPTR A DONOR B PHIL C
128.45
185.70
318.23

PHOB D
247.90

METAL
0

SURF E
654.24

2P15

191.43

397.62

587.40

340.33

0

1039.75

3ERT

188.00

427.37

602.56

299.20

0

1496.72

4J24

87.60

204.93

276.69

223.40

0

564.67

1X7J

96.15

172.19

284.55

266.36

0

628.82

1L2J

116.13

288.99

421.65

394.48

0

1244.09

(a) Hydrogen bond acceptor (b) Hydrogen bond donor (c) Hydrophilic (d) Hydrophobic (e) Total surface

SI 2. SP docking scores (kcal/mol) of redocking and crossdocking of co-crystallized ligands
hERα

hERβ

RMSD

Ligand/PDB

1GWR

2P15

3ERT

1X7J

4J24

1L2J

1GWR-Nativelig

−10.91

−10.78

−8.65

−9.81

−10.81

−9.42

0

2P15-Nativelig

NA

−14.44

NA

NA

NA

NA

0.51

3ERT-Nativelig

NA

−10.77

−11.37

NA

NA

NA

1.90

1X7J-Nativelig

−10.06

−9.81

−9.38

−10.55

−9.43

−9.43

0.29

4J24-Nativelig

−10.91

−10.78

−8.65

−9.81

−10.81

−9.42

0

1L2J-Nativelig

−11.09

−11.17

−9.36

−11.08

−11.33

−11.92

0.40

130

SI 3. Compounds from Glycyrrhiza glabra
No.

Name (G. glabra)

M. Formula

CAS

G1

C25 H26 O4

91433-17-9

diprenyl-flavone

G2

Prenyllicoflavone A=
Licoflavone B
3-Hydroxyglabrol

C25 H28 O5

74148-41-7

Flavanone-3-ol

169-170

G3

Glabrol

C25 H28 O4

59870-65-4

diprenylflavanone

169-170

G4

6''-O-Acetylliquiritin

C23 H24 O10

166531-17-5

Flavanone-glucoside

DNP

G5

Liquiritoside =Liquiritin

C21 H22 O9

551-15-5

flavanone glycoside

171

G6

Liqcoumarin

C12 H10 O4

36695-19-9

Coumarin

172

G7

Glucoliquiritin apioside

C32 H40 O18

157226-47-6

flavanone glycoside

46, 171

G8

Pinocembroside

C21 H22 O9

75829-43-5P

flavanone glycoside

173

G9

Pallidiflorin

C16 H12 O4

133086-79-0

isoflavone

174

G10

Liquiritigenin

C15 H12 O4

578-86-9

Flavanone

170

G11

17991-67-2

C30 H46 O5

17991-67-2

saponin

175

G12

Glabric acid

C30 H46 O5

22327-86-2

saponin

176

G13

24-Hydroxyliquiritic acid

C30 H46 O5

20528-69-2

saponin

177

G14

Isoglabrolid

C30 H44 O4

10376-64-4

saponin

178

G15

Liquiritin apioside

C26 H30 O13

74639-14-8

flavanone glycoside

171

G16

Glabroside

C26 H30 O13

152246-80-5

flavanone glycoside

179

G17

Eicosanyl (E)-caffeate

C29 H48 O4

28593-90-0

miscellaneous

DNP

G18

Glychionide B

C22 H20 O11

51059-44-0

flavone glycoside

180

G19

862389-76-2

C21 H24 O4

862389-76-2

prenyl stillbenoid

173

G20

Isoglabranin

C20 H20 O4

55051-77-9

6-prenylflavanone

181

G21

525585-31-3

C19 H22 O3

525585-31-3

prenyl stillbenoid

173

G22

kanzonol D

C25 H24 O4

155233-20-8

prenyl-flavone

182

G23

C15 H16 O4

60640-97-3

stillbenoid

C16 H12 O5

552-59-0

isoflavone

G25

3,3',5'-Trihydroxy-4methoxybibenzyl
7-O-Methylgenistein or
Prunetin
98063-17-3

C31 H48 O4

98063-17-3

saponin

DNP

G26

24-Hydroxyglycyrrhetinic acid

C30 H46 O5

52911-55-4

saponin

184

G27

28-Hydroxyglycyrrhetic acid

C30 H46 O5

56061-86-0

saponin

185

G28

Uralstilbene

C24H30O4

677709-69-2

diprenyl-stilbene

DNP

G29

139101-68-1

C21 H26 O9

139101-68-1

stillbenoid glycoside

DNP

G30

525585-32-4

C20 H24 O4

525585-32-4

prenyl stillbenoid

173

G31

2'-O-Methylglabridin

C21 H22 O4

211099-37-5

pyran-isoflavan

186

G32

4'-O-Methylglabridin

C21 H22 O4

68978-09-6

pyrano-isoflavane

170

G33

525585-33-5

C19 H22 O4

525585-33-5

prenyl stillbenoid

173

G34

Isoglycyrol

C21 H18 O6

23013-86-7

pyran-coumestan

54

G35

Glabridin

C20 H20 O4

59870-68-7

pyrano-isoflavane

170, 187

G36

Gancaonin F

C21 H16 O6

126716-33-4

miscellaneous

169

G37

Licoflavone A

C20 H18 O4

61153-77-3P

prenyl-flavone

171, 188

G24

131

Class

Ref.
169

173
183

G38

Glabrene

C20 H18 O4

60008-03-9

pyrano-Isoflavene

170, 188

G39

Arachidic alcohol

C20 H42 O1

629-96-9

miscellaneous

DNP

G40

525585-30-2

C24 H30 O4

525585-30-2

diprenyl stillbenoid

173

G41

525585-29-9

C24 H30 O3

525585-29-9

diprenyl stillbenoid

173

G42

1201180-35-9

C25 H28 O4

1201180-35-9

prenyl-pyrano-isoflavanone

189

G43

Shinflavanone

C25 H26 O4

157414-03-4

pyrano-prenyl-flavanone

170-171

G44

Licoagrocarpin

C21 H22 O4

202815-29-0

prenyl-pterocarpan

170

G45

Xambioona

C25 H24 O4

82345-36-6

dipyrano-flavanone

188

G46

Glycyrrhizin

C42 H62 O16

1405-86-3

saponin glycoside

171

G47

Glycycoumarin

C21 H20 O6

94805-82-0P

coumarin

46

G48

Glyinflanin B

C20 H18 O5

142750-23-0

miscellaneous

190

G49

3,4-Didehydroglabridin

C20 H18 O4

214283-58-6

pyrano-isoflavene

170

G50

Glabrocoumarin

C20 H16 O5

866021-47-8

Coumarin

188

G51

Glabrone =Eurycarpin B

C20 H16 O5

60008-02-8

pyrano-Isoflavone

170

G52

56262-33-0

C30 H46 O4

56262-33-0

saponin

191

G53

C19 H16 O4

164123-54-0

pyrano-1-benzofuran

G54

Glabrocoumarone B
=Glyinflanin H
Glyzarin

C18 H14 O4

62820-28-4

isoflavone

170

G55

2-Methyl-7-acetoxyisoflavone

C18 H14 O4

3211-63-0

isoflavone

192

G56

7-Methoxy-2-methylisoflavone

C17 H14 O3

19725-44-1

isoflavone

192

G57

7-Hydroxy-2-methylisoflavone

C16 H12 O3

2859-88-3

isoflavone

192

G58

11-Deoxoglycyrrhetinic acid

C30 H48 O3

564-16-9

saponin

53

G59

14884-88-9

C30 H46 O3

14884-88-9

saponin

DNP

G60

Glyinflanin A

C25 H28 O5

142542-83-4

propanedione

190

G61

Hispaglabridin A

C25 H28 O4

68978-03-0

prenyl-pyrano-Isoflavane

170

G62

944257-60-7

C25 H26 O4

944257-60-7

dipyrano-chalcone

187

G63

Hispaglabridin B

C25 H26 O4

68978-02-9

dipyrano-Isoflavane

170

G64

Licoagroside B

C18 H24 O12

325144-72-7

miscellaneous

190

G65

3'-Methoxyglabradin

C21 H22 O5

74046-05-2

pyran-isoflavan

193

G66

944257-63-0

C65 H108 O8

944257-63-0

neolignan lipid esters

187

G67

Kanzonol T

C25 H26 O7

181476-22-2

Kanzonol Z

C25 H26 O5

220860-37-7

170

G69

Kanzonol V

C24 H24 O4

184584-65-4

pyrano-prenyl-isoflavone
pyrano-prenyl-Flavanone-3ol
prenyl-pyrano-benzofuran

194

G68

G70

Isoglycycoumarin

C21 H20 O6

117038-82-1

coumarin

DNP

G71

FCO69-H

C21 H18 O5

FCO69-H

prenyl-isoflavene

DNP

G72

Kanzonol B

C20 H18 O4

155233-19-5

pyrano-chalcone

170

G73

Kanzonol W

C20 H16 O5

184584-82-5

pyrano-Arylcoumarin

170

G74

isoderon

C20 H16 O5

121747-89-5

pyrano-isoflavone

DNP

G75

Glabrocoumarone A

C19 H16 O4

178330-48-8

pyrano-1-benzofuran

170

G76

944257-62-9

C63 H104 O8

944257-62-9

neolignan lipid esters

187

G77

944257-61-8

C61 H100 O8

944257-61-8

neolignan lipid esters

187

132

170

169

G78

1201180-37-1

C36 H58 O7

1201180-37-1

saponin glycosides

189

G79

Glycyrrhetol

C30 H48 O3

14226-18-7

saponin

195

G80

Liquiritic acid

C30 H46 O4

10379-72-3

saponin

196

G81

18α-Glycyrrhetinic acid

C30 H46 O4

1449-05-4

saponin

197

G82

C30 H46 O4

471-53-4

saponin

G83

18β-Glycyrrhetinic acid=
Enoxolone
Kanzonol Y

C25 H30 O5

184584-87-0

diprenyldihydrochalcone

170

G84

Licoagrodin

C45 H44 O9

325144-66-9

miscellaneous

190

G85

Licoagrochalcone D

C21 H22 O5

325144-69-2

chalcone

190

G86

Licochalcone A

C21 H22 O4

58749-22-7

prenylated Chalcone

171

G87

Licoagrodione

C20 H20 O6

220860-12-8

miscellaneous

198

G88

Methoxyphaseollin

C21 H20 O5

157226-48-7

pyrano-pterocarpin

171

G89

Licoagrochalcone B

C21 H20 O4

325144-67-0

pyrano-chalcone

199

G90

phaseolinisoflavin

C20 H20 O4

40323-57-7

pyran-isoflavan

193

G91

Isoglabrone

C20 H16 O5

1115012-65-1

pyrano-Isoflavone

170

G92

Licochalcone B

C16 H14 O5

58749-23-8P

chalcone

188

G93

Deoxyglabrolide

C30 H46 O3

10379-62-1

saponin

199

G94

Licoricidin

C26 H32 O5

30508-27-1

diprenyl-isoflavan

200

G95

Licoagroside A

C23 H24 O12

30508-27-1

190

G96

Licocoumarin A

C25 H26 O5

222034-74-4

isoflavonoids glycosides
coumarin

DNP

G97

Kanzonol R

C22 H26 O5

156250-73-6

prenyl-Isoflavan

169

G98

Glyasperin K

C22 H24 O6

156162-03-7

prenyl-isoflavanone

DNP

G99

licoagrochalcone C

C21 H22 O5

325144-68-1

chalcone

190

G100

Morachalcone A

C20 H20 O5

76472-88-3P

prenyl-chalcone

188

G101

Isolicoflavonol

C20 H18 O6

94805-83-1

prenyl-3-OH-flavone

DNP

G102

Isomucronulatol

C17 H18 O5

64474-51-7

isoflavan

200

G103

Folerogenin

C16 H14 O6

35815-06-6

3-OH-flavanone

201

G104

glyzaglabrin

C16 H10 O6

65242-64-0

isoflavone

202

G105

Liquiridiolic acid

C30 H48 O5

20528-70-5

saponin

177

G106

C20 H20 O5

119240-82-3

prenyl-flavanone

G107

Licoflavanone =3'Prenylnaringenin
6-Prenylnaringenin

C20 H20 O5

68236-13-5

prenyl-flavanone

169

G108

Gancaonin L

C20 H18 O6

129145-50-2P

prenyl-Isoflavone

188

G109

Licoagrochalcone A

C20 H20 O4

202815-28-9

prenyl-Chalcone

170

G110

Licoagroaurone

C20 H18 O5

325144-70-5

prenyl-Benzofuranone

190

G111

Erythrinin B =Wighteone

C20 H18 O5

51225-30-0

prenyl isoflavone

203

G112

C20 H18 O5

104691-86-3

prenyl-Isoflavone

G113

8-Prenylgenistein
=Lupiwighteone
163121-02-6

C15 H12 O4

163121-02-6

chalcone

DNP

G114

18184-25-3

C30 H44 O5

18184-25-3

saponin

204

G115

10401-33-9

C30 H44 O4

10401-33-9

saponin

205

G116

Licuraside

C26 H30 O13

29913-71-1

chalcone glycoside

171

G117

Kanzonol X =Tenuifolin B

C25 H30 O4

182745-37-5

diprenyl-Isoflavane

170

133

46

173

170

G118

Isoliquiritin

C21 H22 O9

5041-81-6

chalcone glycoside

171

G119

Neoisoliquiritigenin

C21 H22 O9

59122-93-9

chalcone glycoside

171

G120

Glychionide A

C21 H18 O11

119152-50-0

flavone glycoside

180

G121

Licochalcone C

C21 H22 O4

144506-14-9

prenyl chalcone

199

G122

Calycosin

C16 H12 O5

20575-57-9

isoflavone

55

G123

(−)-Naringenin

C15 H12 O5

480-41-1

Flavanone

173

G124

Formononetin=Biochanin B

C16 H12 O4

485-72-3

Isoflavone

47

G125

Isoliquiritigen

C15 H12 O4

961-29-5

Chalcone

170

G126

Kumatakenin B

C15 H10 O4

2196-14-7

flavone

206

G127

Glicoricone

C21 H20 O6

161099-37-2

prenyl-isoflavone

DNP

G128

R)-(−)-Vestitol

C16 H16 O4

35878-41-2P

isoflavan

188

G129

C21 H20 O9

20633-86-7

flavone-glycoside

G130

4',7-Dihydroxyflavone 7-Dglucoside
1217305-76-4

C21 H20 O5

1217305-76-4

G131

1217305-78-6

C20 H20 O5

1217305-78-6

benzaldehyde-pyranoisoflavan
prenyl-Flavanone-3-ol

G132

201157-06-4

C16 H16 O5

201157-06-4

isoflavan

188

G133

Echinatin =Retrochalcone

C16 H14 O4

34221-41-5P

chalcone

171, 188

G134

131319-67-0

C15 H14 O5

131319-67-0

dihydrochalcone

188

G135

938190-29-5

C25 H28 O5

938190-29-5

diprenyl-chalcone

188

G136

151135-83-0

C25 H26 O5

151135-83-0

prenyl-pyrano-chalcone

188

G137

Euchrenone a5

C25 H26 O4

125140-20-7

pyrano-prenyl-flavanone

188

G138

905708-40-9

C21 H22 O6

905708-40-9

prenyl-chalcone

188

G139

C21 H22 O5

175554-11-7

pyrano-isoflavane

G140

3'-Hydroxy-4'-Omethylglabridin
938190-32-0

C21 H20 O5

938190-32-0

prenyl-isoflavone

188

G141

Glabroisoflavanone B

C21 H20 O5

866021-46-7

isoflavanone

207

G142

Glabroisoflavanone A

C20 H18 O5

204700-00-5

isoflavanone

207

G143

400900-10-9

C21 H24 O10

400900-10-9

chalcone glycoside

208

G144

131319-67-0

C15 H14 O5

131319-67-0

dihydrochalcone

188

G145

Rocymosin B

C21 H24 O10

150036-01-4

chalcone glycoside

DNP

G146

Glabraisoflavanone B

C30 H38 O5

1201428-07-0

prenyl flavanone

189

G147

p-Hydroxychalcone

C15 H12 O2

20426-12-4

chalcone

209

G148

Shinpterocarpin

C20 H18 O4

157414-04-5

pyrano-pterocarpan

188

G149

Cordifolin

C16 H14 O5

53219-84-4

chalcone

DNP

G150

Licoagrone

C45 H42 O10

228099-12-5

miscellaneous

DNP

G151

3-Methyl-3-hepten-2-one

C8 H14 O1

39899-08-6

miscellaneous

DNP

G152

8-Prenylphaseollinisoflavan

C25 H28 O4

175554-12-8

prenyl-pyrano-isoflavane

170

G153

DHY67-Q

C25 H28 O6

DHY67-Q

Diprenyl-isoflavanone

G154

Glyasperin B

C21 H22 O6

142488-54-8

prenyl-isoflavanone

DNP

G155

135432-48-3

C26 H30 O13

135432-48-3

flavanone glycoside

210

G156

Abyssinone II =3'Prenylliquiritigenin

C20 H20 O4

77263-08-2

prenyl-flavanone

134

54
188
188

188

DNP

170

G157

Isoviolanthin

C27 H30 O14

40788-84-9

flavone C-glycoside

211

G158

1217888-51-1

C25 H30 O6

1217888-51-1

miscellaneous

212

G159

4''-Hydroxyglabridin

C20 H20 O5

938190-33-1P

pyrano-isoflavan

188

G160

O-Methylshinpterocarpin

C21 H20 O4

157479-38-4P

pyrano-pterocarpan

171, 188

G161

938190-31-9

C14 H16 O4

938190-31-9

188

G162

1217888-54-4

C14 H16 O3

1217888-54-4

188

G163

938190-35-3

C20 H22 O6

938190-35-3

prenyl-dihydrochalcone

188

G164

905708-41-0

C21 H20 O6

905708-41-0

pyrano-isoflavanone-3-ol

188

G165

Ononin 6''-O-acetate

C24 H24 O10

120727-10-8

isoflavone-glucoside

NCNPR

G166

Isoliquiritigenin-4'-Me-ether

C16 H14 O4

32274-67-2

chalcone

NCNPR

G167

demethylvestitol

C15 H14 O4

isoflavan

G168

Resorcinol

C6 H6 O2

ZA17-Gg64190-84-7
Gg2-ZA13

phenolic

NCNPR

G169

ZA15-Gg

C21 H22 O7

ZA15-Gg

arylcoumarine

NCNPR

G170

ZA19-Gg

C20 H18 O6

ZA19-Gg

Prenyl-isoflavone

NCNPR

G171

Erythbidin A

C20 H20 O4

210050-83-2

pyran-isoflavan

NCNPR

G172

ZA20-Gg

C27 H26 O9

ZA20-Gg

miscellaneous

NCNPR

G173

ZA41-Gg

C36 H38 O16

ZA41-Gg

miscellaneous

NCNPR

G174

ZA21-Gg

C20 H18 O5

ZA21-Gg

arylcoumarine

NCNPR

G175

GDY88-C

C25 H28 O6

GDY88-C

diprenylisoflavanone

DNP

G176

Erybacin B

C19 H18 O5

1314877-89-8

G177

Parvisoflavone A

C20 H16 O6

50277-01-5

135

NCNPR

170
pyran-isoflavone

170

SI 4. Compounds from Glycyrrhiza uralensis
No.

M. Formula

CAS

Class

Ref

U1

Name (G. uralensis)
Licorice glycoside C2

C36 H38 O16

202657-55-4

flavanone glycoside

DNP

U2

342433-16-3

C22 H24 O9

342433-16-3

flavanone glycoside

213

U3

Rhizobialide

C18 H32 O3

928213-29-0

stearolactone

214

U4

Neoliquiritin

C21 H22 O9

5088-75-5

flavanone glycoside

50

U5

Cyclolicocoumarone

C20 H20 O5

1253641-17-6

pyrano-benzofuran

215

U6

Kumatakenin

C17 H14 O6

3301-49-3

flavone-3-ol

216

U7

Uralenneoside

C12 H14 O8

143986-30-5

miscellaneous

217

U8

Licorice glycoside D2

C35 H36 O15

202657-65-6

flavanone glycoside

53

U9

76884-47-4

C8 H10 N2 O1

76884-47-4

pyrrolo-pyrimidine

218

U10

Licorice glycoside D1

C35 H36 O15

202657-63-4

flavanone glycoside

53

U11

Licorice glycoside E

C35 H35 N1 O14

202657-66-7

miscellaneous

219

U12

C27 H32 O14

93446-18-5

flavanone glycoside

U13

Liquiritigenin 7,4'diglucoside
134250-13-8

C42 H64 O16

134250-13-8

saponin glycosides

221

U14

Glycycarpan

C26 H32 O6

1346768-08-8

prenyl-pyran-pterocarpan

222

U15

Gancaonin R

C24 H30 O4

134958-53-5

diprenyl-dihydrostillbenoid

169

U16

Gancaonin S

C24 H30 O4

134958-54-6

diprenyl-dihydrostillbenoid

169

U17

Gancaonin U

C24 H28 O4

134958-56-8

U18

Glycyrin

C22 H22 O6

66056-18-6

diprenylDihydrophenancerene
coumarin

U19

Gancaonin I

C21 H22 O5

126716-36-7

prenylated-benzofuran

211

U20

Gancaonin D

C21 H20 O7

124596-88-9

prenyl-isoflavone

223

U21

Licoricesaponin G2

C42 H62 O17

118441-84-2

saponin glycoside

50

U22

Glycybenzofuran

C21 H22 O5

1253641-15-4

prenylated-benzofuran

215

U23

Licocoumarone

C20 H20 O5

118524-14-4

prenylated-benzofuran

215

U24

Gancaonin C

C20 H18 O6

124596-87-8

prenyl-isoflavone

223

U25

Gancaonin V

C19 H20 O4

134958-57-9

prenyl-Dihydrophenancerene

169

U26

Uralsaponin A

C42 H62 O16

103000-77-7

saponin glycoside

224

U27

Licorice glycoside C1

C36 H38 O16

202657-31-6

flavanone glycoside

225

U28

C31 H48 O5

18184-26-4

saponin

U29

24-Hydroxyglycyrrhetic
acid
Glyuranolide

C31 H44 O6

123914-44-3

saponin-lactone

227

U30

Licoricesaponin A3

C48 H72 O21

118325-22-7

saponin glycoside

50

U31

Glypallidifloric acid

C30 H46 O3

17991-81-0

saponin

DNP

U32

Kanzonol L

C30 H32 O6

156281-31-1

diprenyl-pyrano-isoflavone

DNP

U33

Licobichalcone

C32 H26 O10

637338-06-8

biflavonoid

DNP

U34

Kanzonol I

C27 H32 O5

152546-94-6

prenyl-pyran-isoflavan

228

U35

Kanzonol H

C26 H32 O5

152511-46-1

prenyl-pyran-isoflavan

228

U36

Kanzonol J

C26 H30 O5

152511-47-2

dipyrano-isoflavan

228

U37

Kanzonol F

C26 H28 O5

152511-44-9

prenyl-pyran-pterocarpan

228

136

220

169
216

226

U38

Kanzonol M

C23 H26 O6

156250-70-3

prenyl-isoflavan

DNP

U39

Kanzonol N

C22 H24 O6

156250-71-4

prenyl-isoflavan

DNP

U40

Uralsaponin B

C42 H62 O16

105038-43-5

saponin glycoside

211

U41

Glicophenone

C20 H22 O6

303175-66-8

U42

Glycyrrhizol B

C21 H18 O5

877373-01-8

pterocarpan

DNP

U43

Licoricesaponin B2

C42 H64 O15

118536-86-0

saponin glycoside

229

U44

C42 H64 O15

134250-15-0

saponin glycoside

U45

22-Dehydroxyuralsaponin
C
Licoricesaponin K2

C42 H62 O16

135815-61-1

saponin glycoside

230

U46

134449-15-3

C42 H62 O15

134449-15-3

saponin glycoside

229

U47

Licoricesaponin C2

C42 H62 O15

118525-49-8

saponin glycoside

53

U48

Uralsaponin W

C42 H62 O15

1616062-88-4

saponin glycoside

229

U49

C31 H48 O4

1477-44-7

saponin

U50

18β-Glycyrrhetic acid
methyl ester
Licorisoflavan A

C27 H34 O5

129314-37-0

diprenyl-isoflavan

216

U51

Kanzonol G

C26 H30 O6

152511-45-0

diprenyl-isoflavanone

228

U52

1-Methoxyficifolinol

C26 H30 O5

129280-35-9

diprenyl-pterocarpan

228

U53

Kanzonol K

C26 H28 O6

156281-30-0

diprenyl-isoflavan

231

U54

Glycyrrhizol A

C26 H28 O5

877373-00-7

pterocarpan

232

U55

Isoangustone A

C25 H26 O6

129280-34-8

diprenylated-isoflavone

211

U56

Glyurallin B

C25 H26 O6

199331-53-8

diprenylated-isoflavone

233

U57

Gancaonin Q

C25 H26 O5

134958-52-4

diprenyl-flavone

169

U58

22β-Acetoxyglycyrrhizin

C44 H64 O18

938042-17-2

saponin glycoside

211

U59

150853-98-8

C21 H20 O7

150853-98-8

prenyl-flavone

234

U60

C21 H20 O7

151776-21-5

prenyl-3-OH-flavone

U61

gancaonin P-3'-methyl
ether
Uralene

C21 H20 O7

150853-99-9

prenyl-flavone

234

U62

Glycryrurol

C21 H20 O7

1415339-39-7

miscellaneous

236

U63

Licoleafol

C20 H20 O7

677709-68-1

prenyl flavanone

237

U64

Uralenol

C20 H18 O7

139163-15-8

prenyl-isoflavone-3-ol

211

U65

Gancaonin P

C20 H18 O7

129145-54-6

prenyl-flavone-3-ol

169

U66

Neouralenol

C20 H18 O7

C20 H18 O7

prenyl-3-OH-flavone

DNP

U67

119418-01-8

C44 H64 O16

119418-01-8

saponin glycoside

238

U68

Phaseol

C20 H16 O5

88478-02-8

coumestan

DNP

U69

Isotrifoliol

C16 H10 O6

329319-08-6

coumestan

236

U70

Galangin

C15 H10 O5

548-83-4

3-OH-flavone

239

U71

Licorice glycoside A

C36 H38 O16

202657-28-1

chalcone-glycoside

53

U72

Licorice glycoside B

C35 H36 O15

202657-29-2

chalcone-glycoside

240

U73

166531-18-6

C31 H44 O5

166531-18-6

saponin

DNP

U74

24-Hydroxyglabrolide

C30 H44 O5

98063-18-4

saponin-lactone

226

U75

C26 H30 O13

120926-46-7

chalcone glycoside

U76

Isoliquiritin apioside=
Neolicuroside
118536-87-1

C50 H76 O21

118536-87-1

saponin

238

U77

Sigmoidin A

C25 H28 O6

87746-48-3

diprenyl-flavanone

DNP

137

211

224

226

235

216

U78

Gancaonin E

C25 H28 O6

124596-89-0

diprenyl-flavanone

169

U79

782503-66-6

C25 H26 O6

782503-66-6

diprenyl-flavone

DNP

U80

Vestitol 7-O-glucoside

C22 H26 O9

202533-15-1

flavan glycoside

DNP

U81

Licoricone

C22 H22 O6

51847-92-8

prenyl-isoflavone

211

U82

952481-52-6

C21 H20 O9

952481-52-6

flavone glycoside

DNP

U83

Topazolin

C21 H20 O6

109605-79-0

prenyl-flavone-3-ol

211

U84

Gancaonin N

C21 H20 O6

129145-52-4

prenyl-isoflavone

241

U85

Gancaonin B

C21 H20 O6

124596-86-7

prenyl-isoflavone

DNP

U86

Glycyrol

C21 H18 O6

23013-84-5

prenyl-coumestan

216

U87

Licoflavonol

C20 H18 O6

60197-60-6

prenyl-flavone-3-ol

216

U88

Gancaonin O

C20 H18 O6

129145-53-5

prenyl-flavone

169

U89

AlloLicoisoflavone b

C20 H16 O6

117204-81-6

pyrano-isoflavone

211

U90

60169-66-6

C11 H15 N1

60169-66-6

tetrahydroquinoline

242

U91

28971-03-1

C10 H13 N1

28971-03-1

tetrahydroquinoline

242

U92

Uralsaponin C

C42 H64 O16

1262326-46-4

saponin glycoside

211

U93

166531-19-7

C32 H48 O6

166531-19-7

saponin

DNP

U94

Uralenolide

C30 H44 O4

111150-27-7

saponin

DNP

U95

Licoriquinone A

C27 H32 O6

1346768-10-2

Isoflavan-Quinone

222

U96

Licoriquinone B

C26 H30 O6

1346768-14-6

Isoflavan-Quinone

243

U97

Uralsaponin F

C44 H64 O19

1208004-79-8

saponin glycoside

211

U98

Edudiol

C21 H22 O5

63343-94-2

prenyl-pterocarpan

222

U99

1-Methoxyphaseollidin

C21 H22 O5

65428-13-9

prenyl-pterocarpan

244

U100

Gancaonin A

C21 H20 O5

27762-99-8

prenyl-isoflavone

223

U101

Gancaonin G

C21 H20 O5

126716-34-5

prenyl-isoflavone

243

U102

Gancaonin M

C21 H20 O5

129145-51-3

prenyl-isoflavone

241

U103

646508-72-7

C43 H62 O17

646508-72-7

saponin glycoside

DNP

U104

Glyurallin A

C21 H22 O5

213130-81-5

pterocarpan

DNP

U105

Isobavachalcone

C20 H20 O4

20784-50-3

prenyl-chalcone

245

U106

Licoisoflavone a

C20 H18 O6

66056-19-7

prenyl-isoflavone

211

U107

Uralsaponin E

C42 H60 O17

1262489-45-1

saponin glycoside

224

U108

Kanzonol Q

C15 H16 O4

17053-75-7

miscellaneous

246

U109

Uralsaponin D

C42 H58 O18

1262489-44-0

1262489-44-0

DNP

U110

C25 H28 O6

141846-47-1

diprenyl-isoflavanone

U111

2',4',5,7-Tetrahydroxy3',8-diprenylisoflavanone
Gancaonin H

C25 H24 O6

126716-35-6

prenyl-pyrano-isoflavone

DNP

U112

Kanzonol P

C22 H24 O5

156250-72-5

prenyl-pterocarpan

228

U113

1680176-18-4

C20 H20 O5

1680176-18-4

prenyl-benzofuran

248

U114

1177433-19-0

C21 H18 O6

1177433-19-0

coumestan

248

U115

Demethylglycyrol

C20 H16 O6

1680176-22-0

coumestan

249

U117

1680176-21-9

C19 H18 O5

1680176-21-9

prenyl-benzofuran

248

U118

Semilicoisoflavone B

C20 H16 O6

129280-33-7

pyrano-isoflavone

211

U119

Isokaempferide

C16 H12 O6

1592-70-7

flavone-3ol

215

138

247

U120

6468-37-7

C16 H12 O4

6468-37-7

Coumarin

248

U121

6,8-Diprenylorobol

C25 H26 O6

66777-70-6

diprenyl-isoflavone

248

U122

6,8-Diprenylgenistein

C25 H26 O5

51225-28-6

diprenyl isoflavone

211

U123

Glyasperin D

C22 H26 O5

142561-10-2

prenyl-isoflavan

216

U124

23013-88-9

C23 H22 O6

23013-88-9

prenyl-coumestan

216

U125

1680176-23-1

C22 H22 O6

1680176-23-1

prenyl-isoflavone

216

U126

1680176-20-8

C21 H20 O6

1680176-20-8

coumarine

216

U127

1680176-17-3

C21 H20 O6

1680176-17-3

prenyl-isoflavone

216

U128

Licoarylcoumarin

C21 H20 O6

125709-31-1

prenyl-coumarin

211

U129

Uralsaponin X

C50 H74 O22

1616062-89-5

saponin glycoside

229

U130

Uralsaponin U

C42 H62 O17

1616062-86-2

saponin glycoside

229

U131

Uralsaponin N

C42 H62 O17

1616062-79-3

saponin glycoside

229

U132

Licoricesaponin H2

C42 H62 O16

118441-85-3

saponin glycoside

230

U133

Uralsaponin V

C42 H62 O15

1616062-87-3

saponin glycoside

229

U134

Uralsaponin O

C42 H60 O16

1616062-80-6

saponin glycoside

229

U135

Licoricesaponin E2

C42 H60 O16

119417-96-8

saponin glycoside

230

U136

Araboglycyrrhizin

C41 H62 O14

1622142-49-7

saponin glycoside

216

U137

C32 H48 O5

1614257-31-6

saponin

U138

22βAcetoxyglycrrhetaldehyde
Uralsaponin S

C48 H74 O20

1616062-84-0

saponin glycoside

229

U139

Uralsaponin R

C48 H74 O20

1616062-83-9

saponin glycoside

229

U140

Uralsaponin T

C48 H74 O19

1616062-85-1

saponin glycoside

229

U141

Uralsaponin Y

C48 H70 O20

1616062-90-8

saponin glycoside

229

U142

Uralsaponin Q

C47 H72 O19

1616062-82-8

saponin glycoside

229

U143

Uralsaponin M

C44 H64 O18

1616062-78-2

saponin glycoside

229

U144

Uralsaponin P

C42 H64 O16

1616062-81-7

saponin glycoside

229

U145

Licoricesaponin J2

C42 H64 O16

938042-18-3

saponin glycoside

211

U146

Isoliquiritigenin 4,4'-diO-glucopyranoside

C27 H32 O14

69262-36-8

chalcone glycoside

U147

Glycyuralin B

C21 H22 O5

1879910-23-2

prenyl-pterocarpan

U148

C22 H22 O9

486-62-4

isoflavone glycoside

U149

Ononin=Formononetin 7O-glucoside
Apigenin 4'-O-glucoside

C21 H20 O10

20486-34-4

flavone glycoside

211

U150

Sophoraflavone B

C21 H20 O9

22052-75-1

flavone glycoside

211

U151

Daidzin

C21 H20 O9

552-66-9

isoflavone glycoside

211

U152

Glycyuralin E

C21 H22 O6

1879910-26-5

prenylated-benzofuran

211

U153

Glycyuralin F

C20 H20 O7

1879910-27-6

hydroxyprenyl-isoflavone

211

U154

Syringic acid glucoside

C15 H20 O10

33228-65-8

phenolic-glycoside

211

U155

Luteone

C20 H18 O6

41743-56-0

prenyl isoflavone

211

U156

Vicenin= Apigenin 6,8-diC-glucoside

C27 H30 O15

23666-13-9

flavone-glycoside

U157

Homobutein

C16 H14 O5

34000-39-0

chalcone

139

229

211
211
211

220
211

U158

Pratensein

C16 H12 O6

2284-31-3

isoflavone

211

U159

Isomedicarpin

C16 H14 O4

74560-05-7

pterocarpan

211

U160

C16 H12 O5

7622-53-9

isoflavone

C16 H12 O5

437-64-9

flavone

U162

7-Methoxy-2',4'dihydroxyisoflavone
Apigenin 7-O-methyl
ether
Biochanin A

C16 H12 O5

491-80-5

isoflavone

211

U163

Isoviolanthin

C27 H30 O14

40788-84-9

flavone C-glycoside

211

U164

Kaempferol

C15 H10 O6

520-18-3

flavone-3-ol

211

U165

Daidzein

C15 H10 O4

486-66-8

isoflavone

211

U166

C6 H6 O3

100047-51-6

simple lactone

U167

4-Methoxy-2H-pyran-2one
Schaftoside

C26 H28 O14

51938-32-0

flavone C-glycoside

211

U168

Isoschaftoside

C26 H28 O14

52012-29-0

flavone C-glycoside

211

U169

Glycyuralin A

C26 H34 O6

1879910-22-1

prenyl-pyran-isoflavan

211

U170

Glycyuralin C

C26 H32 O6

1879910-24-3

U171

Angustone a

C25 H26 O6

90686-13-8

hydroxyprenyl-pyranisoflavan
diprenyl-isoflavone

U173

no trivial name

C43 H62 O16

1874227-82-3

saponin glycoside

211

U174

Dehydroglyasperin D

C22 H24 O5

517885-72-2

prenyl-dehydroisoflavan

211

U175

Glyasperin C

C21 H24 O5

142474-53-1

prenyl-isoflavan

211

U176

Dehydroglyasperin C

C21 H22 O5

199331-35-6

prenyl-dehydroisoflavan

250

U177

Glicophenone

C20 H22 O6

303175-66-8

U178

7-O-Methylluteone

C21 H20 O6

122290-50-0

prenylated-isoflavone

211

U179

1307578-72-8

C21 H20 O6

1307578-72-8

prenyl-flavone-3-ol

211

U180

no trivial name

C42 H62 O15

1874227-83-4

saponin glycoside

211

U181

Glyurallin a

C21 H20 O5

199331-36-7

prenyl pterocarpan

211

U182

Hirtellanine

C21 H18 O6

1369378-20-0

pyrano-isoflavone

211

U183

11b-Hydroxy-11b,1dihydromedicarpin

C16 H16 O5

210537-04-5

pterocarpan!

U184

1622179-42-3

C33 H38 O19

1622179-42-3

flavone C-glycoside

211

U185

Glycyroside

C27 H30 O13

125310-04-5

isoflavone glycoside

211

U186

C25 H26 O6

121747-94-2

diprenyl-isoflavone

U187

2'-Hydroxyisolupalbigenin
Isolupalbigenin

C25 H26 O5

162616-70-8

diprenyl-isoflavone

211

U189

ZA13-Gu

C20 H16 O7

ZA13-Gu

miscellaneous

NCNPR

U190

Conferol A

C16 H16 O5

1172120-53-4

isoflavanol

NCNPR

U191

ZA9-Gu

C21 H24 O6

ZA9-Gu

prenyl-isoflavanol

NCNPR

U161
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211
211

211

211
211

211

211

211

SI 5. Glycyrrhiza glabra top scoring compounds sorted by MM-GBSA

G163
G28
G106
G3
G40
G138
G156

Isoform
preference
α
α
α
α
α
α
α

X-ray crystal
structure
2p15
2p15
2p15
2p15
2p15
2p15
2p15

SP docking
score
−10.79
−10.43
−10.54
−11.04
−10.83
−10.55
−10.38

MM-GBSA
energy
−105.92
−105.86
−105.34
−105.11
−104.52
−101.07
−100.18

8
9
10
11
12
13

G112
G38
G174
G163
G33
G108

α
α
α
β
α
α

2p15
2p15
2p15
1L2J
2p15
2p15

−10.41
−10.87
−10.84
−11.35
−10.49
−10.53

−97.60
−96.96
−96.31
−96.15
−95.93
−95.76

14
15
16
17
18
19

G2
G28
G21
G50
G127
G158

β
β
α
α
α
β

1L2J
1L2J
2p15
2p15
2p15
1L2J

−10.45
−10.54
−10.47
−10.95
−10.80
−11.73

−95.35
−94.89
−94.64
−94.43
−93.82
−93.19

20
21
22
23
24
25

G47
G30
G40
G170
G154
G75

α
α
β
α
α
β

2p15
2p15
1L2J
2p15
2p15
1X7J

−10.82
−10.37
−10.43
−10.30
−10.32
−10.74

−93.11
−93.06
−91.87
−90.75
−90.73
−90.66

26
27
28
29
30

G38
G111
G99
G100
G171

β
β
β
β
α

1X7J
1L2J
1L2J
1X7J
1GWR

−10.92
−10.58
−11.00
−11.06
−10.33

−90.10
−89.09
−88.50
−86.56
−85.01

Rank

No.

1
2
3
4
5
6
7
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SI 6. Glycyrrhiza uralensis top scoring compounds sorted by MM−GBSA

α
α
β
α
α

X-ray Crystal
structure
2p15
2p15
1L2J
2p15
2p15

SP docking
score
−11.05
−11.49
−11.03
−10.84
−10.19

MM-GBSA
energy
−122.91
−111.57
−111.36
−105.61
−105.11

U25
U22
U86
U23
U24
U176

α
α
β
β
α
β

2p15
2p15
1L2J
1L2J
2p15
1L2J

−9.92
−10.26
−10.58
−11.14
−10.39
−10.33

−100.44
−100.04
−98.73
−98.39
−98.18
−97.53

12
13
14
15
16
17

U57
U66
U63
U127
U175
U117

β
α
α
α
β
β

1L2J
2p15
1GWR
2p15
1L2J
1L2J

−10.22
−11.15
−11.88
−10.66
−10.85
−10.91

−96.81
−95.79
−95.75
−93.42
−92.92
−92.15

18
19
20
21
22
23

U115
U177
U62
U77
U88
U119

β
α
β
β
β
β

1L2J
2p15
1L2J
1L2J
1L2J
1X7J

−10.47
−10.12
−10.15
−10.47
−10.72
−10.15

−91.79
−91.71
−91.59
−91.24
−91.07
−89.28

24
25
26
27
28
29

U127
U105
U189
U105
U165
U69

β
β
α
α
β
β

1L2J
1X7J
2p15
1GWR
1X7J
1X7J

−10.30
−10.23
−9.95
−10.28
−10.49
−10.59

−88.71
−88.66
−86.80
−84.87
−84.09
−83.22

30

U61

α

2p15

−9.78

−82.03

Rank

No.

selectivity

1
2
3
4
5

U77
U15
U16
U191
U78

6
7
8
9
10
11
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SI 7. Predicted RBA for top 20 compounds in both G. glabra and G. uralensis that scored
(>70%) confidence in estro_filter as calculated in ADMET Predictor™.
Rank
1
2
3

No.
G94
G117
G41

Estro_Filter
Toxic (97%)
Toxic (97%)
Toxic (97%)

Estro_RBA
758.16
699.12
364.00

Rank
1
2
3

No.
U35
U169
U175

Estro_Filter
Toxic (97%)
Toxic (89%)
Toxic (97%)

Estro_RBA
330.74
268.66
184.89

4
5
6
7
8
9

G152
G96
G61
G97
G49
G175

Toxic (97%)
Toxic (97%)
Toxic (97%)
Toxic (97%)
Toxic (97%)
Toxic (76%)

138.98
108.12
98.37
56.62
42.985
37.22

4
5
6
7
8
9

U170
U147
U176
U123
U191
U15

Toxic (76%)
Toxic (73%)
Toxic (97%)
Toxic (97%)
Toxic (97%)
Toxic (97%)

133.40
93.40
75.16
75.05
46.29
46.17

10
11
12
13
14
15

G21
G40
G69
G38
G28
G174

Toxic (97%)
Toxic (97%)
Toxic (89%)
Toxic (97%)
Toxic (76%)
Toxic (97%)

36.00
34.13
33.32
25.32
16.33
12.44

10
11
12
13
14
15

U22
U16
U110
U174
U98
U187

Toxic (97%)
Toxic (97%)
Toxic (76%)
Toxic (89%)
Toxic (97%)
Toxic (73%)

39.45
39.10
38.06
36.04
31.45
31.26

16
17
18
19
20

G3
G159
G47
G19
G73

Toxic (73%)
Toxic (97%)
Toxic (97%)
Toxic (97%)
Toxic (97%)

10.55
10.034
8.77
8.40
6.88

16
17
18
19
20

U117
U104
U99
U23
U186

Toxic (97%)
Toxic (76%)
Toxic (97%)
Toxic (97%)
Toxic (84%)

29.87
29.17
28.60
27.93
24.72
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SI 8. Glycyrrhiza glabra top-scoring compounds against PXR (1NRL) crystal
structure sorted by XP score in kcal/mol

33

G106

Xp
Score
−10.06

−57.69

34

G101

−10.02

−66.64

−12.53

−72.39

35

G159

−9.98

−45.66

G172

−12.52

−70.72

36

G159

−9.98

−9.98

5

G83

−12.33

−88.91

37

G137

−9.98

−9.98

6

G163

−12.18

−75.52

38

G68

−9.97

−9.97

7

G96

−11.95

−80.85

39

G140

−9.94

−9.94

8

G33

−11.91

−66.11

40

G94

−9.91

−9.91

9

G135

−11.69

−74.52

41

G110

−9.96

−9.96

10

G60

−11.58

−87.77

42

G170

−9.89

−9.89

11

G1

−11.54

−41.99

43

G97

−9.88

−9.88

12

G28

−11.26

−74.99

44

G30

−9.84

−9.84

13

G40

−11.09

−69.09

45

G71

−9.83

−9.83

14

G42

−10.99

−72.37

46

G134

−9.82

−9.82

15

G164

−10.99

−60.34

47

G100

−9.84

−9.84

16

G152

−10.91

−35.20

48

G131

−9.74

−9.74

17

G141

−10.80

−62.74

49

G19

−9.70

−9.70

18

G99

−10.87

−74.75

50

G111

−9.69

−9.69

19

G64

−10.72

−80.71

51

G32

−9.69

−9.69

20

G117

−10.72

−58.66

52

G65

−9.67

−9.67

21

G41

−10.56

−67.82

53

G62

−9.65

−9.65

22

G2

−10.47

−65.61

54

G53

−9.60

−9.60

23

G48

−10.42

−71.42

55

G102

−9.60

−9.60

24

G109

−10.46

−77.76

56

G138

−9.63

−9.63

25

G61

−10.28

−20.10

57

G132

−9.58

−9.58

26

G98

−10.25

−68.26

58

G139

−9.56

−9.56

27

G108

−10.24

−66.42

59

G35

−9.55

−9.55

28

G21

−10.21

−57.29

60

G88

−9.54

−9.54

29

G90

−10.21

−41.13

61

G91

−9.54

−9.54

30

G142

−10.21

−64.10

62

G69

−9.52

−9.52

31

G144

−10.12

−63.78

63

G154

−9.50

−9.50

32

G3

−10.07

−63.40

1

G158

Xp
Score
−13.36

2

G136

−12.59

3

G146

4

Rank

No.

Glide
emodel
−82.20

Rank
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No.

Glide
emodel
−67.56

SI 9. Glycyrrhiza uralensis top-scoring compounds against PXR (1NRL)
crystal structure sorted by XP score in kcal/mol
Rank
1
2

No
U77

XP
score
−12.26
−12.18

Emodel
score
−61.88
−75.86

Rank

No

XP score

29
30

U54
U34

−10.07
−10.04

Emodel
score
−53.88
−52.24

−11.72
−11.32
−11.16

−62.73
−34.46
−20.64

31
32
33

U128
U106
U191

−10.04
−10.03
−10.00

−61.43
−67.06
−66.84

3
4
5

U186
U121
U79
U52

6

U187

−11.06

−73.77

34

U88

−9.99

−70.15

7
8

U111
U51

−11.00
−10.88

−16.83
−63.85

35
36

U105
U60

−10.03
−9.95

−58.39
−73.45

9

U189

−10.87

−54.86

37

U117

−9.92

−60.62

10

U57

−10.72

−44.33

38

U178

−9.86

−66.60

11

U64

−10.71

−73.32

39

U18

−9.85

−68.63

12

U55

−10.69

−69.68

40

U84

−9.83

−65.02

13

U171

−10.67

−34.90

41

U155

−9.78

−63.13

14

U78

−10.66

−63.91

42

U81

−9.77

−61.65

15

U35

−10.60

−43.01

43

U126

−9.76

−67.29

16
17
18

U110
U85
U59

−10.60
−10.53
−10.46

−58.17
−63.83
−75.87

44
45
46

U36
U189
U153

−9.76
−9.76
−9.71

−52.58
−70.68
−67.16

19

U16

−10.45

−73.07

47

U170

−9.70

−10.11

20
21

U38
U65

−10.47
−10.40

−80.33
−70.29

48
49

U19
U174

−9.67
−9.66

−64.20
−73.89

22

U152

−10.37

−70.27

50

U179

−9.66

−68.80

23

U15

−10.34

−73.23

51

U50

−9.65

−19.40

24

U41

−10.44

−78.57

52

U63

−9.64

−70.95

25

U17

−10.21

−61.27

53

U41

−9.79

−76.19

26

U169

−10.21

−4.63

54

U87

−9.53

−68.63

27
28

U39
U122

−10.27
−10.20

−78.75
−52.22

55
56

U25
U178

−9.52
−9.51

−53.86
−65.99
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APPENDIX II.
SPECTRAL DATA
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Resveratrol prenylation products (M2-M10)

1H

13C

NMR (MeOD, 400MHz) spectrum of M2.

NMR (MeOD, 100MHz) spectrum of compound M2

147

IR spectrum of compound M2

ESI-HRMS of compound M2

148

1H

13C

NMR (MeOD, 400MHz) spectrum of M3

NMR (MeOD, 100MHz) spectrum of compound M3

149

IR spectrum of compound M3

ESI-HRMS of compound M3

150

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M4

NMR (acetone-d6, 100 MHz) spectrum of compound M4

151

IR spectrum of compound M4

ESI-HRMS of compound M4

152

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M5

NMR (acetone-d6, 100 MHz) spectrum of compound M5

153

IR spectrum of compound M5

ESI-HRMS of compound M5

154

1H

13C

NMR (acetone-d6, 500 MHz) spectrum of M6

NMR (acetone-d6, 125 MHz) spectrum of compound M6

155

IR spectrum of compound M6

ESI-HRMS of compound M6

156

1H

NMR (acetone-d6, 500 MHz) spectrum of compound M7

13C

NMR (acetone-d6, 125 MHz) spectrum of compound M7

157

IR spectrum of compound M7

ESI-HRMS of compound M7

158

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M8

NMR (acetone-d6, 100 MHz) spectrum of compound M8

159

HSQC spectrum of compound M8

HMBC spectrum of compound M8

160

NOESY spectrum of compound M8

161

IR spectrum of compound M8

ESI-HRMS of compound M8

162

1H

13C

NMR (acetone-d6, 500 MHz)spectrum of M9

NMR (acetone-d6, 125 MHz) spectrum of compound M9

163

HSQC spectrum of compound M9

HMBC spectrum of compound M9

164

NOESY spectrum of compound M9

COSY spectrum of compound M9

165

IR spectrum of compound M9

ESI-HRMS of compound M9

166

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M10

NMR (acetone-d6, 100 MHz) spectrum of compound M10

167

IR spectrum of compound M10

ESI-HRMS of compound M9

168

DHS prenylation products (M12-M18)

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M12

NMR (MeOD, 100 MHz) spectrum of compound M12

169

IR spectrum of compound M12

ESI-HRMS of compound M12

170

1H

NMR (acetone-d6, 100 MHz) spectrum of M13

13C

NMR (acetone-d6, 100 MHz) spectrum of M13
171

IR spectrum of compound M13

ESI-HRMS of compound M13

172

1H

NMR (MeOD, 400MHz) spectrum of compound M14

173

13C

NMR (MeOD, 100MHz) spectrum of compound M14

IR spectrum of compound M14

ESI-HRMS of compound M14

174

1H

NMR (acetone-d6, 500 MHz) spectrum of compound M15

13C

NMR (acetone-d6, 125 MHz) spectrum of compound M15

175

IR spectrum of compound M15

ESI-HRMS of compound M15

176

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M16

NMR (acetone-d6, 100 MHz) spectrum of compound M16
177

IR spectrum of compound M16

ESI-HRMS of compound M16

178

1H

13C

NMR (acetone-d6, 400 MHz) spectrum of M17

NMR (acetone-d6, 100 MHz) spectrum of compound M17
179

IR spectrum of compound M17

ESI-HRMS of compound M17

180

1H

NMR (CDCl3, 400 MHz) spectrum of compound M18

13C

NMR (CDCl3, 100 MHz) spectrum of compound M18

181

IR spectrum of compound M18

ESI-HRMS of compound M18
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